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The thesis entitled “The design and synthesis of novel N-heterocyclic compounds, 
and their evaluation of anti-cancer and anti-viral activity" is divided into three 
chapters. 
The title of the thesis clearly reflects the importance of nitrogen heterocycles 
compounds: in fact they are extremely pivotal structural motifs responsible for 
eliciting various biological activities in natural products and synthetic medicines. 
This has attracted the medicinal chemists towards the synthesis of various 
compounds having nitrogen heterocycles as useful medicines to treat various 
diseases. It is also evident by a large number of marketed pharmaceutical products 
possess nitrogen heterocycles. In each chapter different heterocycle moieties 
belonging to β-carboline, indoles and isoindolinones nucleus respectively are 
presented. 
In the first chapter we presented β-carboline derivatives and their anticancer 
activity on different cell lines. Our lead compound was harmine, which  is the 
most representative β-carboline alkaloid endowed with antitumor properties 
showing high cytotoxicity both in vitro against different human tumor cell lines 
and in vivo. It also exhibited remarkable DNA intercalation capacity and 
significant Topo I inhibition activity. We designed and synthesized novel β-
carbolines derivatives with the aim to evaluate their antiproliferative properties, to 
acquire more information about the structural requirements for the possible 
improvement of the cytotoxic potential and to elucidate SARs between substituent 
properties and antitumor activities. Most of the compounds were evaluated for 
Topo I inhibitory activity and compaired to harmine. Almost all compounds 
demonstrated interesting cytotoxic activities in particular against prostate cancer 
cells PC-3 with IC50 in low micromolar range. Compound X was found to be the 
most potent one with IC50 value of 8 µM. 
In the second chapter we reported the design and synthesis of new arbidol 
derivatives as antiviral agents: arbidol is an indole compound launched in the 
Russian Federation for the prophylaxis and treatment of influenza A and B and 
other acute respiratory viral infections, but due to its relatively high CC50 value, a 
clinical application is forbidden. So in order to reduce its toxicity and improve its 
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antiviral properties, we carried out some structural modifications at position 2, 4, 
5 and 6 on indole nucleus and we evaluated their effect in vitro, on anti- influenza 
virus (HA), hepatitis C virus (HCV) and chikungunya virus (CHIKV) activities. 
Viral infections are in fact the most common illnesses experienced by people of 
all ages and they are also one of the major causes of morbidity and mortality in 
elderly people and young children throughout the world. Currently, treatments are 
limited and the increasing prevalence of drug-resistant pathogens highlighted the 
need for new anti-viral drugs with novel mechanisms of action. Biological 
evaluation led us to discovery of a new potent influenza virus replication 
inhibitor, identified in compound 15.  Particularly it showed activity against all 
the tested viruses, both A and B type; moreover it seemed to lead to a better 
inhibition of some viruses in comparison to Arbidol. This compound was also 
found to be a promising lead compound for the design of new HCV virus 
replication inhibitors. Actually, biological studies are in course to better study 
mechanism underwent the action of compound 15, which could act non only as 
virus replication inhibitor but also as fusion inhibitor. Then a focused analysis on 
the interaction of this compound with the HA protein will be carried out. 
The third chapter is divided into two sections.  
Section A provided a brief introduction about aldol addition to 1,3-dicarbonyl 
compounds and described a simple and effective multicomponent regioselective 
one pot aldol addition/protection reaction of β-ketoesters to a series of aldehydes 
in the presence of Me3SiCl and i-Pr2EtN. The analysis of the scope and 
application of reaction revealed a dramatic dependence of the reactivity on the 
used substrates.  
Section B described a simple and general access to a series of new phthalimidines 
derivatives, (mentioned in Section A) in the presence of tertiary amines under 
very mild conditions exploiting the aldol addition of readily enolizable 1,3 
dicarbonyl compounds to 2-cyanobenzaldehyde. Recently, it has been recognized 
that 3-substituted isoindolinones possess a variety of biological activities, 
consequently, considerable effort has been devoted to the synthesis of this 
nitrogen heterocycle, which also act as useful synthetic building blocks and 
intermediates in organic synthesis.  
The obtained 3-substituted isoindolinones were preliminary tested on two 
different virus strains (HCV and CHIKV virus) to evaluate potential activity on 
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the virus replication, but unfortunately it was found that all compounds were not 
active. However further studies are desirable focusing on activities like hypnothic, 





























In medicine, biotechnology and pharmacology drug discovery is the process 
by which drugs are discovered and/or designed. In the past most drugs have been 
discovered either by identifying the active ingredient from traditional remedies or 
by serendipitous discovery. The discovery, development and exploitation of 
antibiotics were one of the most significant advances in medicine in the 20
th
 
century. Early drug discovery involves several phases from target identification to 
preclinical development. The majority of pharmaceutical drug discovery programs 
currently, begins with a known macromolecular target, and seeks to indentify a 
suitable small molecule modulator. The process of optimizing the lead molecule 
into a candidate drug is usually the longest and most expensive stage in the drug 
discovery.
 
The identification of small molecule modulators of protein function and 




        The first step of drug discovery involves the identification of new active 
compounds, often called “hits”, which are typically found by screening many 
compounds for the desired biological properties. These hits can come from natural 
sources, such as plants, animals or fungi. More often, hits can come from 
synthetic sources, such as historical compound collections and combinatorial 
chemistry. Another step in drug discovery involves further chemical modifications 
in order to improve the biological and physiochemical properties of a given 
candidates compounds library. Despite advances in technology and understanding 
of biological system, drug discovery is still a long process with low rate of new 
therapeutic discovery. The idea that effects of drug in human body are mediated 
by specific interactions of the drug molecule with biological macromolecules, 
(proteins or nucleic acid in most cases) led scientists to the conclusion that 
individual chemicals are required for the biological activity of the drug. This 
made for the beginning of the modern era in pharmacology, as pure chemicals, 
instead of crude extracts, became the standard drug. Organic chemistry also leads 
to the synthesis of many chemicals isolated from biological sources. Despite the 
rise of combinatorial chemistry as an integral part of lead discovery process, the 
natural products still play a major role as starting material for drug discovery.  
CHAPTER-I:Synthesis and Cytotoxic Activity of New β-Carboline Derivatives 
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    A report was published in 2007, the 974 small molecules, new chemical 
entities, 63% were natural derived or semisynthetic derivatives of natural 
products. For certain therapy areas, such as antimicrobials, antineoplastics, 
antihypertensive and anti-inflammatory drugs, the numbers were higher.  
     In literature synthetic approaches to a number of carboline derivatives having 
antitumor activity are described. Several carboline derivatives show activity at 
nanomolar concentrations and so are of keen interest for possible development 
into clinically useful antitumor agents. Carbolines are pyridoindoles and are 
classified as α, β, γ or δ according to the mode of ring fusion, as illustrated below 
(Fig. 1). 
              NH
N
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N
 




     The β-carboline alkaloids are a large group of natural and synthetic indole 
alkaloids that possess a common tricyclic pyrido[3,4-b]indole ring structure,
2,3
 
have attracted attention regarding several aspects of medicinal chemistry as 
illustrated below (Fig. 2). Numerous reports also disclosed that other simple and 
complicated β-carboline alkaloids were extensively presented in extracts from the 





Figure 2:  β-carboline skeleton 
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       The β-carboline alkaloids were originally isolated from Peganum harmala 
(Zygophillaceae, Syrian Rue), which is being used as a traditional herbal drug as 
an emmenagogue and abortifacient in the Middle East and North Africa.
4
 In the 
Amazon basin plants containing β-carbolines were widely used as hallucinogenic 
drinks or snuffs. Besides, the extracts of the seeds of Peganum harmala have been 
traditionally used for hundreds of years to treat the alimentary tract cancers and 




Figure 3.  Peganum harmala 
      These molecules can be categorized according to the saturation of their N-
containing, six membered ring. Unsaturated members are named as fully aromatic 
β-carboline (βCs), whereas the partially or completely saturated ones are known 
as dihydro β-carboline (DHβCs) and tetrahydro-β-carbolines (THβCs), 
respectively. The pyridinic nitrogen is more basic then the pyrrolic one, while its 
basicity increases upon excitation 
6, 7
 and is affected by the substitutions presence 
in the structure.
8
  Depending upon pH
 
and solvent, β-carboline can exist in four 
forms the cation, the neutral form, a zwitterions (or an alternative quinine type 
canonical forms), and  an anion.
9
 
      These compounds possess a wide diversity of important biochemical effects 
and pharmacological properties. Numerous previous reports investigated the 
effects of β-carboline alkaloids on the central nervous system (CNS), such as their 
affinity with benzodiazepine receptors (BZRs), 5-HT2A and 5-HT2C receptors.
10-12 
Recent interest in these alkaloids has been focused on their potent antitumor 





 on the synthesis of a variety of β-carboline 
derivatives and the evaluation of their antitumor activities unraveled that β-
carbolines demonstrated potent antitumor activities and the activity was correlated 
to both the planarity of the molecule and the presence of the ring substituents. 
Recently it is discovered that β-carboline derivatives may function their antitumor 
activity through multiple mechanisms, such as intercalating into DNA
26
, 




, and IKK (IkB kinase complex).
30
 
       Harmine (Figure 4) is the most representative β-carboline alkaloid endowed 
with antitumor properties. It showed high cytotoxicity both in vitro against 
different human tumor cell lines and in vivo in mice bearing both Lewis lung 
cancer and Sarcoma 180. It exhibited remarkable DNA intercalation capacity and 
significant Topo I inhibition activity.
19,22
 Tetracyclic systems in which another 
ring has been fused to the β-carboline nucleus have also shown promising 








Figure 4. Chemical structure of Harmine 
In particular, 1-methoxycanthin-6-one (Fig. 5), a natural product isolated from 
the medicinal plant Ailanthus altissima, showed interesting antiproliferative 
properties, suppressing the growth of a panel of human tumor cell lines, including 
epiderimoid carcinoma of the nasopharynx (KB), ileocecal carcinoma (HCT-8), 








Fig. 5. 1-methoxycanthin-6-one 
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       Ammirante et al. demonstrated that 1-methoxycanthin-6-one induced 
apoptosis via a JNK-dependent mechanism. c-Jun NH2-terminal kinase (JNK), a 
member of the mitogen activated protein kinase (MAPK) family, is a key 
regulator of apoptosis. Modulation of its activity can either promote or inhibit 
apoptotic processes, depending on cell system and contexts. Indeed, the kinase 
acts on a variety of targets, including, in addition to c-Jun, other transcription 
factors (ATF2, Elk-1, p53, and c-Myc) and proapoptotic and anti-apoptotic 
members of the Bcl-2 family (Bcl-2, Bcl-xL, Bim, and BAD), thereby influencing 
levels and activities of molecules that variously participate in cell death 
mechanisms. Furthermore, the compound synergized with human recombinant 
tumor necrosis factor (TNF)–related apoptosis-inducing ligand (hrTRAIL) in 
apoptosis induction. TRAIL, a member of the TNF gene superfamily, interacts 
with a complex system of receptors consisting of two proapoptotic death receptors 
(TRAIL-R1 and TRAIL-R2) and three decoy receptors (TRAIL-R3, TRAIL-R4, 
and osteoprotegerin). As a stable soluble trimer, the cytokine selectively induces 
apoptosis in many transformed cells but not in normal cells; differential 
expression levels of decoy versus proapoptotic receptors and other mechanisms 
seem to account for normal cell resistance to TRAIL induced cell death. TRAIL 
action involves the formation of a death inducing signaling complex (DISC) and 
activation of caspase-8; the apoptotic processes then follow two pathways: the 
mitochondrial independent activation of caspase-3 and mitochondrial-dependent 
apoptosis due to cleavage of BID by caspase-8. The JNK-activating and 
proapoptotic properties of 1-methoxycanthin-6-one render this molecule a 
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1.3 PRESENT WORK 
       In the present investigation, we designed and synthesized novel 1, 4-
disubstituted, 1,4,9-trisubstituted β-carbolines and 1-methoxycanthin-6-one 





I     R = H
II    R = CH3
IX
X
VII  R = COOCH3





































Figure 6: Chemical structure of 1,4-disubstituted, 1,4,9-trisubstituted β-carbolines 
and tetracyclic derivatives. 
       
     The purpose of this study is to evaluate the antiproliferative properties of these 
compounds in order to acquire more information about the structural requirements 
for the possible improvement of the cytotoxic potential and to elucidate SARs 
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1.3.1 RESULTS AND DISCUSSION 
Chemistry 
The preparation of derivatives I-IV is summarized in Scheme 1.  
 
Scheme 1. Synthesis of compounds I-IV 
 
Reagents and conditins: a) MeLi 1.6M in ether, THF, rt, o.n., 84%; b) glycine ethyl 
ester hydrochloride, NaBH(OAc)3, TEA, AcOH, dry 1,2-dichloroethane, rt, 24 h, 89%; c) 
HCO2Et, HCOOH, rt, 12 h, 94%; d) MeSO3H, 70°C, 1h, 96%; e) Me2C(OMe)2, p-TsOH, 
benzene; then p-chloranil, rt, 12h, 50%; f) , CH3I, NaH, THF-DMF, rt, 30', 80%; g) 
(CH3CO)2O, C6H5CHO, reflux, 24h, 67%; h) MeSO3,H, 70% in H2O, 70°C, 1h, 95%. 
 
       Treatment of indole-2-carboxylic acid (1) with a solution of methyl lithium in 
ether afforded 2-acetylindole (2) in very good yield. 2 was converted to the 
glycine derivative (3) via reductive amination, using sodium 
triacetoxyborohydride as reducing agent in presence of triethylamine and acetic 
acid. Ethyl 2-[1-(1H-indol-2-yl)ethylamino]acetate (3) was treated with 
ethylformate and formic acid to furnish the key intermediate 4. Cyclization of 4 
with methanesulfonic acid gave intermediate 5 in excellent yield. 
CHAPTER-I:Synthesis and Cytotoxic Activity of New β-Carboline Derivatives 
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    4-Methoxy-1-methyl-β-carboline (I) was obtained in a one-step conversion. 
This reaction was achieved by treatment of 5 with 2, 2-dimethoxypropane, 
dehydrogenation of intermediate with chloranil, followed by ready methanolysis 
of N-formyl pyridinium intermediate. Methylation of the N-9 position of 
compound I has been achieved by the action of sodium hydride in a mixture of 
anhydrous DMF/THF followed by addition of methyl iodide, affording compound 
II in good yield. 1-Benzylidine substituted β-carboline III was readily prepared 
by reaction of 1,9-dimethyl-4-methoxy β-carboline II with benzaldehyde in 
refluxing acetic anhydride. Treating 4 with methanesulfonic acid 70% in water we 
obtained compound IV in which cyclization and deformylation were 
accomplished simultaneously.  
    Compounds V, VI, VII, VIII, and 1-methoxycanthin-6-one (IX) were 
prepared according to the literature procedures.
33, 34
 (Scheme-2). 
Scheme 2: Synthesis of compound (V-X) 
Reagents and condtions: a) glycine ethyl ester hydrochloride, NaBH3CN, EtOH, 14h 0 
°C ,89%; b) HCO2Et, HCOOH, rt, 12 h, 79%; c) MeSO3H, 70 °C, 1h, 75%; d) 
Me2C(OMe)2, p-TsOH, benzene; p-chloranil, rt, 12h, 72%; e) m-CPBA, CH2Cl2,  rt, 24h, 
70%; f) DEPC, TEA, CH3CN, 70 °C, 5h, 45%;g) HCl-MEOH , CH2Cl2, 24h, rt -22h 
reflux 84%; h) DIBAL-H, CH2Cl2, -40 °C, 5', 70%; i) LiHMDS, THF, 15', -78 °C, 88%; 
j) BnBr, EtOAc, reflux, 7h, 67%. 
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    The indole-2-carboxaldehyde was subjected to reductive amination, by 
treatment with ethyl glycinate hydrochloride in the presence of sodium 
cyanoborohydride providing the intermediate 7 with a yield of 89%, after 
purification by flash chromatography. This intermediate was first formylated and 
then subjected to cyclization in the presence of methanesulfonic acid to give the 
compound 9 with a yield of 59%.  
     Aromatization and following formation of 4-methoxy-β-carboline core were 
performed in the presence of 2,2-dimethoxypropane and chloranil as oxidizing 
agent (Scheme 2a). Subsequently rapid methanolysis of the intermediate N-formyl 
pyridinium (c) gave the compound V with a yield of 72%. Acidic treatment of the 
intermediate V with m-chloroperbenzoic acid afforded the corresponding N-oxide 
(VI) in 70% yield. Then cyano group was introduced into position 1 of the β-
carboline ring. In our synthetic scheme we used a modified Reissert-Henze 
reaction
35
 which involves the use of diethyl phosphorocyanidate in an aprotic 
solvent such as acetonitrile. The reaction was maintained at 70 °C for 5 h giving 
the intermediate 10 with a yield of 45%, after purification by column 
chromatography.  
Scheme 2a 
     This intermediate was then subjected to acid-catalyzed methanolysis to afford 
the desired compound (VII) in excellent yields. The reduction of the ester group 
to aldehyde was carried out using a solution of 1M DIBAL-H in dichloromethane 
CHAPTER-I:Synthesis and Cytotoxic Activity of New β-Carboline Derivatives 
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and maintaining the solution at -40 °C for 5 minutes. The 4-methoxy-β-carboline-
1-carbaldehyde (VIII) was isolated by flash chromatography with a yield of 70 %. 
The cyclization and formation of the tetracyclic nucleus of 1-methoxy-6-cantin-
one (IX) was performed using a cyclization-aldol condensation reaction carried 




     This reaction involves the use of lithium hexamethyldisilazide (LiHMDS) as 
base, generated in situ by adding 1,1,1,3,3,3-hexamethyldisilazane (HMDS) and 
n-BuLi in THF at -78 °C under inert atmosphere. Addition of ethyl acetate to the 
solution led to formation of lithium 1-ethoxyenolate, which reacts with 4-
methoxy-β-carboline-1-carbaldehyde giving lithium enolate (11). This 
intermediate is treated with ethanol to generate the ester (12) which rearranges to 
form the 4, 5-dihydro-4-hydro-4-hydroxycanthin-one (13). This compound in the 
presence of lithium ethoxide, generated in situ, undergoes dehydration to form 1-
methoxycanthin-6-one. 
     3-benzyl-1-methoxycanthin-6-onium bromide (X) was synthesized from 1-
methoxycanthin-6-one by the simple quaternarization with benzyl bromide in 
refluxing ethyl acetate. 
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1.4 BIOLOGICAL ACTIVITY 
1.4.1 ANTI-PROLIFERATIVE ACTIVITY 
The cytotoxic potential of all synthesized compounds was evaluated in vitro 
against a panel of human tumor cell lines. The tumor cell line panel consisted of 
human T-cell lymphoblast-like cells (Jurkat), human breast cancer (MCF-7), 
human colon carcinoma (HT-29), human lung adenocarcinoma epithelial (A549), 
human prostate cancer (PC3), human melanoma (M14), human anaplastic thyroid 
carcinoma (ARO), and human glioblastoma (T98G). IC50 values for I-X and 
harmine (for comparison) are reported in Table 1. 
 





M14 MCF-7 HT-29 A549 PC-3 Jurkat ARO T98G 
Harmine ns ns 79.4±0.9 ns 22±0.8 ns 26.5±0.7 35±1.1 
I ns ns 50±1.5 80±0.5 20±1.2 ns 50±0.8 ns 
II 36±0.6 32±0.1 27±0.2 50±0.4 22±1.2 65±0.8 30±0.5 40±1.2 
III ns ns ns ns 60±0.9 ns ns ns 
IV ns ns ns ns 24±0.8 ns 18±0.6 ns 
V ns ns ns ns ns ns 64±1.2 ns 
VI ns ns ns ns ns ns ns ns 
VII ns ns ns ns 50± ns ns ns 
VII 38.9±0.1 35±0.45 90±0.3 45±1.2 25±0.2 28.8±0.9 39±0.4 ns 
IX 50±1.1 50±0.3 31±0.1 ns 26±0.1 50±0.2 15±0.6 90±0.7 
X 37±0.3 46±0.75 72±0.4 ns 8±0.9 ns 28±1.0 ns 
 
a
IC50= compound concentration required to inhibit tumor cell proliferation by 50 %; n.s. not 
significant. Data represent the mean values of three independent determinations performed in 
triplicate. 
 
In this study we evaluated cytotoxic effects of β-carboline derivatives and 
compared with harmine, a natural alkaloid highly cytotoxic against human tumor 
cell lines. In addition, 1-methoxycanthin-6-one (IX) was tested for cytotoxicity 
against a panel of several tumor cells. Our experiments confirmed the cytotoxic 
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effect of 1-methoxycanthin-6-one (IX) and, for the first time, we demonstrated the 
potential cytotoxic activity of compounds I-VIII and X in different cancer cell 
lines. From the above data, the following conclusions were drawn.  
       The shift of methoxy group from position 7 to 4 (harmine vs I) led to an 
increase of activity against HT-29 and A549 cell lines while no significant 
activities were detected in the other cell lines. The introduction of methyl group 
into position-9 of compound I led to compound II which demonstrated an 
improvement of activity to all tumor cell lines. When methyl group in position 1 
was replaced with benzylidine substituent there is a loss of activity. Compounds V 
and VI, with no substituent at position-1, were inactive to all tumor cell lines. 
Interestingly, the compound bearing a carboxyaldehyde substituent in position 1 
(VIII) of β-carboline ring system displayed a strong anti-proliferative effect 
against almost all tumor cell lines. In addition, the compound with a carboxylate 
(VII) substituent in position-1 was inactive to all tumor cell lines except to PC-3. 
Tetrahydro-β-carboline derivative IV showed good activity only against PC-3 and 
ARO cells. 
       As almost of the synthesized compounds of the present study showed 
interesting anticancer activity especially against PC-3 and ARO cell lines, oral 
bioavailability was considered to play an important role for the development of 
bioactive molecules as therapeutic agents. Therefore, a computational study for 
prediction of ADME properties of the molecules was performed by determination 
of lipophilicity, topological polar surface area (TPSA), absorption (% ABS) and 
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Table 2. Predicted ADME, Lipinski Parameters and Molecular Properties of the 
























Harmine 95 37.92 1 1 3 2.626 212.25 0 
I 95 37.92 1 1 3 2.796 212.25 0 
II 99 27.06 1 0 3 2.864 226.28 0 
III 99 27.06 3 0 3 5.192 314.39 1 
IV 94 44.89 0 2 3 1.829 200.24 0 
V 96 37.92 1 1 3 2.575 198.23 0 
VI 92 50.48 1 1 4 0.943 214.22 0 
VII 87 64.22 3 1 5 2.646 256.26 0 
VIII 90 54.99 2 1 4 2.604 226.24 0 
IX 94 43.61 1 0 4 2.891 250.26 0 
X 97 34.61 3 0 4 0.816 341.39 0 
a 
% ABS: Percentage of absorption, TPSA: topological polar surface area, n-ON: number of 
hydrogen bond acceptors, n-OHNH: number of hydrogen bond donors, n-ROTB: number of 
rotatable bonds. Calculations were performed using Molinspiration online property calculation 
toolkit (http://www.molinspiration.com).  
 
 
Calculations were performed using Molinspiration online property calculation 
toolkit.
37
 Table 2 represents a calculated percentage of absorption (% ABS), 
topological polar surface area (TPSA) and Lipinski parameters of the synthesized 
compounds. Percentage of absorption (% ABS) was estimated using the equation: 
% ABS = 109 - 0.345 x TPSA, according to Zhao et al.
38
 TPSA was also 
calculated using Molinspiration online property calculation toolkit
37
 according to 
the fragment-based method of Ertl et al.
39
  
Polar surface area, together with lipophilicity, is an important property of a 
molecule in transport across biological membranes. Too high TPSA values give 
rise to a poor bioavailability and absorption of a drug. According to the above 
criterions, calculated percentages of absorption for compounds ranged between 87 
and 99%. 
      As a whole, the present results showed that all the compounds studied, except 
V and VI, showed a very selective activity against prostate cancer cells PC-3 at 
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IC50 values nearly to 20 µM. In particular, X demonstrated an important anti-
proliferative effect at low concentration (IC50 8 µM). Moreover the most active 
compounds II, VIII, IX and X appear to be suitable as leads for further anticancer 
molecules development efforts on the fact their size and chemical properties are 
appropriate to classify them as drug-like compounds as they follow all the 
Lipinski‟s rule of five. 
 
1.4.2 TOPOISOMERASE-I ACTIVITY 
        Topoisomerase-targeting agents have long been considered an attractive 
target for the design of cancer chemotherapeutics because they can cause 
permanent DNA damage that triggers a series of cellular events, inducing 
apoptosis and finally causing cell death.
40
 DNA topoisomerases have been shown 




      Selected compounds (I, II, IV, VIII, IX and X) have been subjected to further 
studies to investigate their mechanism of antiproliferative activity. Especially, 
they have been evaluated for their ability to inhibit Topoisomerase I.  
They have been tested for their intercalation, inhibition of relaxation activity, and 
poisoning at the concentration of 312 µM. Compounds I, II and X demonstrated 
intercalation and inhibition of relaxation activity (IC50 are reported in Table 3).  
       Table 3.  Inhibition activity of compounds against DNA Topoisomerases I  








   Note: (-) indicates that the compound is inactive (negative at 312 μM or with IC50>250 μM ) 
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Other three compounds do not show any activity. Compound X exhibits strong 
Topoisomerase I inhibition, I and II show respectively moderate and weak 
activity. It appears of interest that: i) the regioisomer of harmine (compound I) 
maintains the same activity of the lead harmine (61.44 µM vs 65 µM); ii) the 
substitution of methyl group in position 1 with a carboxyaldehyde (VIII) is not 
effective; iii) N-9-methylation of β-carboline nucleus (compound II) is 
detrimental for the activity; iv) the loss of aromaticity of pyridine ring (IV) leads 
to an inactive compound; v) 1-methoxycanthin-6-one (IX) is unable to inhibit 
Topo I, while its N-2-benzylated analog (X)  shows to be the most potent inhibitor 




    We systematically designed and synthesized a number of novel β-carboline 
derivatives by efficient synthetic routes, and were proved to be selective and 
potent agent against prostate cancer. This important first step will allow us to 
determine preliminary relationship between structure and cytotoxic activities. The 
in vitro experiments revealed that the shift of methoxy group in position 4 of β-
carboline ring of harmine led to enhanced cytotoxic activity, substituents at 
position-1 were essential for high activity towards specific tumor types. From the 
above data we have also demonstrated that substitution at the position 3 of 1-
methoxycanthin-6-one with benzyl increased activity against most of the cell lines 
tested. The presented data suggest that several derivatives are potential candidates 
for clinical development with models of prostate cancer.  
      Most of the compounds were evaluated for Topo I inhibitory activity and 
compared to harmine. The compounds (I, II and X) demonstrated intercalation 
and inhibition of relaxation activity. It was observed that the N-2 benzylated 
analog (X) exhibited strong Topoisomerase I inhibition, better than the harmine. 
As well as compound I and II showed respectively moderate and weak activity. 
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1.6 EXPERIMENTAL SECTION 
 a)  Biology 
i) Cell Cultures 
     Human melanoma (M14), breast (MCF-7), glioblastoma (T98G), lung (A549), 
colon (HT-29) cancer cells were cultured in DMEM medium supplemented with 2 
mM L-glutamine, 10% heat-inactivated fetal bovine serum (FBS), 1% 
penicillin/streptomycin (all from Cambrex Bioscience, Verviers, Belgium) and 
human T-cell lymphoblast-like cells (Jurkat), anaplastic thyroid (ARO), prostate 
(PC3) cancer cells were cultured in RPMI medium supplemented with 2 mM L-
glutamine, 10% FBS, 1% penicillin/streptomycin at  37 °C in an atmosphere of 
95% O2 and 5% CO2. The cells were used up to a maximum of 10 passages. 
 
ii) MTT Bioassay 
     Human cancer cells (3×10
3
) were plated in 96-well culture plates in 90 μL of 
culture medium and incubated at 37 °C in humidified 5% C02. The day after, 10 
μL aliquot of serial dilutions of compounds (1–50 μM) was added to the cells and 
incubated for 48 h. Cell viability was assessed through MTT assay [1]. Briefly, 25 
μL of MTT (5 mg/mL) were added and the cells were incubated for an additional 
3 h. Thereafter, cells were lysed and the dark blue crystals solubilized with 100 
μL of a solution containing 50% (v:v) N,N-dimethylformamide, 20 % (w:v) SDS 
with an adjusted pH of 4.5. The optical density (OD) of each well was measured 
with a microplate spectrophotometer (Titertek Multiskan MCC/340) equipped 
with a 620 nm filter. Cells viability in response to treatment was calculated as 
percentage of control cells treated with solvent DMSO at the final concentration 
0.1 % : % viable cells = (100 x OD treated cells)/ OD control cells. 
 
iii) Chemicals and Reagents: 
      Supercoiled pHOT-1 DNA, 10 × TGS buffer, and Human Topo I enzyme 
were obtained from Topo GEN, Inc. (Port Orange, FL). pHOT-1 DNA was 
purchased at a concentration of 250 ng/µL in 10 mM Tris-HCl buffer (pH 7.5) 
containing 1 mM EDTA and was used as is after dilution in 1 x TGS buffer. 
Human Topo I was purchased in solution at 2 U/µL (where 1 U is the amount of 
CHAPTER-I:Synthesis and Cytotoxic Activity of New β-Carboline Derivatives 
18 
 
enzyme needed to relax 0.25 µg of pHOT-1 DNA in 30 min at 37 ºC). Proteinase 
K was obtained from Promega Corp. (Madison, WI). Agarose (molecular biology 
grade) was purchased from Midwest Scientific (St. Louis, MO) and sodium 
dodecyl sulfate (SDS) was purchased from EMD Biosciences (San Diego, CA). 
Dimethyl sulfoxide (DMSO; ACS grade), bromophenol blue (electrophoresis 
grade), and ethidium bromide (EtBr; electrophoresis grade) were purchased from 
Fisher Scientific (Fair Lawn, NJ). 
 
b) Chemistry 
      All reactions were performed in oven-dried (140 °C) or flame-dried glassware 
under dry N2. CH2Cl2 was reagent grade and was dried and distilled immediately 
from CaH2 before use. Column chromatographic purification of products was 
carried out using silica gel 60 (70–230 mesh, Merck). The reagents (Aldrich and 
Fluka) were used without further purification. The NMR spectra were recorded on 
Bruker DRX 400, 300, 250 spectrometers [400 MHz, 300 MHz, 250 MHz (
1
H); 
100 MHz, 75 MHz, 62.5 MHz (
13
C)]. Spectra were referenced to residual CHCl3 




C)]. Yields are given for isolated products showing one 
spot on a TLC plate and no impurities detectable in the NMR spectrum. Mass 
spectral analyses were carried out using an electrospray spectrometer, Waters 4 
micro quadrupole. Elemental analyses were performed with FLASHEA 1112 
series-Thermo Scientific for CHNS-O apparatus.   
 
c) Procedures and Characterization data 
 
2-Acetylindole (2) 
   To a solution of indole-2-carboxylic acid (0.5 g, 3 mmol) in anhydrous THF (5 
mL) at 0 °C was added methyl lithium (1.6 M in diethyl ether, 7.68 mL, 12 mmol) 
under nitrogen atmosphere in a dropwise manner. After addition, the reaction 
mixture was allowed to slowly warm to room temperature, stirred overnight, and 
treated with a saturated aqueous ammonium chloride solution. Ethyl acetate (400 
mL) was added and organic layer was separated. The aqueous layer was extracted 
with ethyl acetate (3x200 mL). The combined organic layers were dried (Mg2SO4) 
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and concentrated. The residue was purified by a flash chromatography on silica 
gel (CH2Cl2) to afford the title compound (411 mg, 84%).  
1
HNMR (300 MHz; CDCl3): δ 9.01 (br s, 1H), 7.69 (d, J = 8 Hz, 1H), 7.45 (d, J = 
8 Hz, 1H), 7.00-7.35 (m, 3H), 2.59 (s, 3H). 
MS (ESI) =  m/z 160.73 ([M+H]
+
). 
Anal. Calcd for C10H9NO: C, 75.45; H, 5.70; N, 8.80. Found: C, 75.25; H, 5.83; 
N, 8.56. 
Ethyl 2-[1-(1H-indol-2-yl)ethylamino]acetate (3) 
    The mixture solution of ethyl glycinate (3.299 g, 24 mmol) and Et3N (3.327 
mL, 24 mmol) in dry 1,2-dichloroethane (40 mL) was stirred at room temperature 
for 0.5 h, the 1-(1H-indol-2-yl)ethanone (1.9 g, 12 mmol) was added, treated with 
sodium triacetoxyborohydride (6.59 g, 30 mmol) and HOAc (1.78 mL, 30 mmol). 
The mixture was stirred at room temperature for 24 h. The reaction was quenched 
with saturated NaHCO3 and extracted with CH2Cl2. The combined organic layers 
were dried (Mg2SO4) and concentrated. The residue was purified by flash 
chromatography using petroleum ether/ethyl acetate 1:1 to give desired compound 
(2.6 g, 89 % yield).  
1
H NMR (300 MHz; CDCl3): δ 8.84 (br s, 1H), 7.54 (d, J = 7.9 Hz, 1H), 7.32 (d, 
J = 7.9 Hz, 1H), 7.14 (t, J = 7.9 Hz, 1H), 7.05 (t, J = 7.9 Hz, 1H), 6.34 (s, 1H), 
4.15 (m, 3H), 3.34 (dd, J = 6.7 Hz, 12 Hz, 2H), 2.31 (br s, 1H), 1.75 (d, J = 6.7 
Hz, 3H), 1.62 (t, J = 7.2 Hz, 3H). 
MS (ESI) = m/z 246.81 ([M+H]
+
); MS (ESI) m/z 269.12 ([M+Na]
+
). 
Anal. Calcd for C14H18N2O2: C, 68.27; H, 7.37; N, 11.37. Found: C, 68.44; H, 
7.34; N, 11.56. 
Ethyl 2-[1-(1H-indol-2-yl)ethyl]-N-formylaminoacetate (4) 
     Ethyl 2-[1-(1H-indol-2-yl)ethylamino]acetate (2.4 g, 9.6 mmol) was dissolved 
in a mixture of ethylformate (31.2 mL) and formic acid (0.336 mL), and stirred at 
55 °C for 9h. The organic layer was diluted with AcOEt, washed with aqueous 
NaHCO3, dried over anhydrous MgSO4 and evaporated to dryness in vacuo. The 
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residue was purified by flash chromatography using petroleum ether/ethyl acetate 
1:1 to give the title compound (2.5 g, 94%). 
1
HNMR (300 MHz; CDCl3): δ 9.50 (brs, 1H), 8.19 and 8.26 (each s, lH), 7.01-
7.72 (m, 4H), 6.43 and 6.48 ( each br s, 1H), 4.15-4.30 (m, 3H), 3.36 (dd, J = 6.7 
Hz & 12 Hz, 2H), 1.62 and 1.72 (each d, J = 7.9 Hz, 3H), 1.05 and 1.25 (each t, J 
= 8.0 Hz, 3H). 
MS (ESI) = m/z 275.81 ([M+H]
+
). 
Anal. Calcd for C15H18N2O3: C, 65.68; H, 6.61; N, 10.21. Found: C, 65.88; H, 
6.24; N, 10.96. 
2-Formyl-1-methyl-4-oxo-1,2,3,4-tetrahydro β-carboline (5) 
    A mixture of ethyl 2-[1-(1H-indol-2-yl)ethyl]-N-formylaminoacetate  (2.2 g, 
7.9 mmol) and methanesulfonic acid (20.7 mL) was stirred at 70 °C for 1 h. The 
reaction mixture was poured into ice-water, and neutralized with 10% aqueous 
NaHCO3, and extracted with AcOEt. The organic layer was washed with saturated 
aqueous NaHCO3 and brine, dried over anhydrous MgSO4 and evaporated to 
dryness in vacuo. The residue was subjected to flash chromatography using ethyl 
acetate: hexane (6:4) to give the title compound (1.73g, 96%). 
1
HNMR (300 MHz; DMSO-d6): δ 8.19 and 8.26 (each s, lH), 7.92 (d, J = 7.9 Hz, 
1H), 7.42 (d, J = 7.9 Hz, 1H), 7.01-7.32 ( m, 2H), 5.35 and 5.60 (m, 1H), 3.80 and 
4.60 (each d, 2H), 1.45 and 1.72 (each d, J = 7.9 Hz, 3H). 
MS (ESI) =  m/z 229.31 ([M+H]
+
).  
Anal. Calcd for C13H12N2O2: C, 68.41; H, 5.30; N, 12.27. Found: C, 68.28; H, 
5.24; N, 12.19. 
4-Methoxy-1-methyl β-carboline (I) 
     A solution of p-toluenesulfonic acid monohydrate (0.76 g, 3.9 mmol) in 
benzene (25 mL) was heated under azeotropic conditions for 1h. After cooling, 2-
formyl-1-methyl-4-oxo-1,2,3,4-tetrahydro-β-carboline (0.9 g, 3.9 mmol) and 
dimethoxypropane (1.47 mL, 0.85 mmol) was added to the benzene solution, and 
the mixture was stirred at room temperature for 1h. Chloranil (1.94 g, 7.80 mmol) 
was then added, and the whole was stirred at room temperature for 12h. The 
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reaction mixture was poured into 5% aqueous NaOH, and extracted with CH2Cl2. 
The organic layer was washed with brine, dried over anhydrous MgSO4, and 
evaporated to dryness in vacuo. The residue was subjected to flash-
chromatography using CHCl3/MeOH (9:1) to give the title compound (0.42 g, 
50%). 
1
H NMR (300 MHz; CDCl3): δ 10.22 (br s, 1H), 8.35 (d, J = 7.9 Hz, 1H), 8.01 (s, 
1H), 7.47-7.51 (m, 2H), 7.22-7.33 (m, 1H), 4.1 (s, 3H), 2.7 (s, 3H). 
13
C-NMR (75 MHz; CDCl3): 19.7, 56.1, 111.0, 117.8, 120.1, 120.3, 121.2, 124.3, 
127.0, 135.1, 135.5, 139.5, 150.7. 
MS (ESI) = m/z 213.33 ([M+H]
+
). 
Anal. Calcd for C13H12N2O: C, 68.41; H, 5.30; N, 12.27. Found: C, 68.18; H, 
5.14; N, 12.98. 
1,9-Dimethyl-4-methoxy-β-carboline (II) 
      A mixture of 4-methoxy-1-methyl-β-carboline (2.12 g, 10 mmol), anhydrous 
DMF (50 mL), and anhydrous THF (50 mL) was stirred at rt until clear, and then 
60% NaH (0.6 g, 15 mmol) and iodomethane (2 mL, 30 mmol) were added and 
stirred at rt for 30 min. Later the mixture was evaporated in reduced pressure. The 
resulting solution was poured into H2O (100 mL), and extracted with ethyl acetate 
(3 x 150 mL). The organic phase was washed with water and brine, then dried 
over anhydrous sodium sulfate, filtered, and evaporated. The oil obtained was 
purified by silica column chromatography with ethyl acetate as the eluent. Upon 
recrystallization, white crystals of compound were obtained (1.8 g, 80 %),  
1
H NMR (300 MHz; CDCl3): δ 8.39 (d, J = 7.9 Hz, 1H), 8.04 (s, 1H), 7.44-7.53 
(m, 2H), 7.24-7.32 (m, 1H), 4.22 (s, 3H), 4.14 (s, 3H), 2.73 (s, 3H). 
13
C NMR (100 MHz; CDCl3): δ 19.4, 34.3, 56.1, 111.0, 117.8, 120.0, 120.3, 
121.2, 124.3, 127.1, 135.1, 135.7, 139.4, 150.8. 
MS (ESI) = m/z 227.87 ([M+H]
+
). 
Anal. Calcd for C14H14N2O: C, 74.31; H, 6.24; N, 12.38. Found: C, 74.45; H, 
6.03; N, 11.98. 
 




    A mixture of 4-methoxy-1,9-dimethyl-β-carboline (2.26 g, 10 mmol), acetic 
anhydride (50 mL) and benzaldehyde (5.25 g, 50 mmol) was refluxed for 24 h. 
After completion of the reaction as indicated by TLC, the solution was poured 
into ice-water (200 mL) and made basic with sodium bicarbonate. The aqueous 
mixture was extracted with ethyl acetate, and the organic phase was washed with 
water and brine and then dried over anhydrous sodium sulfate. The solvent was 
removed under vacuum, and the residue was dissolved in ethanol and made acidic 
with concentrated hydrochloric acid. The solvent was evaporated in reduced 
pressure and the resulting oil was crystallized from acetone to give yellow solid. 
The solid was dissolved in water and made basic with sodium bicarbonate, and the 
aqueous mixture was extracted with ethyl acetate. The organic phase was washed 
with water and brine, dried over anhydrous sodium sulfate, concentrated under 
vacuum. The oil residue was crystallized to give desired compound in 67 % yield. 
1
H NMR (300 MHz; CDCl3): δ 8.39 (d, J = 7.9 Hz, 1H), 8.04 (s, 1H), 7.44-7.53 
(m, 2H), 7.15-7.32 (m, 6H), 6.94-6.95 (d, J = 8.5 Hz, 2H), 4.14 (s, 3H), 2.73 (s, 
3H). 
13
C NMR (75MHz; CDCl3): δ 37.3, 56.1, 111.0, 117.8, 120.0, 120.3, 121.2, 
124.3, 127.1, 127.4, 127.9, 128.5, 128.6, 135.1, 135.7, 137.2, 139.4, 150.8. 
MS (ESI) =  m/z 315.33 ([M+H]
+
). 
Anal. Calcd for C21H18N2O: C, 80.23; H, 5.77; N, 8.91. Found: C, 80.04; H, 6.01; 
N, 7.98. 
1-Methyl-4-oxo-1,2,3,4-tetrahydro β-carboline (IV) 
     A mixture of ethyl 2-[1-(1H-indol-2-yl)ethyl]-N-formylaminoacetate  (2.2 g, 
7.9 mmol) and methanesulfonic acid 70 % in water (22.7 mL) was stirred at 70 °C 
for 1 h. The reaction mixture was poured into ice-water, and neutralized with 10 
% aqueous NaHCO3, and extracted with AcOEt. The organic layer was washed 
with saturated aqueous NaHCO3 and brine, dried over anhydrous MgSO4 and 
evaporated to dryness in vacuo. The residue was subjected to flash 
chromatography using CHCl3/MeOH (9:1) to give the title compound (1.53 g, 95 
%). 




H NMR (300 MHz ; CD3OD): δ 7.92 (d, J = 7.8 Hz, 1H), 7.42 (d, J = 7.8 Hz, 
1H), 7.01-7.32 (m, 2H), 5.35 and 5.60 (m, 1H), 3.80 (dd, J =  6.7 Hz & 12 Hz, 
2H), 1.72 (d, J = 7.9 Hz, 3H). 
13
C NMR (75 MHz ; CD3OD): δ 20.2, 54.3, 58.6, 109.7, 111.3, 119.8, 121.6, 
121.8, 126.3, 134.4, 135.3, 196.5. 
MS (ESI) = m/z 201.31 ([M+H]
+
). 
Anal. Calcd for C12H12N2O: C, 71.98; H, 6.04; N, 13.99. Found: C, 71.17; H, 
5.84; N, 13.87. 
Ethyl 2-[(1H-indol-2-yl)methylamino]acetate(7): 
     Indole -2-carboxaldehyde (4.8 g, 1.0 eq, 32.736 mmol) was treated with Et3N 
(5.056 ml, 1.1 eq, 36.01 mmol), NaBH3CN (12.992 g, 6.0 eq, 196.41 mmol) and 
ethyl aminoacetatate HCl (13.846 g, 3.0 eq, 98.20 mmol) in ethanol (110 ml) was 
added at 0 °C and stirred rt for 4 days. The reaction was monitored by TLC. Then 
the reaction mixture was poured into ice water and extracted with ethyl acetate. 
The organic layer was washed with brine, dried over anhy. MgSO4, and evaporate 
to dryness in vaccum. The residue was subjected to column chromatography using 
hexane-ethyl acetate (1:1) to give pure product (5.800 g, 76%). 
Nature of compound: pale brown solid; mp 72-74 °C 




H NMR (400 MHz, CDCl3): 8.68 (br s, 1H), 6.92-7.69 (m, 4H), 6.30 (br s, 1H), 
4.14 (q, J = 7 Hz, 2H), 3.35 and 9.92 (each s, 2H), 2.04 (br s, 1H), 1.21 (t, J = 7 
Hz, 3H). 
MS (ESI) = m/z-233.57 [(M+H)
+
]. 
Anal. Calcd for C13H16N2O2,: C, 67.22: H, 6.94; N, 12.06. Found: C, 67.20; H, 
7.00; N, 11.92. 
Ethyl N-[(indol-2-yl)methyl]-N-formylaminoacetate (8) 
     The mixture of amine (5.700 g, 1.0 eq, 24.29 mmol), ethyl formate 1.2 eq. of 
95% formic acid (1.158 ml, 1.2 eq, 29.15 mmol) in toluene (200 ml) was heated 
under reflux using a dean stark trap for overnight. The progress of the reaction 
was monitored by TLC, and starting material disappeared. The reaction mixture 
was evaporated to give the crude product. The evaporation residue was purified 
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by column chromatography using ethyl acetate: hexane (3:7) to give pure product 
(6.075 g, 96%). 




H NMR (400 MHz; CDCl3): δ 9.18 and 9.61 (s, lH), 8.08 and 8.28 (each s, lH), 
7.01-7.72 (m, 4H), 6.40 and 6.45 (each br s, lH), 4.13 (q, J = 8 Hz, 2H), 3.88, 
4.01, 4.61 and 4.69 (each s, 4H), 1.17 and 1.27 (each t, J = 8 Hz, 3H), 
MS (ESI) = m/z 259.09 [(M+H)
+
]. 
Anal. Calcd for C14H16N2O3: C, 64.60; H, 6.20; N, 10.76. Found: C, 64.53; H, 
6.14; N, 1.87. 
3, 4-Dihydro-4-oxo-1H-pyrido[3,4-b]indole-2(9H)-carbaldehyde (9) 
     Ethyl N-[(indol-2-yl)methyl]-N-formylaminoacetate (500 mg, 1.0 eq, 1.93 
mmol) was treated with methanesulfonic acid (5 mL) at 70 °C for 3.5 h. The 
reaction mixture was poured into ice-water, and neutralized with 10% aqueous 
NaHCO3 and extracted with ethyl acetate. The organic layer was washed with sat. 
aqueous NaHCO3 and brine, dried over anhy. MgSO4 and evaporated to dryness 
in vacuum. The residue was subjected to column chromatography using ethyl 
acetate:hexane (2:1) to give the title compound (310 mg, 75 %). 
 Nature of compound: Solid; mp 224-225 °C.  




H-NMR (400 MHz; DMSO-d6): δ 12.18 (br s, lH),  8.21 and 8.31 (each s, lH), 
7.93 (dif. d, J = 7.5 Hz, lH), 7.52 (dif. d, J = 7.5 Hz, lH), 7.24 (dif. t, J = 7.5 Hz, 
lH), 7.21 (dif. t, J = 7.5 Hz, lH), 4.20, 4.24, 4.91, and 4.94 (each s, 4H). 
MS (ESI) = m/z-215.09 [(M+H)
+
]. 
Anal. Calcd for C12H10N2O2: C, 67.28; H, 4.71; N, 13.08. Found: C, 67.37; H, 
4.64; N, 13.01. 
4-Methoxy-9H-pyrido[3,4-b]indole (V) 
     A solution of p-toluenesulfonic acid monohydrate (1.033 g, 1.0 eq, 5.321 
mmol) in benzene (100 mL) was heated under azeotropic condition for 1 h. After 
cooling, initial compound (9) (1.0 eq, 5.321 mmol) and dimethoxypropane (2.003 
ml, 3.0 eq, 15.963 mmol) was added to a benzene solution, and mixture was 
CHAPTER-I:Synthesis and Cytotoxic Activity of New β-Carboline Derivatives 
25 
 
stirred at rt for 1 h. Chloranil  (2.643 g, 2.0 eq, 10.642 mmol) was added and 
whole reaction mixture was stirred at rt for overnight. The reaction mixture was 
poured into 5 % NaOH, and extracted with CH2Cl2. The organic layer was washed 
with brine, dried over anhy. MgSO4 and evaporated to dryness in vacuum to give 
a title product (925 mg, 72%).   
Nature of compound: Solid; mp: 250-252 °C. 




H NMR (400 MHz; CDCl3): δ 11.63 (br s, lH), 8.56 (s, lH), 8.17 (dif. d, J = 7.3 
Hz, lH), 8.06 (s, lH), 7.59 (dif. d, J = 7.3 Hz, lH), 7.51 (dif. t, J = 7.3 Hz, lH), 7.24 
(dif. t, J = 7.3 Hz, lH), 6: 4.12 (S, 3H). 
MS (ESI) = m/z 199.56 [(M+H)
+
]. 
Anal. Calcd for C12H10N2O: C, 72.71; H, 5.08; N, 14.13; O, 8.07. Found: C, 
72.77; H, 5.04; N, 14.17; O, 8.13. 
4-Methoxy-β-carboline-N-oxide monohydrate (VI) 
     m-CPBA (250 mg, 1.5 eq, 1.437 mmol) was added to a suspension of 4-
methoxy-β-carboline (200 mg, 1.0 eq, 0.958 mmol) in CH2Cl2 at rt and then 
stirred at rt for 24 h. Hexane was added to the mixture. The precipitate was 
collected by filtration, then residue was extracted with CH2Cl2, washed with 10 % 
aq. K2CO3 and water and dried over sodium sulphate and under reduced pressure 
to give the product. The solid residue was dissolved in CH2Cl2 and washed with 
10% K2CO3 and water then dried over sodium sulphate and solvent evaporated 
under reduced pressure to give title product (145 mg, 70%). 
 Nature of compound: Solid; mp: 273-276 °C   




H-NMR (400 MHz; DMSO-d6): δ 11.11 (br s. 1H), 8.25 (d, J = 1.5 Hz, lH), 8.00 
(dif. d, J = 7 Hz, lH), 7.84 (d, J = 1.5 Hz, lH), 6.99-7.60 (m, 3H), 4.01 (s, 3H,). 
MS (ESI): m/z = 215 [M + H
+
]. 
Anal. Calcd for  C12H10N2O2. H2O: C, 62.06; H, 5.21; N, 12.06. Found: C, 61.84; 
H, 5.17; N, 11.99.  
 
 




9-Diethoxyphophoryl-1-cyano-4-methoxy- β-carboline (10) 
….4-methoxy β-carboline-N-oxide monohydrate (268 mg, 1.0 eq, 1.238 mmol) 
was treated with DEPC (1.116 mL, 5.4 eq, 6.710 mmol) and Et3N (0.376 mL, 2.1 
eq, 2.674 mmol) in CH3CN (22 mL) at 70 °C for 3 h. The mixture was poured into 
ice water and extracted with CH2Cl2. The organic layer was washed with brine, 
dried over anhy. MgSO4, and evaporated to dryness in vacuum. The residue was 
subjected to column chromatography using ethyl acetate: hexane (3:7) to give 
pure title product  (45%). 
Nature of compound: Solid; mp: 139-142°C  
IR (KBr): 2240 (CN) cm
-1
   
1
H NMR (400 MHz; CDCl3): δ 8.24 (s, 1H), 8.10-8.59 (m, 2H), 7.15-7.71 (m, 
2H), 4.02-4.55 (m, 4H), 4.20 (s, 3H,), 1.34 (t, J = 7 Hz, 6H). 
MS (ESI) m/z 360.1 [(M+H)
+
]. 
Anal. Calcd for C17H18N3O4P: C, 56.83; H, 5.05; N, 11.69. Found: C, 56.71; H, 
5.00; N. 11.60. 
4-Methoxy-1-methoxycarbonyl- β-carboline (VII) 
The substrate of (100 mg, 1.0 eq, 0.276 mmol) was treated in methanol (10 ml) 
saturated with dry, HCl gas at rt for 24 h, and then heated under reflux for 22 h. 
Solvent was evaporated in vacuum. Saturated aq. NaHCO3 was added to the 
residue, and the mixture was extracted with ethyl acetate. The organic layer was 
washed with saturated aq. NaHCO3 and brine, dried over anhy. sodium sulphate, 
and evaporated to dryness in vacuum. The residue was subjected to column 
chromatography using ethyl acetate: hexane (7:3) to give title product (59 mg, 84 
%). 
Nature of compound: Solid; mp: 196-197°C. 




H NMR (400 MHz; CD3OD): δ 11.60 (br s, 1H), 8.23 (S, 1H), 8.21 (dif. d. J = 
7.8 Hz. lH), 7.79 (dif. d, J = 7.8 Hz, lH), 7.57 (dif. t, J = 7.8 Hz, lH), 7.30 (dif. t, J 
= 7.8 Hz, lH), 4.25 (s, 3H), 3.97 (s, 3H). 
MS (ESI) = m/z 257.56 [(M+H)
+
]. 
CHAPTER-I:Synthesis and Cytotoxic Activity of New β-Carboline Derivatives 
27 
 
Anal. Calcd for C14H12N2O3: C, 65.62; H, 4.72; N, 10.93. Found: C, 65.77; H, 
4.64; N, 10.83. 
4-Methoxy- β-carboline-1-carbaldehyde (VIII) 
     To a stirred solution of compound (VII) (52 mg, 1.0 eq, 0.201 mmol) in 
CH2Cl2 (3.0 ml) was added DIBAL (142.22 ml, 6.0 eq, 1.206 mmol) solution at -
40 °C under nitrogen atmosphere. The reaction mixture was stirred at -40 °C for 
15 min. and then quenched by the sequential addition of MeOH (0.3 ml) and 10% 
NaOH (0.3 ml) at -40 °C. Then mixture was stirred at rt for an additional 30 min. 
Then reaction mixture was diluted with CHCl3, dried over anhy. MgSO4, and then 
evaporated to vacuum. The residue was subjected to column chromatography 
using ethyl acetate: hexane (1:1) to give a title product (29 mg, 70%). 
Nature of compound:  Colourless Solid; mp: 209-210 °C. 




H NMR (400 MHz; DMSO-d6): δ 12.08 (br s, 1H), 10.24 (s, 1H), 8.41 (s, 1H), 
8.21 (br d, J = 8.0 Hz, 1H), 7.79 (br d, J = 8.0 Hz, 1H), 7.57 (br t, J = 8.0 Hz, 1H), 
7.32 (br t, J = 8.0 Hz, 1H), 4.38 (s, 3H). 
MS (ESI) = m/z 227.36 [(M+H)
+
]. 
Anal. Calcd for C13H10N2O2: C, 69.02; H, 4.45; N, 12.38. Found: C, 68.94; H, 
4.39; N, 12.48. 
 
1-Methoxycanthin-6-one (IX) 
    To a stirred mixture of HMDS (0.199 ml, 8.0 eq, 0.994 mmol) in THF, n-BuLi 
(2M in hexane) (0.283 mL, 6.0 eq, 0.708 mmol) was added at -78 °C under 
nitrogen atmosphere. The mixture was warmed to rt within 30 min. with stirring 
and then recooled to -78 °C. Ethyl acetate (0.054 mL, 4.6 eq, 0.543 mmol) in THF 
(2.8 mL) was added to the solution and then stirred for 15 min. at -78 °C. To this 
solution, compound VIII (27 mg, 1.0 eq.  0.118 mmol) in THF was added and 
then stirred for 15 min. at -78 °C. To the reaction mixture, ethanol (1.8 mL) was 
added and then stirred for 30 min at rt. The whole reaction mixture was poured 
into aq. sat. NH4Cl (9.2 ml), extracted with ethyl acetate, washed with brine, dried 
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over anhy. sodium sulphate and evaporated in vacuum. The crude solid was 
purified by silica gel column chromatography using ethyl acetate: hexane (7:3) to 
give the colorless title product (29 mg, 88%). 





H NMR (400 MHz; CDCl3): δ 8.70 (br d, J = 8.0 Hz, 1H), 8.51 (s, 1H), 8.24 (br 
d, J = 8.0 Hz, 1H), 7.98 (d, J = 10 Hz, 1H), 7.68 (br t, J = 8 Hz, 1H), 7.53 (br t, J 
= 8 Hz, 1H), 6.86 (d, J = 10 Hz, 1H), 4.27 (s, 3H). 
13
C NMR (75 MHz; CDCl3): δ 55.1, 115.6, 118.6, 121.8, 122.7, 124.1, 126.6, 
127.1, 127.9, 128.1, 129.3, 137.6, 138.2, 150.2, 158.3. 
MS (ESI) m/z 251.08 [(M+H)
+
] 
Anal. Calcd for C15H10N2O2: C, 71.99; H, 4.03; N, 11.19. Found: C, 71.91; H, 
4.09; N, 11.13. 
3-Benzyl-1-methoxycanthin-6-onium bromide (X) 
   A mixture of 1-methoxycanthin-6-one (30 mg, 0.120 mmol) and benzyl bromide 
(0.106 mL, 0.9 mmol) in ethyl acetate (5 ml) was refluxed for 7h. After 
completion of the reaction as indicated by TLC, the solution was cooled and 
filtered and crystallized to afford X in 67% yield. 
1
H NMR (300 MHz; CD3OD): δ 9.1 (s, 1H), 8.51 (br d, J = 8 Hz, 1H), 8.24 (br d, 
J = 8 Hz, 1H), 7.98 (d, J = 10 Hz, 1H), 7.68 (br t, J = 8 Hz, 1H), 7.53 (br t, J = 8 
Hz, 1H), 7.48 (br m, 5H), 6.86 (d, J = 10 Hz, 1H), 6.36 (s, 2H), 4.47 (s, 3H). 
13
C NMR (100 MHz; CD3OD): δ 56.8, 58.2, 116.8, 117.1, 123.5, 124.3, 125.5, 
125.7, 128.6, 129.0. 129.4, 130.1, 130.5, 132.9, 134.2, 138.2, 138.8, 151.9, 160.0. 
MS (ESI) ) m/z 422.40 ([M+H]
+
). 
Anal. Calcd for C22H17BrN2O2: C, 62.72; H, 4.07; Br, 18.97; N, 6.65. Found: C, 
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Synthesis of new indoles arbidol like 


















      The field of antiviral drugs is expanding rapidly and antiviral drugs are 
becoming important and vital agents in medicine, in particular since new human 
viruses have appeared. Thus the effort to develop effective drugs to combat these 
new threats has been intensified and these concerns led to national and global 
surveillance activities as well as to specific and detailed research studies. In 
addition increasing prevalence of drug-resistant pathogens highlights the need for 
new antimicrobial drugs. Among a number of different biological active 
heterocyclic moieties, the indole nucleus constitutes an important block in 
numerous natural or synthetic alkaloids in medicinal chemistry. Due to the 
existence of a vast array of structurally diverse and biologically active indoles, it 
is not surprising that the synthesis and reactivity of indole derivatives have been a 










Figure 1: Skeleton structure of Indole 
 
  In this chapter the development of new indole structure based inhibitors against 
influenza virus (HA), hepatitis C virus (HCV) and chikungunya virus (CHIKV) 
are described 
 
2.1.1. INFLUENZA VIRUS 
        Influenza viral respiratory infections are the most common illnesses 
experienced by people of all ages. They are also one of the major causes of 
morbidity and mortality in elderly people and young children throughout the 
world.
1-3
 Approximately 200 viral respiratory pathogens, the most important are 
influenza and respiratory syncytial viruses (RSV): other viruses include 








     Influenza is caused by RNA viruses of the family Orthomyxoviridae and they 
are classified in: 
a. Influenza virus A 
b. Influenza virus B 
c. Influenza virus C  
 
       Influenza B is less common than influenza A and influenza C is less common 
than the other types and usually only causes mild disease in children. Wild aquatic 
birds are the natural hosts for a large variety of influenza A. Occasionally; viruses 
are transmitted to other species and may then cause devastating outbreaks in 
domestic poultry or give rise to human influenza pandemics. The type A viruses 
are the most virulent human pathogens among the three influenza types and cause 





           Figure 2. Structure of Influenza virus 
 
     Hemagglutinin (HA) and neuraminidase (NA) are the two large glycoproteins 
on the outside of the viral particles (Figure 2). HA is a lectin that mediates binding 
of the virus to target cells and entry of the viral genome into the target cell, while 
NA is involved in the release of progeny virus from infected cells, by cleaving 
sugars that bind the mature viral particles.
5
 Thus, these proteins are targets for 
antiviral drugs. 
6
 Furthermore, they are antigens to which antibodies can be raised. 
Influenza A viruses are classified into subtypes based on antibody responses to 
HA and NA: 
7  
 




 H1N1, which caused Spanish Flu in 1918, and Swine Flu in 2009 
 H2N2, which caused Asian Flu in 1957 
 H3N2, which caused Hong Kong Flu in 1968 
 H5N1, which caused Bird Flu in 2004 
 H7N7, which has unusual zoonotic potential  






    Worldwide influenza pandemics have occurred at irregular and unpredictable 
intervals throughout history and the impact of pandemic influenza is substantial in 
terms of morbidity, mortality and economic cost. The chemotherapy options were 
limited to admantidine or rimantidine, which are only effective against influenza 
A and often cause side-effects and rapid viral resistance. Recently the launch of 
the neuraminidase inhibitors zanamivir and oseltamivir give a new option: 




2.1.2. HEPATITIS C VIRUS 
      Hepatitis C virus is the cause of hepatitis C in humans: this infection currently 
affects approximately 170 million people worldwide and is resolved in only a 
minority of patients.
9 
The chronic viral infection frequently progresses to end-
stage liver disease, cirrhosis and in some cases, to the development of 
hepatocellular carcinoma. Therefore, hepatitis C is now the most frequent 
indication for liver transplantation. Hepatitis C virus (HCV) is a small enveloped 
single-stranded RNA virus of the family Flaviviridae: the genetic material (RNA) 
is surrounded by an icosahedral protective shell of protein, and further encased in 
a lipid (fatty) envelope of cellular origin. In the lipid envelope are embedded two 
viral envelope glycoproteins E1 and E2 (Figure 3). 










Figure 3. Structure of Hepatitis C virus 
     There is no therapeutic or prophylactic vaccine available for HCV, and the 
only effective antiviral therapy, pegylated recombinant interferon a (IFN-a) and 
ribavirin, produces sustained viral clearance in less than 50% of treated patients.
10
 
New anti-HCV drugs with novel mechanisms of action are needed.  
2.1.3. CHIKUNGUNYA VIRUS 
      Chikungunya infection is commonly an acute disease marked by febrile 
arthralgia and a frequent rash: persisting arthralgia has been reported in a 
significant number of cases.
11
 Chikungunya virus (CHIKV) is an arthropod-borne 
viral disease, this is usually found in tropics and hence the reason why 
Chikungunya is predominantly seen in asian countries. First described in Tanzania 
in 1952 which has reemerged since 2005 in Eastern Africa, the Indian Ocean, 
India and South-East Asia and even reached Europe in 2007.
12
 From 2005, this 
new variant has been responsible for millions of cases of CHIKV disease. Lethal 
infections are rare but severe cases have been described including neurological 
presentations and neonatal contaminations which were documented during the 
outbreak in Reunion Island.
13 
Current treatments of Chikungunya fever are for 
symptoms with no effective licensed vaccine nor specific antiviral drug available. 
The utilization of the antimalarial chloroquine proved to be poorly active in vivo 
despite it‟s in cellulo antiviral effect on CHIKV infection.
14,15
 Similarly, it has 
been shown that the combination of interferon-alpha and ribavirin is effective on 




CHIKV replication in vitro but these compounds have not been tested in animal 
models and/or clinical trials.
16
 
2.1.4. ARBIDOL: A BROAD-SPECTRUM ANTI-VIRAL INDOLE 
COMPOUND 
     Arbidol (Fig. 4) is an anti-influenza therapeutic developed in the Russian 
Research Chemical-Pharmaceutical Institute about 20 years ago
17
 and since 1990 
this drug has been used in Russia for prophylaxis and treatment of acute 









Figure 4. Structure of Arbidol 
 
       Until now, it has been shown that ARB exhibits a wide range of activity 
against a number of RNA, DNA, enveloped and non-enveloped viruses.
18
 It shows 
a broad and potent antiviral activity against a large number of viruses including 












      The broad-spectrum antiviral activity demonstrated by Arbidol against a 
number of enveloped and non-enveloped viruses could in part be to due its 
membrane tropism. Indole derivatives have been shown to exhibit a preference for 
membrane interfaces due to the flat rigid structure of these molecules, and to their 
aromaticity which allows them to establish cation-π interactions with the 
positively-charged quaternary ammonium lipid head groups. The S-phenyl groups 
of ARB could also interact with the hydrophobic fatty acid chains of 
phospholipids inside the bilayer. The amino groups could bond the phosphate 




moieties of phospholipids, and establish a salt bridge between two adjacent 
phospholipid molecules as an ion-pair complex.
24
 Indeed, it has been shown that: 
 
a) ARB was an entry inhibitor of influenza virus infection by stabilizing the 
influenza HA and preventing the endosomal membrane fusion.  
b) Similarly, ARB proved to be active in vitro against HCV virus and the 
antiviral mechanism was related to inhibition of the HCV glycoprotein 
conformational changes needed for the membrane fusion process. Arbidol 
also exerted a clear inhibitory effect on HCV replication, with loss of 
protein expression and decline in RNA level. One can therefore speculate 
that ARB-induced inhibition of HCV non-structural protein interactions 
with organelle membranes that are required for HCV replication might 
also contribute to ARB's anti HCV actions.
25
 
c) Recently ARB was found to be a potent inhibitor against in vitro CHIKV 





2.2. PRESENT WORK   
         a) Arbidol derivatives 
By its tropism for membranes and its inhibitory effect on viruses entry, 
fusion and replication, Arbidol opens promising perspectives in the search 
for new and efficient antiviral compounds,
24
 but since it has a relatively 
high CC50 value and it means toxic, its clinical application is forbidden.
22
 
So with the aim to reduce its toxicity and improve its antiviral properties a 
series of novel arbidol derivatives were designed and synthesised focusing 
our attention on different positions of the indole nucleus (Figure 5).  
 





              Figure 5. Structural modification on Arbidol, chosen as our lead compound 
      First of all the N,N-dimethylamino methyl group in position 4 was removed 
(compound 6 and 7). Then phenolic OH in position 5 was homologated in 
hydroxyl methyl group (compounds 15 and 21) and subsequently with the aim to 
investigate the role of phenyl sulfanyl methyl group on the antiviral activity, we 
introduced a methyl group at the position 2 (compounds 16 and 18). In addition, 
to evaluate the role of hydroxy group of compound 15 and 16 in position 5, a new 
library of compounds were prepared replacing this group with several aliphatic 
amines and cyclic amines (Table 1).  









Figure 6      
    Table 1. Amine indoles derivatives synthesized 
 
Alkyl amines with different chains length and some constrained amines 
(pyrrolidine, morpholine, piperazine) were used. Bromine was removed from of 
all amines derivatives since preliminary results showed that bromine was not 
essential for biological activity. 
Compound R R1 
23a -CH3 -N(CH3)2 
23b  -CH3 -N(CH2CH3)2 
23c  -CH3 -N(CH3)CH2CH2CH2N(CH2CH3)2 
23d  -CH3 -pyrrolidine 
23e  -CH3 -N-methyl piperazine 
23f  -CH3 2-piperazin-1-ylethylamino 
23g  CH3 -N(CH3)CH2CH2N(CH2CH3)2 
23h -CH3 -N(CH2CH3)CH2CH2N(CH2CH3)2 
23i  -CH3 NHCH2CH2NHCH3 
23j  -CH3 -NHCH2CH2N-COOt-Bu 
23k -CH3 -NHCH2CH2N(CH3)2 
23l  -CH3 -NHCH2CH2OH 
23m  -CH3 -NHCH2CH2NHCH2CH2OH 
25  -CH3 -NH2 
28a  -CH2SPh -N(CH3)2 
28b  -CH2SPh -N(CH2CH3)2 
28c   -CH2SPh -N(CH3)CH2CH2CH2N(CH2CH3)2 
28d  -CH2SPh -pyrrolidine 
28e  -CH2SPh -N-methyl piperazine 
28f  -CH2SPh -N-tert-butoxycarbonyl piperazine 
28g -CH2SPh -N-(2,4 difluoro)phenyl piperazine 
28h  -CH2SPh -morpholine 
29  -CH3 -diazepan 




















2.2.1. RESULTS AND DISCUSSION 
The desired products were obtained following different schemes. Compound 6 
and compound 7 were synthesized according to Scheme 1. Protection of 
commercially available, ethyl 5-hydroxy-2-methyl-1H-indole-3-carboxylate 1 was 
carried out using acetic anhydride in pyridine under reflux for 1h to give 2, which 
was submitted to N-methylation dissolving the derivative in DMF, adding NaH 
60% and methyl iodide for 1h at room temperature.
26 
Bromination of compound 3 
in CCl4 using N-Bromosuccinimide gave 4 and 5,which were easily separated by 
silica gel column chromatography.
27
 In last step nucleophilic displacement of 
bromine of bromo mrthyl at position 2 by thiophenol in MeOH, using KOH as 






































5 X=Br  
Scheme 1 
Reagents and conditions: a) acetic anhydride, pyridine, 1h, reflux. b) CH3I, NaH 60%, 
DMF, 1h, rt c) NBS, benzoyl peroxide, CCl4, overnight, reflux. d) Thiophenol, KOH, 
CH3OH, 3h, rt. 
Compound 15 and 16 were synthesized according to Scheme 2. Intermediate 8 
was prepared as reported in literature starting from 4-amino ethyl benzoate I.
 28
 
This was submitted to a copper-catalyzed (Ullmann-type) reaction using two 
different β-ketoesters (ethyl-3-oxo-4 (phenylthio) butanoate 9
29
 or ethyl 
acetoacetate 10 to give indoles cyclization products 11 and 12,
30
 in moderate 
yields. Then they were methylated under similar condition reported in Scheme 1. 




Removal of dimethyltert-butylsilyl group was achieved using tetrabutylamonium 
































 1 1  R =CH 2SPh 
 1 2  R =CH 3
 1 3  R =CH 2SPh 
 1 4  R =CH 3
 1 5  R =CH 2SPh 
 1 6  R =CH 3
a b c
 III II I
 
Scheme 2 
Reagents and conditions: a) NaIO4, KI, NaCl, Acetic acid/water, r.t; b) DIBAL-H 1M 
CH2Cl2, anhy. THF, 0 °C; c) TBDMSiCl, imidazole, DMF, r.t; d) ethyl-3-oxo-4 
(phenylthio)butanoate 9 or ethyl acetoacetate 10, CuI, BINOL, Cs2CO3, anhy. DMSO, 50 
°C; e) CH3I, KOH,  Acetone, r.t; f) Tetrabutylammonium fluoride, THF, 0 °C. 
Compound 18 and 21 with bromine in position 6 were synthesized according to 
Scheme 3 starting from intermediate 14. Bromination using 1 equivalent of N-
bromosuccinimide as previously reported gave derivative 17 with bromine in 
position 6 of indole nucleus. Removal of dimethyltert-butylsilyl group as 
previously reported was achieved using tetrabutylamonium fluoride in THF 0 °C 
to give 18. Bromination using 2 equivalent of N-bromosuccinimide gave a 
mixture complex in which aldehyde 19 was isolated. This intermediate was then 
submitted to a selective reduction of carbonyl function using NaBH4 in 
THF/MeOH and in the last step nucleophilic displacement of bromine 
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Reagents and conditions: a) N-Bromosuccinimide (1 equiv.), dibenzoylperoxide, CCl4, 
2h, reflux; b) N-Bromosuccinimide (2 equiv.), dibenzoylperoxide, CCl4, 2h, reflux; c) 
Tetrabutylammonium fluoride, THF, 1h, 0 °C; d) NaBH4, THF/MeOH, 1h, 0 °C; e) 
PhSH, KOH, EtOH, r.t, 3h. 
 
 
To synthesize amines derivatives two different routes were employed. Amines 
23a-e and 25 were prepared as reported in Scheme 4 starting from intermediate 
16. Hydroxyl group of 16 was converted into chloride 22 using triphenyl 
phosphine in CCl4/DMF for 16 h at room temperature.
31
 Then nucleophilic 
displacement of halide by aliphatic amines in DMF in the presence of Cs2CO3 
under reflux afforded the desired products in moderate yields. When potassium 
phtalimide was used, intermediate 24 was obtained in quantitative yield according 
to Gabriel synthesis and following deprotection of subjected to using hydrazine 
hydrate gave the amine 25.
32
 






Reagents and conditions: a) PPh3, CCl4/DMF, 16h, r.t; b) Aliphatic amines, Cs2CO3, 
DMF, overnight, reflux; c) Potassium phtalimide, DMF, 2h, reflux; d) Hydrazine, EtOH, 
2h, reflux. 
 
The relative low yield obtained with the previously described method led us to 
modify our synthetic approach. All the other amines derivatives (23 f-n, 28 a-h) 
were prepared as reported in Scheme 5 starting from intermediate 15 and 16 
respectively, which were oxidized to aldehydes using a solution of pyridinium 
dichromate in CH2Cl2. Then reductive amination was carried out in dry 1,2 





Reagents and conditions: a) Pyridinium dicromate, CH2Cl2, 1h, r.t; b) Aliphatic amines, 
Acetic acid, NaBH(OAc)3, dry 1,2 dichloroethane, r.t. 





Deprotection of amine 23n prepared as reported in Scheme 5 was achieved using 






Reagents and conditions: a) CF3COOH, CH2Cl2,  
 
 










 28 d  30
a
 Scheme 7 
Reagents and conditions: a) CH3I, ethyl acetate, 3h, r.t. 
 




2.3. BIOLOGICAL ACTIVITY OF SYNTHESIZED COMPUNDS 
The compounds described herein were tested against influenza virus (HA), 
hepatitis C virus (HCV) and chikungunya virus (CHIKV). Cytotoxicity assays 
were also performed to evaluate the toxicity of synthesized compounds. 
2.3.1. INFLUENZA VIRUS  
The 10 used influenza virus strains were from the World Influenza Centre stock at 
NIMR, Mill Hill, London and they are reported in Table 2. 
Table 2: Virus strains tested 
             Virus name Subtype 
1. A/California/7/2009  H1N1v 
2. A/Brisbane/59/2007 H1N1 
3. A/PR8/34 (Puertorico) H1N1 
4. A/Wuhan/359/1995 H3N2 
5. AX31 H3N2 
6. A/duck/czech/56 H4N6 
7. A/Turkey/Italy/214 845 H7N3 
8. A/Ty/Ontario/6118 H8N4 
9. A/Dk/Memphis/546/74  H11N9 
10. B/Brisbane/60/06  B/Vic 
 
 
The cytotoxicity assay were performed in MDCK cell line exposed to different 
concentration of Arbidol and its analogues at 24 and 48h of treatment. Virus 
growth and titration were evaluated by hemagglutination assay. Modified enzyme-
linked immunoassay (ELISA) (Belshe et al., 1988; Grambas and Hay, 1992) was 
used to measure the inhibition of virus replication by Arbidol and its analogues. 
CC50 of compounds of alcoholic series and amines series are reported in Table 3 
and Table 4 respectively. 
 
































As is possible to note, the most part of the tested compounds showed a low 
cytotoxicity (LC) at the highest tested concentration. Compund 6 has CC50 value 
similar to that of Arbidol and it was not tested, while 23c and 28c showed an high 
cytotoxicity.  
Neutral red assay CC50 
  24h 48h 
ARBIDOL 115.2μM   
6 125 31.25 
7 LC LC 
15 LC LC 
16 LC LC 
18 LC LC 
21 LC LC 
Neutral red assay CC50 
  24h 48h   24h 48h 
ARBIDOL 115.2μM         
23a LC LC 28a 42.56μM 50.44μM 
23b LC LC 28b 30.52μM 18.9μM 
23c 52.03μM 49.67μM 28c High cytotoxicity 
23d NT NT 28d 49.3μM 90.3μM 
23 NT NT 28e 24.6μM 71.8μM 
23f 179.4μM 89.5μM 28f LC 175μM 
23g 239μM 183μM 28g LC 225μM 
23h 239μM 186.3μM 28h LC 147μM 
23i LC LC 29 LC 193μM 
23j LC LC 30 LC LC 
23k LC LC    
23l LC LC    
23m LC LC    
25 LC LC    




All the Arbidol derivatives were tested at the different concentration (from 3.9 to 
125 μM) for their ability to reduce the plaques number induced by different 
influenza virus strains in MDCK cells. The data obtained are showed in the Tables 
5-7, reported below. 
 
Table 5. Results of antiviral activity  of compounds belonging to alcoholic series 
 
 










































ARB 11.75 15.6 23.41 15.6 7.8 31.2 15.6 15.6 - 31.2 
23a 125 62.5 - 125 - - - - -  
23b 62.5 125 125 15.6 125 - - 125 125 125 
23c 7.9 7.9 7.9 15.6 7.9 15.6 15.6 31.25 15.6 125 
23d 7.9 125 - 31.50 62.5 125 125 - - - 
23e NT NT NT NT NT NT NT NT NT NT 
23f 31.25 - 31.25 - 62.5 - - - - - 
23g 31.25 - 31.25 - - - - - - - 
23h 31.25 - 31.25 - - - - - - - 
23i 31.25 - 31.25 - 62.5 - - - - - 
23j 31.25 - 31.25 - 62.5 - - - - - 
23k 31.25 - 31.25 - 62.5 - - - - - 
23l 31.25 - 31.25 - 62.5 - - - - - 
23m 31.25 - 31.25 - 15.6 - - - - - 
25 - - - - - - - - - - 
29 - - - - - - 125 - - - 













































ARB 11.75 15.6 23.41 15.6 7.8 31.25 15.6 15.6 - 31.2 
7 31.25 62.5 31.25 31.25 31.2 62.5 - - 62.25  
15 15.6 31.2 15.6 15.6 3.9 7.8 125 31.25 31.25 62.5 
16 - - - - - 125 - - 125 - 
18 7.9 125 7.9 - - 7.9 31.25 7.9 7.9 - 
21 - - - - - 125 - - 125 - 
















































ARB 11.75 15.6 23.41 15.6 7.8 31.25 15.6 15.6 - 31.2 
28a 7.9 15.6 7.9 7.9 3.9 7.9 31.25 7.9 7.9 31.25 
28b 3.9 15.6 3.9 7.9 3.9 7.9 31.25 7.9 7.9 31.25 
28c 3.9 3.45 3.9 7.9 15.6 7.9 7.9 7.9 7.9 15.6 
28d 7.9 31.25 7.9 7.9 15.6 7.9 46..8 15.6 7.9 125 
28e 7.9 31.25 7.9 7.9 15.6 7.9 31.25 15.6 7.9 - 
28f 31.25 - 31.25 - 62.5 - - - - - 
28g 31.25 - 31.25 - 62.5 - - - - - 
28h 31.25 - 31.25 - 62.5 - - - - - 
30 31.25 NT 31.25 NT 62.5 NT NT NT NT NT 
NT= not tested.  
 
 
Safety Index is the ratio between the CC50 and the IC50. 
It has been calculated only for the compounds with the lowest cytotoxicity and the 
highest capability to reduce the number of plaques. The data of TI are reported in 
the Tables 8-10 below. 
 















































ARB 7.38 7.38 7.38 7.38 14.7 14.6 7.38 1.84 - 3.68 
7 8 4 8 8 8 4 - - 4 - 
15 16.02 8 16.02 16.02 32.05 32.05 2 8 32.05 4 
16 - - - - - 2 - - 2 - 
18 31.64 2 31.64 - - 31.64 8 31.64 31.64 - 
21 - - - - 4 2 - 2 2 - 















































ARB 7.38 7.38 7.38 7.38 14.7 14.5 7.38 1.84 - 3.68 
23a ND ND ND ND ND ND ND ND ND ND 
23b ND ND ND ND ND ND ND ND ND ND 
23c - 6.58 6.58 3.33 6.58 3.33 3.33 1.66 4.42 1.66 
23d ND ND ND ND ND ND ND ND ND ND 
23e NT NT NT NT NT NT NT NT NT NT 
23f 8 - 8 - 4 - - - - - 
23g 7.6 - 7.6 - 3.82 - - - - - 
23h 7.6 - 7.6 - 3.82 - - - - - 
23i 8 - 8 - 4 - - - - - 
23j 8 - 8 - 4 - - - - - 
23k 8 - 8 - 4 - - - - - 
23l 8 - 8 - 4 - - - - - 
23m 8 - 8 - 4 - - - - - 
25 ND ND ND ND ND ND ND ND ND ND 
29 ND ND ND ND ND ND ND ND ND ND 
 
ND= not determined. NT= not tested. 
 










































ARB 7.38 7.38 7.38 7.38 14.7 14.58 7.38 1.84 - 3.68 
28a 5.38 2.72 5.38 5.38 10.9 5.38 1.36 5.38 5.38 1.36 
28b 8.03 15.6 8.03 3.33 8.03 3.86 0.97 3.86 3.86 0.97 
28c ND ND ND ND ND ND ND ND ND ND 
28d 62.4 31.25 62.4 62.4 3.16 62.4 1.05 3.16 62.4 0.39 
28e 3.11 0.78 3.11 3.11 1.57 3.11 0.78 - 3.11 - 
28f 8 - 8 - 4 - - - - - 
28g 8 - 8 - 4 - - - - - 
28h 8 - 8 - 4 - - - - - 
30 8 ND 8 ND 4 ND ND ND ND ND 
 
ND= not determined. 
 
In the alcohol series the elimination of N,N-dimethylamino methyl group in 
postion 4 of Arbidol structure as well as the bromine removal led to compound 6 




with lower antiviral activity, suggesting the importance of the N,N-dimethylamino 
methyl and bromine groups  into 5-hydroxy indole derivatives.  Homologation 
into 5-hydroxymethyl indole derivative 15 led to a potent replication inhibition, 
which is comparable to Arbidol, but no cytotoxic effect was observed, as 
confirmed by good value of safety index (SI = 19.9). The removal of thiophenol 
moiety was detrimental, since compound 16 was not active at all. Surprisingly the 
introduction of bromine in position 6 (compound 18 and 21) led to substancial 
increase of activity in compound 16 but no in compound 15. In summary, among 
these analogues compound 15 showed activity against all the tested viruses, both 
A and B type; moreover it seems to lead to a better inhibition of some viruses in 
comparison to Arbidol. It showed a better safety index for the most part of viruses 
tested compared to Arbidol and the others analogues except for compound 18. 
But, 18 was not efficient on all viruses tested and particularly didn‟t show any 
effect on B Virus.  
For the compounds belonging to the amine series, aliphatic amines possessing 
different length chains and substitutions were chosen as well as some constrained 
amines (pyrrolidine, morpholine, piperazine). In particular compounds 23c and 
28c in which it is possible to recognise the same amine of cloroquine showed very 
good antiviral activity in comparison with Arbidol, but unfortunately they were 














2.3.2. HEPATITIS C VIRUS  
Arbidol and its analogues were tested to evaluate their effect on the replication of 
Hepatitis C virus (type 1b, Con1 strain) in Cell Huh 7 cells containing 
subgenomic HCV replicons (Huh 5-2). The cytotoxicity assay were performed in 











Table 11: Anti-HCV activities and cytotoxicity of synthesized compounds in vitro 
Comps X n R R1 CC50 EC50 SI 
Arbidol     9.94 4.13 2.41 
6 Br 0 -CH2SPh -OH >146 146 ND 
7 H 0 -CH2SPh -OH >119 50 2.39 
15 H 1 -CH2SPh -OH 132 6.64 19.9 
16 H 1 -CH3 -OH 102 50 2.04 
18 Br 1 -CH3 -OH NT NT   NT 
21 Br 1 -CH2SPh -OH 115 25.6 4.37 
23a  H 1 -CH3 -N(CH3)2 17.2 3.9 4.39 
23b  H 1 -CH3 -N(CH2CH3)2 16.8 3.8 4.42 
23c  H 1 -CH3 -N(CH3)CH2CH2CH2N(CH2CH3)2 4.1 1.03 3.98 
23d  H 1 -CH3 -pyrrolidine NT NT   NT 
23e) H 1 -CH3 -N-methyl piperazine 32.5 15.2   NT 
23f  H 1 -CH3 2-piperazin-1-ylethylamino >139 61.9 2.25 
23g  H 1 CH3 -N(CH3)CH2CH2N(CH2CH3)2 15.3 2.95 5.19 
23h H 1 -CH3 -N(CH2CH3)CH2CH2N(CH2CH3)2 17.6 5.97 2.95 
23i  H 1 -CH3 NHCH2CH2NHCH3 NT NT NT 
23j  H 1 -CH3 -NHCH2CH2Ntert-butoxy carbonyl NT NT NT 
23k  H 1 -CH3 -NHCH2CH2N(CH3)2 NT NT NT 
23l  H 1 -CH3 -NHCH2CH2OH NT NT NT 
23m H 1 -CH3 -NHCH2CH2NHCH2CH2OH NT NT NT 
25 H 1 -CH3 -NH2 ND >406 ND 
28a  H 1 -CH2SPh -N(CH3)2 0.609 0.298 2.05 
28b  H 1 -CH2SPh -N(CH2CH3)2 2.29 2.12 1.08 
28c   H 1 -CH2SPh -N(CH3)CH2CH2CH2N(CH2CH3)2 <0.80 <0.80 ND 





ND= not determined. NT= not tested. CC50 (mg/ml) = 50% Cytostatic/Cytotoxic Concentration 
(concentration at which 50% adverse effect is observed in the host cells. EC50 (mg/ml) = Effective 




Significant inhibitory effect on HCV virus replication was observed for most of 
the compounds. 
In the alcohol series the elimination of dimethylamino group in postion 4 of 
Arbidol structure as well as the bromine removal were detrimental for antiviral 
activity since compound  6 and 7 have EC50=146 mg/mL and 50 mg/mL 
respectively. This suggest the importance of  the dimethylamino and bromine 
groups  into 5-hydroxy indole derivatives.   
Further homologation of both compounds gave important elucidation about 
structure activity relationship into 5-hydroxymethyl indole derivatives, because 
even if compound 15 showed a replication inhibitory effect, comparable to 
Arbidol however  it was  no cytotoxic as confirmed by good value of safety index 
(SI = 19.9).  
As observed in the case of influenza virus, the introduction of bromine in position 
6 (compound 21) didn‟t lead to an increase of activity, while the replacement of 
thiophenol moiety in position 2 by a methyl was detrimental (compound 16). In 






28d H 1 -CH2SPh -pyrrolidine 1.94 1 1 
28e  H 1 -CH2SPh -N-methyl piperazine NT NT NT 
28f  H 1 -CH2SPh -N-tert-butoxycarbonyl piperazine 24.8 11 1.94 
28g H 1 -CH2SPh -N-(2,4 difluoro)phenyl piperazine 36.2 5.17 6.99 
28h  H 1 -CH2SPh -morpholine 2.05 <0.94 2.18 
29  H 1 -CH3 -diazepan NT NT NT 










In the amines series all the compounds were highly cytotoxic even though they 
showed significant inhibitory effect on HCV virus replication. Thus structural 
modifications could be desirable to try to reduce toxicity, for example converting 
compounds 28a-h in sulfoxides: infact it know that the oxidation of sulfide into 





2.3.3. CHIKUNGUNYA VIRUS  
The effect on the replication of Chikungunya virus of Arbidol and its analogues 
were tested in vero cells. The cytotoxicity assay were performed in the same cell 
line. The results are reported in Table 12. 
Most of the compounds didn‟t show any inhibitory effect on Chikungunya virus 
replication. In the alcohol series, no activity was found and only compound 15 
showed EC50 = 56 mg/mL, higher than our lead compound. Four compounds in 
the amine series (28 b-d and 28 f) showed an interesting activity when compared 
to Arbidol, but unfortunately they have very high cytotoxicity in the host cells. It 
is worthy to note that all these compounds possess a thiophenol moiety in position 
2 of the indole nucleus, and when we compared the same compounds in which 
thiophenol moiety was removed (for example compounds 28 c and 23 c) it was 






















Fig. 9  
Table 11: Anti-CHIKV activities and cytotoxicity of synthesized compounds in vero cells 
 
ND= not determined. NT= not tested. CC50 (mg/ml) = 50% Cytostatic/Cytotoxic Concentration 
(concentration at  which 50% adverse effect is observed in the host cells. EC50 (mg/ml) = Effective 
Concentration (concentration at which  50% inhibition of virus replication is observed. SI= safety index 
(CC50/EC50). 
 
Comps X n R R1 CC50 EC50 SI 
Arbidol     83 18.4 4.52 
6 Br 0 -CH2SPh -OH >238 152 1.57 
7 H 0 -CH2SPh -OH ND >293 ND 
15 H 1 -CH2SPh -OH ND >56 ND 
16 H 1 -CH3 -OH ND >404  ND 
18 Br 1 -CH3 -OH NT NT  NT 
21 Br 1 -CH2SPh -OH ND >231 ND 
23a  H 1 -CH3 -N(CH3)2 ND >364 ND 
23b  H 1 -CH3 -N(CH2CH3)2 119 36 3.27 
23c  H 1 -CH3 -N(CH3)CH2CH2CH2N(CH2CH3)2 ND >258 ND 
23d  H 1 -CH3 -pyrrolidine NT NT   T 
23e H 1 -CH3 -N-methyl piperazine ND 304   D 
23f  H 1 -CH3 2-piperazin-1-ylethylamino ND >364 ND 
23g  H 1 CH3 -N(CH3)CH2CH2N(CH2CH3)2   ND >278 ND 
23h H 1 -CH3 -N(CH2CH3)CH2CH2N(CH2CH3)2   ND ND ND 
23i  H 1 -CH3 NHCH2CH2NHCH3 NT NT NT 
23j  H 1 -CH3 -NHCH2CH2Ntert-butoxy carbonyl NT NT NT 
23k  H 1 -CH3 -NHCH2CH2N(CH3)2 NT NT NT 
23l  H 1 -CH3 -NHCH2CH2OH NT NT NT 
23m H 1 -CH3 -NHCH2CH2NHCH2CH2OH NT NT NT 
25 H 1 -CH3 -NH2 ND 406 ND 
28a  H 1 -CH2SPh -N(CH3)2 ND ND ND 
28b  H 1 -CH2SPh -N(CH2CH3)2 21.6 4.16 5.18 
28c   H 1 -CH2SPh -N(CH3)CH2CH2CH2N(CH2CH3)2 2.93 <1.61 1.81 
28d H 1 -CH2SPh -pyrrolidine 16.6 5.41 3.07 
28e  H 1 -CH2SPh -N-methyl piperazine NT NT NT 
28f  H 1 -CH2SPh -N-tert-butoxycarbonyl piperazine 15.5 4.3 3.61 
28g H 1 -CH2SPh -N-(2,4 difluoro)phenyl piperazine ND ND ND 
28h  H 1 -CH2SPh -morpholine ND >236 ND 
29  H 1 -CH3 -diazepan NT NT NT 
30 H 1 -CH2SPh -N-methyl-pyrrolidine iodide NT NT NT 




This suggested that the introduction of thiophenol moiety is essential for the 
activity on virus replication but also responsible of cytotoxicity in the host cells. 








In conclusion a library of indole Arbidol like derivatives have been designed and 
synthesized for testing their antiviral activity on three different virus (influenza 
virus (HA), hepatitis C virus (HCV) and chikungunya virus (CHIKV)). Biological 
evaluation led us to discovery of a new potent influenza virus replication, 
identified in compound 15. This compound was also found to be a promising lead 
compound for the design of new HCV virus replication inhibitors. Thus further 
structural modifications are  planning by focusing on the thiophenol ring 
(elettronrich, elettronpoor substituents or bulky groups could be introduced) or 
replacing the methyl group on the nitrogen atom of indole nucleus with other 
moieties. Currently biological study are in course to better study mechanism 
underwent the action of compound 15, which could act non only as virus 
replication inhibitor but also as fusion inhibitor. Then a focused analysis on the 
interaction of this compound with the HA protein will be carried out. 
 
2.5. EXPERIMENTAL SECTION 
a) Biology 
i) Cell line and virus 
Madin Darby Canine Kidney (MDCK) cells were grown in Dulbecco‟s Modified 
Eagle Medium (Sigma D6429), supplemented with 10% foetal calf serum (FCS) 
inactivated 56 
o
C for 1h, Penicillin (100 μg/ml) and streptomycin (100 μg/mL) 
(Sigma P0781) in a humidified atmosphere at 5% CO2. The influenza virus strains 
tested were from the World Influenza Centre stock at NIMR, Mill Hill, London. 
Virus stocks were grown in the allantoic cavities of 11-day-old embryonated hen 




eggs for use in all the experiments. The allantoic fluid was cleared by low-speed 




ii) Virus titration  
Virus growth and titre were evaluated by hemagglutination assay. Briefly: to 50 μl 
of virus dilution (2-fold from 1:2 to 1:4096) in PBS, 50 μl of 1% for guinea pig 
red blood cells (TCS Biosciences PB031) suspension were added and incubated 
for 60 min at room temperature. The same protocol was performed using 50 μl of 
0.75% Turkey red blood cells too (from HPA, Colindale, London) and incubated 
for 30 minutes at RT. The results obtained using the two different red blood cells 
are then compared. After the incubation, the agglutinated RBCs settle as a diffuse 
layer in contrast to the control RBCs which form a compact button on the bottom 
of the wells. Haemagglutination was determined by tilting the plates and noting 
the absence of tear-shaped streaming of erythrocytes, which flow at the same rate 
as RBC controls. The highest dilution of virus that causes complete 
haemagglutination is considered the HA titration end point. The HA titre is the 
reciprocal of the dilution of virus in the last well with complete 
haemagglutination. 
iii) Cytotoxicity assay: evaluation of cell viability with neutral red assay 
The neutral red assay determines the accumulation of the neutral red dye in the 
lysosomes of viable (uninjured) cells after incubation with test agents. MDCK 
cells were plated in 96-well and incubated for 24 h in a humidified atmosphere at 
5% CO2. The cells were exposed to the compounds, dissolved in DMEM with 5% 
FCS at different concentration (250 μM, 125 μM, 62.5 μM, 31.25 μM, 15.6 μM, 
7.8 μM and 3.9 μM), and incubated for 24h and 48h. 
Then, cells were washed with PBS and incubated for 2 h with neutral red dye (3-
amino-7-dimethylamino-2-methyl-phenazine hydrochloride-Sigma, N4638) 
dissolved in serum free medium (DMEM) at a final concentration of 40 µg/mL. 
Cells were then washed again with a PBS solution, to remove the dead cells. The 
dye was then extracted from the intact cells with a 1% glacial acetic acid in 50% 
ethanol destaining solution (Glacial acetic acid Sigma, 537020; Ethanol Riedel-de 
Haen, 32294). The absorbance of the solution was read at spectrofluorimeter with 




excitation and emission wavelengths of 530 and 645 nm, respectively. The 
absorbance recorded is related to the concentration of viable cells. Three 
independent experiments were performed and the CC50 (drug concentration 
required to reduce cell growth by 50%) was calculated at 24h and 48h. 
iv) Plaque reduction assay 
A modified enzyme-linked immunoassay (ELISA) (Belshe et al., 1988; Grambas 
and Hay, 1992) was used to measure the inhibition of virus replication by Arbidol 
and its analogues. Briefly, MDCK cells 3x10
3
 cells per well were seeded in 96-
well plates in DMEM containing 10% FBS, 100U/ml penicillin, 100 μg/mL 
streptomycin sulphate. Cells were incubated at 37 
◦
C at 5% CO2 until 90% cell 
confluence was reached, then the cells were washed four times with fresh DMEM 
with pen/strep. Each micro-titre plate included uninfected control wells, virus-
infected control wells and virus-infected wells to which ARB or its derivatives 
were added. Each compound was two-fold serial diluted to obtain different 
concentration from 125 to 3.9 μM and added to the MDCK monolayer. After 
incubation for 30 min at 37 
◦
C, 100 μl of virus-containing allantoic fluid 
(approximately 0.1 PFU/cell) was added to each well, except uninfected control 
cells. After 3h of infection, cells were overlaid with DMEM medium 
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All reagents were analytical grade and purchased from Sigma–Aldrich (Milano, 
Italy). Flash chromatography was performed on Carlo Erba silica gel 60 (230–400 
mesh; CarloErba, Milan, Italy). TLC was carried out using plates coated with 





NMR spectra were registered on a Brucker AC 300. Chemical shifts are reported 
in ppm. The abbreviations used are follows: s, singlet; d, doublet; dd double 




doublet; bs, broad signal. MS spectrometry analysis ESI-MS was carried out on a 
Finnigan LCQ Deca ion trap instrument. Microanalyses were carried out on a 
Carlo Erba 1106 elemental analyzer. Melting points were performed by Stuart 
melting point SMP30 and are uncorrected. 
 
d) Procedures and characterization data 
Ethyl 5-acetoxy-2-methyl-1H-indole-3-carboxylate (2) 
A mixture of ethyl 5-hydroxy-2-methyl-1H-indole-3-carboxylate (1) (3 g, 13.55 
mmol), acetic anhydride (26 mL, 270 mmol) and pyridine (3.32 mL, 40.65 mmol) 
was refluxed for 1h. The cooled reaction medium was then poured into saturated 
sodium bicarbonate solution. After extraction with ethyl acetate, the combined 
organic layers were washed with water, dried over sodium sulfate anhydrous and 
then concentrated. The product was purified by flash chromatography using 
hexane/ethyl acetate (7/3). 
Nature of compound:  White powder; Yield: 74%. 
 
1
H NMR (300 MHz, CDCl3) δ 8.32 (N-H), 7.75 (d, J = 1.76 Hz, 1H), 7.24 (d, J = 
8.79 Hz, 1H), 6.90 (dd, J = 8.79, 1.76 Hz, 1H), 4.38 (q, J = 7.1 Hz, 2H), 2.73 (s, 
3H), 2.34 (s, 3H), 1.43 (t, J = 7.1 Hz, 3H). 
MS (ESI): m/z = 262 [M + H
+
]. 
Anal. Calcd for C14H15NO4: C, 64.36; H, 5.79; N, 5.36. Found: C, 64.52; H, 5.30; 
N, 6.68. 
Ethyl 5-acetoxy-1, 2-dimethyl-1H-indole-3-carboxylate (3) 
A mixture of ethyl 5-acetoxy-2-methyl-1H-indole-3-carboxylate (2) (1.86 g, 6.96 
mmol) and anhydrous DMF (30 mL) was stirred at rt until clear, and then 60% 
NaH (0.255 g, 10.44 mmol) and iodomethane (1.31 mL, 20.37 mmol) were added. 
The mixture was stirred at rt for 1 h, The resulting mixture was poured into H2O, 
and extracted with ethyl acetate. The organic phase was washed with water and 
brine, then dried over anhydrous sodium sulfate, filtered and evaporated. The 
residue obtained was purified by silica column chromatography with hexane/ethyl 
acetate (8/2) as an eluent.  
Nature of compound:  White powder; Yield: 70%. 





H NMR (300 MHz, CDCl3) δ 7.77 (d, J = 1.76 Hz, 1H), 7.25 (d, J = 8.79 Hz, 
1H), 6.93 (dd, J = 8.79, 1.76 Hz, 1H), 4.37 (q, J = 7.1 Hz, 2H), 3.67 (s, 3H), 2.75 
(s, 3H), 2.32 (s, 3H), 1.42 (t, J = 7.1 Hz, 3 H). 
MS (ESI): m/z = 298 [M + Na
+
]. 
Anal. Calcd for C15H17NO4: C, 65.44; H, 6.22; N, 5.09. Found: C, 65.27; H, 6.65; 
N, 5.43. 
Ethyl 5-acetoxy-2-(bromomethyl)-1-methyl-1H-indole-3-carboxylate (4) and 
ethyl 5-acetoxy-6-bromo-2-(bromomethyl)-1-methyl-1H-indole-3-carboxylate 
(5) 
Ethyl 5-acetoxy-1, 2-dimethyl-1H-indole-3-carboxylate (3) (0.814 g, 2.89 mmol) 
and N-bromosuccinimide (0.521 g, 2.89 mmol) were dissolved in degassed CCl4 
(100 mL). Benzoyl peroxide (50 mg, 0.20 mmol) was added and the reaction was 
refluxed over night.  The solution was cooled to rt and diluted with CH2Cl2. The 
organic phase was washed with water, brine and dried over anhydrous Na2SO4. 
The product was purified by flash chromatography using toluene/ethyl acetate 
(95/5) as an eluent.  
Nature of compound: Pale yellow powder; Yield: 46%. 
 
1
H NMR (300 MHz, CDCl3) δ 7.84 (d, J = 1.76 Hz, 1H), 7.34 (d, J = 8.79 Hz, 
1H), 7.04 (dd, J = 8.79, 1.76 Hz, 1H), 5.16 (s, 2H), 4.44 (q, J = 7.1 Hz, 2H), 3.82 
(s, 3H), 2.34 (s, 3H), 1.46 (t, J = 7.1 Hz, 3H). 
MS (ESI): m/z = 355 [M + H
+
]. 
Anal. Calcd for C15H16BrNO4: C, 50.86; H, 4.55; N, 3.95. Found: C, 50.47; H, 
4.65; N, 3.43. 
 
From this purification we recovered also ethyl 5-acetoxy-6-bromo-2-
(bromomethyl)-1-methyl-1H-indole-3-carboxylate (5).  
Nature of compound: Pale yellow powder; Yield: 6%. 
 1
H NMR (300 MHz, CDCl3) δ 7.87 (s, 1H), 7.55 (s, 1H), 5.08 (s, 2H), 4.42 (q, J 








General procedures for (6 and 7) 
To a solution containing KOH (3.0 eq.) in 1 mL of methanol at room temperature 
different thiophenols were added (1 eq). After 15 minutes, 4 or 5 (1 eq.) was also 
added. The mixture was allowed to stay to room temperature for 3 h followed by 
neutralizing with a diluted acetic acid. The mixture was evaporated and the 
product was purified by flash chromatography. 
 
Ethyl 5-hydroxy-1-methyl-2-(phenylthiomethyl)-1H-indole-3-carboxylate (6) 
Elution with hexane/ethyl acetate (7.5/2.5).  
Nature of compound: White powder; Yield: 93 %; mp. 168°C-172 °C. 
1
H NMR (DMSO-d6): 9.02 (s, OH), 7.19-7.39 (m, 7H), 6.73 (dd, J = 8.79, 1.76 
Hz, 1H), 4.82 (s, 2H), 4.20 (q, J = 7.1 Hz, 2H), 3.67 (s, 3H), 1.28 (t, J = 7.1 Hz, 
3H). 
MS (ESI):m/z = 364.42 [M + Na
+
].  
Anal. calcd for C19H19NO3S: C, 66.84; H, 5.61; N, 4.10; S, 9.39, Found: C, 66.79; 
H, 5.55; N, 4.04; S, 9.44 
Ethyl 6-bromo-5-hydroxy-1-methyl-2-(phenylthiomethyl)-1H-indole-3-
carboxylate (7) 
Elution with hexane/ethyl acetate (9/1)  
Nature of compound : Pale yellow powder; Yield: 41%. mp. 165-169 °C. 
1
H NMR (300 MHz, CDCl3) δ 7.72 (s, 1H), 7.48 (s, 1H), 7.28-7.43 (m, 5H), 4.72 
(s, 2H), 4.42 (q, J = 7.1 Hz, 2H), 3.64 (s, 3H), 1.43 (t, J = 7.1 Hz, 3H). 
MS (ESI): m/z =  443.32  [M + Na
+
].  
Anal. calcd for C19H18BrNO3S: C, 54.29; H, 4.32; Br, 19.01; N, 3.33; S, 7.63, 
Found: C, 54.34; H, 4.22; Br, 19.07; N, 3.30; S, 7.55. 
General procedure for the synthesis of compounds (11 and 12)  
A mixture of amine 8 (4.17 mmol), ethyl-3-oxo-4 (phenylthio) butanoate (9) or 
ethylacetoacetate (10) (4.58 mmol), CuI (0.42 mmol), BINOL (0.500 mmol) and 
Cs2CO3 (4.17 mmol) in dry DMSO (15 mL) was stirred at 50 °C for 7 h under an 
atmosphere of nitrogen. The mixture was partitioned between ethyl acetate and 
saturated NH4Cl, the organic layer was washed with brine, dried over anhy. 




MgSO4 and concentrated on vacuum, affording a dark oil. The residue was 
purified by flash chromatography (hexane/ethyl acetate 9/1). 
Ethyl 2-(phenylsulphanylmethyl) 5-((tert-butyldimethylsilyloxy)methyl)-1H-
indole-3 carboxylate  (11)  
Nature of compound: White solid; Yield: (0.700 g) 37%. 
1
H NMR (300 MHz, CDCl3): δ 8.98 (s, 1H), 8.03 (s, 1H), 7.28-7.34 (m, 7H), 4.80  
(s, 2H), 4.72 (s, 2H), 4.41 (q, J = 7.2 Hz, 2H), 1.46 (t, J = 7.2 Hz, 3H), 0.97 (s, 
9H), 0.13 (s, 6H). 
MS (ESI): m/z =  478.20 [M + Na
+
].  
Anal. calcd for C25H33NO3SSi: C, 65.89; H, 7.30; N, 3.07; S, 7.04, Found: C, 
65.34; H, 7.22; N, 3.30; S, 7.55. 
Ethyl 2-methyl 5-((tert-butyldimethylsilyloxy)methyl)-1H-indole-3 
carboxylate (12)  
Nature of compound : White solid; Yield: (0.235 g). 56%.  
1
H NMR (300 MHz, CDCl3): δ 8.10 (s, 1H), 8.08 (s, 1H), 7.28 (br s, 2H), 4.88 (s, 
2H), 4.41 (q, J = 7.2 Hz, 2H), 2.79 (s, 3H), 1.46 (t, J= 7.2 Hz, 3H), 0.97 (s, 9H), 
0.13 (s, 6H). 
MS (ESI): m/z =  370.19 [M + Na
+
].  
Anal. calcd for C19H29NO3Si: C, 65.67; H, 8.41; N, 4.03. Found: C, 65.34; H, 
8.22; N, 4.30. 
 
General procedure for the synthesis of compounds (13 and 14) 
To a solution of compound 11 or 12 (1.52  mmol) in acetone (20 mL), KOH 
pellets (7.65 mmol) was added. After 30 minutes, CH3I (191 µL, 3.04 mmol) was 
added dropwise and the mixture was allowed to stirred for 1h. The solvent was 
removed, the residue taken up with ethyl acetate and washed with brine. The 








Ethyl 1-methyl 2-(phenysulphanyl)methyl) 5-((tert-
butyldimethylsilyloxy)methyl)-1H-indole-3 carboxylate (13)  
Nature of compound : White solid; Yield: (0.702 g) 98%. 
 
1
H NMR (300 MHz, CDCl3): δ 8.03 (s, 1H) 7.28-7.34 (m, 7H), 4.80 (s, 2H), 4.72 
(s, 2H), 4.41 (q, J = 7.2 Hz, 2H), 3.79 (s, 3H), 1.46 (t, J= 7.2 Hz, 3H), 0.97 (s, 
9H), 0.13 (s, 6H). 
MS (ESI): m/z =  492.21 [M + Na
+
].  
Anal. calcd for C26H35NO3SSi: C, 66.48; H, 7.51; N, 2.98; S, 6.83, Found: C, 
66.34; H, 7.72; N, 2.40; S, 6.25. 
Ethyl 1, 2-dimethyl 5-((tert-butyldimethylsilyloxy) methyl)-1H-indole-3 
carboxylate (14)  
Nature of compound : White solid; Yield: (0.380 g). 82%.  
1
H NMR (300 MHz, CDCl3): δ 8.08 (s, 1H), 7.28 (br s, 2H), 4.88 (s, 2H), 4.41 (q, 
J = 7.2 Hz, 2H), 3.72 (s, 3H), 2.79 (s, 3H), 1.46 (t, J = 7.2 Hz, 3H), 0.97 (s, 9H), 
0.13 (s, 6H). 
MS (ESI): m/z =  362.55 [M + H
+
].  
Anal. calcd for C20H31NO3Si: C, 66.44; H, 8.64; N, 3.87. Found: C, 66.67; H, 
8.97; N, 3.30. 
General procedure for the synthesis of compounds (15 and 16) 
A solution of compound 13 or 14 (0.895 mmol) in  THF (8 mL) was chilled at 0 
°C and tetrabutylammonium fluoride (1.0 ml, 1.0 mmol, 1 M in THF) was added 
keeping the reaction under magnetic stirring for 2 h. The reaction was quenched 
by the addition of saturated aqueous solution of NaHCO3 (15 ml). Then water (10 
mL) was added and the product was extracted with ethyl acetate (3 × 5 mL). The 
combined organic layer were dried over anhydrous MgSO4 and evaporation of the 










carboxylate (15)  
Nature of compound: White solid; Yield: (0.702 g) 98%.
 
Mp: 111-112 °C.  
1
H NMR (300 MHz, CDCl3): δ 8.08 (s, 1H), 7.25-7.35 (m, 7H), 4.81 (s, 2H), 4.68 
(s, 2H), 4.27 (q, J = 7.2 Hz, 2H), 3.81 (s, 3H), 1.39 (t, J = 7.2 Hz, 3H). 
MS (ESI): m/z =  356.12  [M + H
+
].  
Anal. calcd for C20H21NO3S: C, 67.58; H, 5.95; N, 3.94; S, 9.02, Found: C, 68.34; 
H, 5.12; N, 3.30; S, 8.55. 
Ethyl 1, 2-dimethyl-5-(hydroxymethyl)-1H-indole-3-carboxylate (16)  
Nature of compound : White solid; Yield: (0.700 g) 93%. 
 
1
H NMR (300 MHz, CDCl3): δ 8.13 (s, 1H), 7.31 (br s, 2H), 4.82 (s, 2H), 4.43 
(q, J = 7.2 Hz, 2H), 3.74 (s, 3H), 2.80 (s, 3H), 1.47 (t, J = 7.2 Hz, 3H). 
MS (ESI): m/z =  270.12  [M + Na
+
].  
Anal. calcd for C14H17NO3: C, 68.00; H, 6.93; N, 5.66, Found: C, 67.34; H, 6.12; 
N, 5.10. 
Ethyl-6-bromo-1,2-dimethyl-5-((tert-butyldimethylsilyloxy)methyl)-1H-
indole-3 carboxylate  (17)  
A solution of 14 (0.110 g, 0.301 mmol) in CCl4 (5 mL) was brought to reflux: N-
bromosuccinimide (0.54 g, 0.301 mmol) and dibenzoyl peroxide (0.04 g, 0.015 
mmol) were then added. The mixture was stirred at reflux temperature for 2h. The 
solid was filtered off, the filtrate concentrated and then  purified by flash 
chromatography (toluene/acetone 98/2) recovering a 0.021 g of a white solid.  
Nature of compound: White solid; Yield: (0.040 g) 34% 
1
H NMR (300 MHz, CDCl3): δ 8.08 (s, 1H), 7.32 (s, 1H), 4.88 (s, 2H), 4.41 (q, J 
= 7.2 Hz, 2H), 3.72 (s, 3H), 2.79 (s, 3H), 1.46 (t, J = 7.2 Hz, 3H), 0.97 (s, 9H), 
0.13 (s, 6H). 
MS (ESI): m/z =  462.12  [M + Na
+
].  
Anal. calcd for C20H30BrNO3Si: C, 54.54; H, 6.87; Br, 18.14; N, 3.18, Found: C, 
54.03; H, 6.22; Br, 17.07; N, 3.30. 
 
 




Ethyl 6-bromo-1,2-dimethyl-5-(hydroxymethyl)-1H-indole-3-carboxylate (18) 
Prepared as described for compounds 15 and 16.  
Nature of compound: White solid; Yield: (0.094 g) 90%.  
1
H NMR (300 MHz, CDCl3): δ 8.17 (s, 1H), 7.51 (s, 1H), 4.82 (s, 2H), 4.43 (q, J 
= 7.2 Hz, 2H), 3.75 (s, 3H), 2.81 (s, 3H), 1.45 (t, J = 7.2 Hz, 3H). 
MS (ESI): m/z = 326.03  [M + H
+
].  
Anal. calcd for C14H16BrNO3: C, 51.55; H, 4.94; Br, 24.50; N, 4.29, Found: C, 
52.13; H, 3.72; Br, 23.67; N, 3.90. 
Ethyl 6-bromo 5-formyl 2-(bromomethyl)-1-methyl-1H-indole-3 carboxylate 
(19)  
Prepared as described for compound 17 using 2.25 equivalents of N-
bromosuccinimide. Purified by flash chromatography (toluene/acetone 98/2) 
recovering a 0.021 g of a white solid. 
Nature of compound: White solid; Yield: 15%.
   
1
H NMR (300 MHz, CDCl3): δ 10.4 (s, 1H), 8.74 (s, 1H), 7.62 (s, 1H), 5.15 (s, 
2H), 4.49 (q, J = 7.2 Hz, 2H), 3.85 (s, 3H), 1.51 (t, J = 7.2 Hz, 3H). 
MS (ESI): m/z = 423.93  [M + Na
+
].  
Anal. calcd for C14H13Br2NO3: C, 41.72; H, 3.25; Br, 39.65; N, 3.48, Found: C, 
40.37; H, 3.01; Br, 38.07; N, 2.90. 
Ethyl-6-bromo-2-(bromomethyl)-5-(hydroxymethyl)-1-methyl-1H-indole-3 
carboxylate (20)  
To an ice-cooled solution of the aldehyde 19 (0.021 g, 0.052 mmol) in THF (1 
mL) was added NaBH4 (0.003 g, 0.062 mmol) in methanol (500 µL). Then, the 
resulting mixture was stirred at rt for 1h. After complete conversion, the solvent 
was distilled off under reduced pressure to afford almost pure product (0.020 g).  
Nature of compound: Oil; Yield: (20 mg) 99%.
  
 1
H NMR (300 MHz, CDCl3): δ 8.21 (s, 1H), 7.56 (s, 1H), 5.12 (s, 2H), 4.84 (s, 
2H), 4.42 (q, J = 7.2 Hz, 2H), 3.78 (s, 3H), 1.44 (t, J = 7.2 Hz, 3H).  
MS (ESI): m/z =  403.94  [M + H
+
].  
Anal. calcd for C14H15Br2NO3: C, 41.51; H, 3.73; Br, 39.45; N, 3.46, Found: C, 
41.01; H, 2.92; Br, 38.77; N, 2.80. 





indole-3 carboxylate (21) 
Prepared as described for compound 6 and 7 using ethanol as solvent. Purified 
using toluene/ethyl acetate (8/2) recovering a white solid (12 mg).  
Nature of compound: White solid; Yield: (12 mg) 56%. 
 
1
H NMR (300 MHz, CDCl3): δ 8.18 (s, 1H), 7.55 (s, 1H), 4.86 (s, 2H), 4.71 (s, 
2H), 4.29 (q, J = 7.2 Hz, 2H), 3.66 (s, 3H), 1.38 (t, J = 7.2 Hz, 3H). 
MS (ESI): m/z = 456.03  [M + Na
+
].  
Anal. calcd for C20H20BrNO3S: C, 55.30; H, 4.64; Br, 18.40; N, 3.22; S, 7.12, 
Found: C, 55.03; H, 4.27; Br, 18.07; N, 3.50; S, 7.76. 
Ethyl 5-(chloromethyl)-1,2-dimethyl-1H-indole-3-carboxylate (22)  
Compound 16 (0.400 g, 1.60 mmol) was dissolved in CCl4 and 
triphenylphosphine was added, followed by the addition of 3 mL of DMF. The 
mixture was stirred for 16h, then the solvent was removed and the residue taken 
up with ethyl acetate, washed with water. The organic layer was dried over 
anhydrous MgSO4 to afford oil, purified by chromatography (hexane/ethyl acetate 
6/4).  
Nature of compound: Yellow oil; Yield: (0.280 g) 66%.
   
1
H NMR (400 MHz, CDCl3): δ 8.13 (s, 1H), 7.31 (s, 2H), 4.98 (s, 2H), 4.41 (q, J 
= 7.2 Hz, 2H), 3.69 (s, 3H), 2.73 (s, 3H), 1.47 (t, J = 7.2 Hz, 3H). 
MS (ESI): m/z =  288.09  [M + Na
+
].  
Anal. calcd for C14H16ClNO2: C, 63.28; H, 6.07; Cl, 13.34; N, 5.27, Found: C, 
62.73; H, 5.97; Cl, 12.87; N, 4.90. 
 
General procedure for the synthesis of amines (23a-e) 
A solution of compound 22 (1 equiv.), amines (2 equiv.) and cesium carbonate 
(0.1 equiv.) in dry DMF (2 mL) was magnetically stirred under reflux overnight. 
The mixture was diluted with ethyl acetate and washed twice with a solution of 
saturated aqueous solution of NaHCO3: evaporation of the solvent of the organic 
layer gave a dark oil purified by flash chromatography.  
 






Purified with CHCl3/MeOH 9.5/0.5.  
Nature of compound: Yellow oil; Yield: (0.084 g) 63%. 
 
1
H NMR (300 MHz, CDCl3): δ 8.03 (s, 1H), 7.28 (s, 2H), 4.43 (q, J = 7.2 Hz, 
2H), 3.71 (s, 3H), 3.58 (s, 2H), 2.79 (s, 3H), 2.29 (s, 6H), 1.48 (t, J = 7.2 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ 166.7, 143.9, 136.3, 124.8, 123.9, 120.3, 118.7, 
111.4, 103.7, 65.8, 45.3, 35.8, 15.3, 6.1. 
MS (ESI): m/z =  297.17  [M + Na
+
].  
Anal. calcd for C16H22N2O2: C, 70.04; H, 8.08; N, 10.21, Found: C, 69.73; H, 
7.97; N, 9.90. 
Ethyl 5-((diethylamino)methyl)-1,2-(dimethyl)-1H-indole-3-carboxylate (23b) 
Purified with CHCl3/MeOH 9.5/0.5.  
Nature of compound: Yellow oil; Yield: (0.068 g) 67%.  
1
H NMR (300 MHz, CDCl3): δ 8.07 (s, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.32 (d, J = 
8.4 Hz, 1H), 4.36 (q, J = 7.2 Hz, 2H), 4.19 (s, 2H), 3.68 (s, 3H), 2.96 (q, J = 7.2 
Hz, 4H), 2.73 (s, 3H),  1.36-1.43 (m, 9H). 
13
C NMR (75 MHz, CDCl3): δ 166.3, 141.7, 136.7, 124.3, 123.7, 120.1, 118.3, 
111.4, 103.5, 61.8, 60.3, 49.3, 35.8, 14.3, 13.4, 5.5. 
MS (ESI): m/z = 303.21 [M + H
+
].  




Elution with Hexane/Ethyl acetate 7/3. 
Nature of compound: Yellow oil; Yield: (0.080 g) 96%. 
 
1
H NMR (300 MHz, CDCl3): δ 7.99 (s, 1H), 7.21 (s, 2H), 4.35 (q, J = 7.2 Hz, 
2H), 3.89 (app q, J = 11.7 Hz, 2H, AB system), 2.70 (s, 3H ), 3.62 (s, 3H), 2.36-
2.48 (m, J = 7.2 Hz, 7H), 1.36-1.50 (m, 5H), 1.11 (d, J= 5 Hz, 3H,), 0.99 (t, J = 
7.4 Hz, 6H). 





C NMR (75 MHz, CDCl3): δ 166.2, 140.3, 136.2, 124.4, 123.1, 120.7, 118.7, 
111.3, 103.2, 62.8, 61.1, 54.2, 51.8, 49.1, 43.3, 35.6, 25.2, 14.1, 13.4, 5.3. 
MS (ESI): m/z = 374.87 [M + H
+
].  
Anal. calcd for C22H35N3O2: C, 70.74; H, 9.44; N, 11.25, Found: C, 70.93; H, 
9.77; N, 10.97. 
 
Ethyl- 1,2-dimethyl-5-(pyrrolidin-1-ylmethyl)-1H-indole-3-carboxylate (23d) 
White powder (0.139 g). Yield: 62%. 
1







Elution with hexane/ethyl acetate 7/3. 
Nature of compound: Yellow oil; Yield: (0.090 g) 7%.  
1
H NMR (300 MHz, CDCl3): δ 8.04 (s, 1H), 7.27 (s, 2H), 4.32 (q, J = 7.2 Hz, 
2H), 3.69 (s, 3H), 3.58 (s, 2H), 2.79 (s, 3H), 2.41 (s, 8H), 2.33 (s, 3H), 1.41 (t, J = 
7.2 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ 166.4, 140.7, 136.5, 124.7, 123.3, 120.4, 118.6, 
111.3, 103.2, 61.9, 60.3, 55.2, 52.7, 43.1, 35.9, 14.3, 5.7. 
MS (ESI): m/z = 330.47 [M + H
+
].  
Anal. calcd for C19H27N3O2: C, 69.27; H, 8.26; N, 12.76, Found: C, 68.93; H, 
8.83; N, 11.47. 
Ethyl-1, 2-dimethyl-5-((1, 3-dioxoisoindolin-2-yl)methyl)-1H-indole-3-
carboxylate (24)  
A solution of compound 22 (0.135 g, 0.503 mmol) and potassium phtalimide 
(0.095 g, 0.508 mmol) in DMF (2 mL) was stirred under reflux for 2 h. Ethyl 
acetate was added to the mixture and the organic layer washed with 10% HCl, 
was dried over anhydrous MgSO4 to give a white solid purified by 
chromatography (petroleum ether/ethyl acetate 8/2). 
Nature of compound:  White solid; Yield: (0.165 g) 87%.
   
1
H NMR (400 MHz, CDCl3): δ 8.13 (s, 1H), 7.31 (s, 6H), 4.90 (s, 2H), 4.41 (q, J 
= 7.2 Hz, 2H), 3.69 (s, 3H), 2.73 (s, 3H), 1.47 (t, J = 7.2 Hz, 3H). 





C NMR (75 MHz, CDCl3): δ 169.2, 166.9, 141.3, 135.3, 133.3, 133.1, 132.2, 
128.6, 127.1, 119.2, 117.4, 111.9, 104.3, 61.4, 43.6, 35.8, 14.9, 6.1. 
MS (ESI): m/z =  399.33  [M + Na
+
].  
Anal. calcd for C22H20N2O4: C, 70.20; H, 5.36; N, 7.44, Found: C, 70.03; H, 4.97; 
N, 6.90. 
Ethyl 5-(aminomethyl)-1,2-dimethyl-1H-indole-3-carboxylate (25)  
To a stirred solution of 24 (0.132 g, 0.347 mmol) in absolute EtOH (2 mL) and 
hydrazine (61 µL, 0.69 mmol) were added and the mixture was kept under reflux 
for 2h. The solid residue was filtered off. After evaporation of the filtrate, the 
residue was taken up with EtOAc and extracted with 2N HCl; then, the aqueous 
phase was treated with 2N NaOH and extracted several times with EtOAc. The 
combined organic layers were dried (Na2SO4) and concentrated under vacuum to 
give pure product. 
Nature of compound: slightly yellowish oil; Yield: (0.065 g) 75%.
  
 1
H NMR (250 MHz, CD3OD): δ 7.99 (s, 1H), 7.31 (br s, 2H), 4.43 (q, J = 7.2 Hz, 
2H), 3.97 (s, 2H), 3.74 (s, 3 H), 2.70 (s, 3H), 1.42 (t, J = 7.2 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ 167.6, 141.2, 1136.6, 1129.9, 124.7, 118.6, 109.1, 
103.8, 59.6, 52.2, 35.2, 14.7, 5.8. 
MS (ESI): m/z =  269.13  [M + Na
+
].  
Anal. calcd for C14H18N2O2: C, 68.27; H, 7.37; N, 11.37, Found: C, 68.03; H, 
7.27; N, 10.98. 
General procedure for the synthesis of aldehydes (26) and (27) 
To a solution of pyridinium dicromate (6.68 mmol) in dichloromethane (50 mL), 
compound 15, 16 (1.671 mmol) previously dissolved in dichloromethane (5 mL) 
was added and the mixture was allowed to stirred for 1 h at room temperature. 
Evaporation of the solvent under reduced pressure gave an oil, which was purified 








Ethyl -5-formyl-1-methyl-2 (phenyl sulphanylmethyl)-1H-indole-3 
carboxylate (26)  
Nature of compound: White solid; Yield: (0.500 g) 86%.  
1
H NMR (250 MHz, CDCl3): δ 10.07 (s, 1H), 8.61 (s, 1H), 7.86 (d, J = 8.1 Hz, 
1H,), 7.39 (d, J = 8.1 Hz, 1H,), 7.25-7.35 (m, 5H), 4.74 (s, 2H), 4.27 (q, J = 7.2 
Hz, 2H), 3.75 (s, 3H), 1.37 (t, J = 7.2 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ 192.0, 166.7, 142.7, 140.8, 136.5, 135.9, 128.7, 
126.7, 125.3, 121.9, 113.7, 111.6, 102.7, 60.9, 35.3, 22.7, 14.7. 
MS (ESI): m/z =  376.53  [M + Na
+
].  
Anal. calcd for C20H19NO3S: C, 67.97; H, 5.42; N, 3.96, S, 9.07, Found: C, 67.03; 
H, 5.97; N, 3.90; S, 8.86. 
Ethyl 1, 2-dimethyl-5-formyl-1H-indole-3-carboxylate (27)
10
 
White solid (0.139 g). Yield: 86%.
 1
H NMR data are in agreement with those 
reported in literature.
10 
General procedure for the synthesis of amines derivatives 28a-f and 23f-n  
Under nitrogen atmosphere aldehyde 26 or 27 (1.0 equiv.) was dissolved in dry 
dichloroethane (5 mL) and under magnetic stirring amines (4.0 equiv.), acetic acid 
(1.05 equiv.) and NaBH(OAc)3 (6.0 equiv.) were added respectively. After 
completion of the reaction as monitored by thin layer chromatography (TLC), a 
solution of saturated aqueous solution of NaHCO3 (15 ml) was added and the 
product was extracted with ethyl acetate (3 × 5 mL). The combined organic layer 
was dried over anhydrous MgSO4 and evaporation of the solvent under reduced 
pressure gave a mixture purified by flash chromatography.  
Ethyl-5-(dimethylaminomethyl)-1-methyl-2-(phenylsulfanylmethyl)-1H-
indole-3-carboxylate (28a)  
Purified using CHCl3/MeOH/NH3 1/1/0.1.  
Nature of compound: Beige solid; Yield: (0.140 g) 97%.  
 
1
H NMR (250 MHz, CDCl3): δ 8.00 (s, 1H), 7.19-7.34 (m, 7H), 4.67 (s, 2H), 
4.29 (q, J = 7 Hz, 2H), 3.60 (s, 3H), 3.57 (s, 2H), 2.27 (s, 6H), 1.36 (t, J = 7.1 Hz, 
3H). 





C NMR (75 MHz, CDCl3): δ 167.0, 141.9, 137.1, 129.5, 127.3, 126.2, 125.9, 
120.4, 111.3, 103.4, 65.7, 61.4, 46.7, 35.8, 23.1, 14.3. 
MS (ESI): m/z = 383.51 [M + H
+
].  
Anal. calcd for C22H26N2O2S: C, 69.08; H, 6.85; N, 7.32; S, 8.38, Found: C, 
68.97; H, 6.73; N, 7.18; S, 8.23. 
Ethyl-5-(diethylaminomethyl)-1-methyl-2-(phenylsulfanylmethyl)-1H-indole-
3-carboxylate (28b) 
Purified using Ethyl acetate/MeOH/NH3 1/1/0.1. 
Nature of compound: Dark oil; Yield: (83 mg) 90%. 
 
1
H NMR (300 MHz, CDCl3): δ 8.12 (s, 1H), 7.17-7.47 (m, 7H), 4.75 (s, 2H), 
4.32 (q, J = 7.2 Hz, 2H), 3.76 (s, 2H), 3.68 (s, 3H), 2.60 (q, J = 7.2 Hz, 4H), 1.40 
(t, J = 7.2 Hz, 3H), 1.12 (t, J = 7.2 Hz, 6H). 
13
C NMR (75 MHz, CDCl3): δ 166.3, 141.9, 137.1, 135.3, 130.1, 127.6, 127.1, 
126.1, 125.9, 120.8, 119.0, 111.3, 104.3, 61.3, 60.8, 49.8, 35.9, 23.3, 15.1, 13.8. 
MS (ESI): m/z = 411.63 [M + H
+
].  
Anal. calcd for C24H30N2O2S: C, 70.21; H, 7.36; N, 6.82; S, 7.81, Found: C, 
70.14; H, 7.23; N, 6.78; S, 7.73. 
Ethyl-5-[4-(diethylamino)-1-methyl-butyl]amino]methyl]-1-methyl-2-
(phenylsulfanylmethyl) 1H-indole-3-carboxylate (28c) 
Purified using CHCl3/MeOH/NH3 1/1/0.3  
Nature of compound: Yellow oil; Yield: (0.080 g) 96%. 
 
1
H NMR (300 MHz, CDCl3): δ 8.02 (s, 1H), 7.32-7.36 (m, 2H), 7.21-7.25 (m, 
5H), 4.71 (s, 2H), 4.29 (q, J = 6.75 Hz, 2H), 3.89 (app q, J = 11.7 Hz, 2H, AB 
system), 3.64 (s, 3H), 2.69-2.76 (m, 1H), 2.50 (q, J = 7.5 Hz, 4H), 2.36-2.42 (m, 
2H), 1.41-1.48 (m, 3H), 1.36 (t, J = 6.95 Hz, 3H), 1.11 (d, J = 6.2 Hz, 3H), 0.99 
(t, J = 7 Hz, 6H). 
13
C NMR (75 MHz, CDCl3): δ 166.7, 140.9, 137.1, 135.4, 129.9, 127.3, 127.1, 
126.1, 125.9, 121.1, 119.3, 111.9, 104.3, 64.3, 61.4, 55.2, 52.8, 50.5, 44.3, 36.2, 
26.1, 23.6, 15.1, 13.4. 
MS (ESI): m/z = 482.74 [M + H
+
].  




Anal. calcd for C28H39N3O2S: C, 69.82; H, 8.16; N, 8.72; S, 6.66, Found: C, 
69.74; H, 8.10; N, 8.66; S, 6.55. 
Ethyl-1-methyl-2-(phenylsulfanylmethyl)-5-(pyrrolidin-1-ylmethyl)-1H-
indole-3-carboxylate (28d)  
Purified using CHCl3/MeOH/NH3 1/1/0.2  
Nature of compound: Yellow solid; Yield: (0.098 g) 95%.  
1
H NMR (300 MHz, CDCl3): δ 8.05 (s, 1H), 7.33-7.38 (m, 3H), 7.27-7.29 (m, 
4H), 4.75 (s, 2H), 4.31 (q, J = 7.2 Hz, 2H), 3.81 (s, 2H), 3.69 (s, 3H), 2.62 (app s, 
4H), 1.82 (app s, 4H), 1.39 (t, J = 7.2 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ 166.1, 140.9, 136.7, 135.3, 129.9, 127.1, 126.9, 
125.5, 125.1, 120.3, 119.1, 110.8, 103.9, 61.3, 60.7, 57.8, 35.2, 25.9, 22.7, 14.1. 
MS (ESI): m/z = 409.51 [M + H
+
].  
Anal. calcd for C24H28N2O2S: C, 70.55; H, 6.91; N, 6.86; S, 7.85, Found: C, 
70.41; H, 6.87; N, 6.78; S, 7.79. 
Ethyl-1-methyl-2-(phenylsulfanylmethyl)-5-(4-methyl)piperazin-1-ylmethyl)-
1H-indole-3-carboxylate (28e)  
Purified using ethyl acetate/MeOH (1/1).  
Nature of compound: Beige solid; Yield: (0.083 g) 84%.  
1
H NMR (300 MHz, CDCl3): δ 8.08 (s, 1H), 7.27-7.41 (m, 7H), 4.76 (s, 2H), 4.32 
(q, J = 7.2 Hz, 2H), 3.69 (s, 5H), 2.41 (s, 8H), 2.33 (s, 3H), 1.41 (t, J = 7.2 Hz, 
3H). 
13
C NMR (75 MHz, CDCl3): δ 166.1, 141.3, 136.5, 134.9, 129.3, 126.7, 126.1, 
125.7, 125.3, 120.3, 118.6, 110.9, 104.6, 61.1, 60.7, 55.8, 52.4, 43.3, 35.4, 22.5, 
14.3. 
MS (ESI): m/z = 460.51 [M + Na
+
].  
Anal. calcd for C25H31N3O2S: C, 68.62; H, 7.14; N, 9.60; S, 7.33, Found: C, 









butoxycarbonyl)piperazin-1-ylmethyl)-1H-indole-3-carboxylate (28f)  
Purified using ethyl acetate/hexane (3/7).  
Nature of compound: Pale oil; Yield: (0.040 g) 90%.  
1
H NMR (250 MHz, CDCl3): δ 8.02 (s, 1H), 7.33-7.38 (m, 2H), 7.22-7.29 (m, 
5H), 4.73 (s, 2H), 4.30 (q, J = 7.1 Hz, 2H), 3.67 (s, 5H), 3.45 (app t, J = 4.3 Hz, 
4H),  2.46 (app t, J = 4.3 Hz, 4H), 1.46 (s, 9H,), 1.39 (t, 3H, overlapped to s at 1.46 
ppm, J = 7.4 Hz).  
13
C NMR (75 MHz, CDCl3): δ 166.1, 154.3, 140.9, 136.7, 134.9, 130.0, 127.6, 
127.1, 126.5, 126.1, 121.0, 119.3, 110.9, 104.2, 80.3, 61.2, 60.5, 52.9, 50.1, 35.6, 
29.1, 23.6, 14.7. 
MS (ESI): m/z = 546.73 [M + Na
+
].  
Anal. calcd for C29H37N3O4S: C, 66.51; H, 7.12; N, 8.02; S, 6.12, Found: C, 
66.45; H, 7.07; N, 7.96; S, 6.04. 
Ethyl-1-methyl-2-(phenylsulfanylmethyl)-5-((4-(2,4-
difluoro)phenyl)piperazin-1-ylmethyl)-1H-indole-3-carboxylate (28g)  
Purified using ethyl acetate/hexane (4/6).  
Nature of compound: Yellow oil; Yield: (0.040 g) 88%. 
 
1
H NMR (250 MHz, CDCl3): δ 8.01 (s, 1H), 7.24-7.40 (m, 7H), 6.74-6.90 (m, 
3H), 4.74 (s, 2H), 4.30 (q, J = 7.1 Hz, 2H), 3.72 (s, 2H), 3.68 (s, 3H), 3.05 (app t, 
J = 4.3 Hz, 4H),  2.68 (app t, J = 4.3 Hz, 4H), 1.38 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ 166.1, 157.5, 154.3, 141.0, 137.4, 135.2, 133.2, 
129.7, 126.9, 126.3, 125.9, 125.7, 120.3, 119.2, 118.5, 112.7, 111.2, 106.2, 104.1, 
60.9, 60.6, 53.1, 51.0, 36.1, 23.1, 14.1. 
MS (ESI): m/z = 536.81 [M + H
+
].  
Anal. calcd for C30H31F2N3O2S: C, 67.27; H, 5.83; F, 7.09; N, 7.84; S, 5.99, 









carboxylate (28h)  
Nature of compound: Yellow oil; Yield: (0.034 mg) 98%.  
1
H NMR (250 MHz, CDCl3): δ 8.04 (s, 1H), 7.33-7.39 (m, 2H), 7.22-7.30 (m, 
5H), 4.73 (s, 2H), 4.30 (q, J = 7.1 Hz, 2H), 3.72 (app t, J = 4.3 Hz, 4H), 3.67 (s, 
3H), 3.64 (s, 2H), 2.49 (app t, J = 4.3 Hz, 4H), 1.38 (t, J = 7.1 Hz, 3H).   
13
C NMR (75 MHz, CDCl3): δ 166.0, 141.1, 136.4, 134.8, 129.8, 126.8, 126.1, 
125.3, 125.1, 121.1, 118.4, 111.3, 103.7, 67.1, 61.1, 60.8, 53.3, 35.3, 22.7, 14.2. 
MS (ESI): m/z = 425.67 [M + H
+
].  
Anal. calcd for C24H28N2O3S: C, 67.90; H, 6.65; N, 6.60; S, 7.55, Found: C, 
67.87; H, 6.76; N, 6.67; S, 7.43. 
Ethyl 1,2-dimethyl-5-[(2-piperazin-1-ylethylamino)methyl])-1H-indole-3-
carboxylate (23f)  
Purified using dichloromethane/methanol (9/1).  
Nature of compound: Yellow oil; Yield: (0.060 g) 88%.  
1
H NMR (300 MHz, CDCl3): δ 8.04 (s, 1H), 7.25-7.26 (m, 2H), 4.40 (q, J = 7.2 
Hz, 2H), 3.97 (s, 2H), 3.69 (s, 3H), 2.92 (t, J = 6.2 Hz, 2H), 2.77 (s, 3H), 2.52 (t, 
J= 6.2 Hz, 3H), 2.56- 2.59 (m, 8H), 1.46 (t, J = 7.2 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ 166.1, 141.2, 134.9, 126.8, 126.1, 120.1, 117.3, 
111.3, 103.2, 61.1, 55.3, 53.7, 47.1, 46.3, 35.6, 14.1, 5.3. 
MS (ESI): m/z = 359.16 [M + H
+
].  
Anal. calcd for C20H30N4O2: C, 67.01; H, 8.44; N, 15.63, Found: C, 66.97; H, 
8.13; N, 15.18. 
Ethyl-1,2-dimethyl-5-[[[1-(methylamino)-
2(diethylamino)]ethylamino]methyl]-1H-indole-3-carboxylate  (23g)  
Purified using dichloromethane/methanol (9/1).  
Nature of compound: Yellow oil; Yield: (0.038 g) 51%.  
1
H NMR (300 MHz, CDCl3): δ 8.04 (s, 1H), 7.25-7.28 (m, 2H), 4.41 (q, J = 7.2 
Hz, 2H), 3.74 (s, 2H), 3.69 (s, 3H), 2.77 (s, 3H), 2.66 (s, 3H), 2.56- 2.59 (m, 8H), 
1.46 (t,  J = 7.2 Hz, 3H), 1.02-1.05 (m, 6H). 
13
C NMR (75 MHz, CDCl3): δ 166.1, 141.3, 136.1, 124.8, 123.4, 120.4, 118, 7, 
111.2, 103,1, 62.6, 60.9, 53.7, 51.3, 49.2, 43.2, 35.6, 14.1, 13.4, 5.4. 




MS (ESI): m/z = 360.51 [M + H
+
].  
Anal. calcd for C21H33N3O2: C, 70.16; H, 9.25; N, 11.69, Found: C, 69.97; H, 
9.17; N, 11.16. 
Ethyl-1,2-dimethyl-5-[[[1-(diethylamino)-
2(diethylamino)]ethylamino]methyl]-1H-indole-3-carboxylate  (23h)  
Nature of compound: Yellow oil; Yield: (0.058 g) 77%. 
 
1
H NMR (250 MHz, CDCl3): δ 8.03 (s, 1H), 7.25 (d, J = 3.4 Hz, 2H), 4.41 (q, J 
= 7 Hz, 2H), 3.63-3.74 (m, 7H), 2.78-2.85 (m, 8H), 2.75 (s, 3H), 1.43 (t, J = 7 Hz, 
3H), 1.06-1.08 (m, 9H). 
13
C NMR (75 MHz, CDCl3): δ 166.0, 142.1, 136.3, 124.8, 123.1, 120.5, 118.7, 
111.3, 103.5, 60.9, 60.3, 51.3, 51.2, 49.7, 35.6, 14.1, 13.4, 5.3. 
MS (ESI): m/z = 374.53 [M + H
+
].  
Anal. calcd for C22H35N3O2: C, 70.74; H, 9.44; N, 11.25, Found: C, 70.67; H, 
9.26; N, 11.19. 
Ethyl-1,2-dimethyl-5-[[2-(methylamino)-ethylamino]methyl]-1H-indole-3-
carboxylate (23i)  
Nature of compound: Yellow oil; Yield: (0.050 g) 81%.  
1
H NMR (300 MHz, CDCl3): δ 7.99 (s, 1H), 7.22 (d, J = 5.07 Hz, 2H), 4.36 (q, J 
= 7.1 Hz, 2H), 3.89 (s, 2H), 3.65 (s, 3H), 2.49-2.44 (m, 4H), 2.79 (s, 3H), 2.35 (s, 
3H), 1.42 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ 166.0, 141.1, 134.8, 126.9, 126.1, 119.5, 117.4, 
110.9, 104.0, 60.9, 54.9, 51.6, 48.7, 35.6, 14.1, 5.3. 
MS (ESI): m/z = 304.13 [M + H
+
].  
Anal. calcd for C17H25N3O2: C, 67.30; H, 8.31; N, 13.85, Found: C, 67.35; H, 
8.34; N, 13.78. 
Ethyl-1,2-dimethyl-5-[[2-(tert-butoxycarbonylamino)-ethylamino]methyl]-
1H-indole-3-carboxylate  (23j)  
Nature of compound: Yellow oil; Yield: (0.042 g) 89%.  
1
H NMR (300 MHz, CDCl3): δ 8.15 (s, 1H), 7.33 (s, 2H), 4.85 (s, 2H), 4.45 (q, J 
= 7.3 Hz, 2H), 3.74 (s, 5H), 2.82 (s, 5H), 1.51 (s, 9H), 1.32 (t, J = 7.3 Hz, 3H). 





C NMR (75 MHz, CDCl3): δ 166.6, 156.3, 140.3, 134.7, 126.2, 126.0, 119.2, 
117.4, 110.2, 103.4, 79.5, 60.9, 55.1, 48.7, 42.6, 35.7, 28.7, 14.3, 5.4. 
MS (ESI): m/z = 390.13 [M + H
+
].  
Anal. calcd for C21H31N3O4: C, 64.76; H, 8.02; N, 10.79; O, 16.43, Found: C, 
64.35; H, 8.34; N, 10.58; O, 10.60. 
 
Ethyl-1,2-dimethyl-5-[[2-(diethylamino)-ethylamino]methyl]-1H-indole-3-
carboxylate (23k)  
Purified using dichloromethane/methanol/NH3 9.5/0.5/0.1.  
Nature of compound: Yellow oil; Yield: (0.025 g) 99%. 
 
1
H NMR (250 MHz, CDCl3): δ 8.03 (s, 1H), 7.26 (s, 2H), 4.40 (q, J = 7.1 Hz, 
2H), 3.96 (s, 2H), 3.69 (s, 3H), 2.75-2.78 (m, 5H),  2.47 (t, J = 6.4 Hz, 2H), 2.20 
(s, 6H), 1.44 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ 166.1, 141.3, 136.1, 124.6, 123.9, 119.5, 118.8, 
110.2, 103.0, 60.9, 58.5, 54.5, 46.2, 46.1, 35.6, 14.1, 5.4. 
MS (ESI): m/z = 318.43 [M + H
+
].  
Anal. calcd for C18H27N3O2: C, 68.11; H, 8.57; N, 13.24, Found: C, 67.87; H, 
8.23; N, 12.98. 
Ethyl-1,2-dimethyl-5-[[2-(hydroxy)-ethylamino]methyl]-1H-indole-3-
carboxylate (23l)  
Purified using dichloromethane/methanol/NH3 9/1/0.1.  
Nature of compound: Yellow oil; Yield: (0.020 g) 87%. 
 
1
H NMR (250 MHz, CDCl3): δ 8.04 (s, 1H), 7.24 (d, J = 2.7 Hz, 2H), 4.40 (q, J 
= 7.1 Hz, 2H), 3.93 (s, 2H), 3.64-3.68 (m, 5H), 2.83 (t, J = 5.2 Hz, 2H), 2.75 (s, 
3H), 1.44 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ 166.7, 1403, 136.7, 124.9, 124.1, 120.3, 119.1, 
110.2, 103.1, 61.6, 60.9, 54.8, 52.1, 35.6, 14.3, 5.3.  
MS (ESI): m/z = 313.36 [M + Na
+
].  
Anal. calcd for C16H22N2O3: C, 66.18; H, 7.64; N, 9.65, Found: C, 65.97; H, 7.33; 
N, 9.18. 






Purified using dichloromethane/methanol/NH3 9/1/0.2.  
Nature of compound: Yellow oil; Yield: (0.018 g) 67%.  
1
H NMR (250 MHz, CDCl3): δ 8.05(s, 1H), 7.26 (s, 2H), 4.40 (q, J = 7.1 Hz, 2H), 
3.94 (s, 2H), 3.63-3.68 (s overlapped m, 7H), 2.81 (app s, 2H), 2.78 (s, 3H), 2.33 
(app s, 4H), 1.44 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ 166.2, 140.8, 134.7, 126.7, 126.3, 120.3, 117.8, 
111.5, 103.3, 61.7, 60.9, 55.3, 52.9, 50.1, 49.6, 35.8, 14.1, 5.3. 
MS (ESI): m/z = 334.76 [M + H
+
].  
Anal. calcd for C18H27N3O3: C, 64.84; H, 8.16; N, 12.60, Found: C, 65.17; H, 
7.83; N, 11.18. 
Ethyl-5-((4-(tert-butoxy carbonyl)-1,4-diazepan-1-yl)methyl)-1,2-dimethyl-
1H-indole-3-carboxylate (23n)  
Prepared using 1-BOC homopiperazine.
10 
 
Nature of compound: Yellow solid; Yield: (0.054 g) 69%.  
1
H NMR (400 MHz, CDCl3): δ 8.08 (s, 1H), 7.23-7.31 (m, 2H), 4.39 (q, J = 7.4 
Hz, 2H), 3.79 (s, 2H), 3.67 (s, 3H), 3.45 (m, 6H), 2.73 (s, 3H), 2.63-2.65 (m, 4H), 
1.45 (t, J = 7.4 Hz, 12H). 
13
C NMR (75 MHz, CDCl3): δ 166.4, 154.3, 141.3, 134.8, 126.5, 125.3, 120.3, 
118.3, 110.8, 103.7, 79.8, 60.9, 60.8, 56.4, 53.6, 48.4, 47.0, 35.6, 28.5, 26.6, 14.1, 
5.5.  
MS (ESI): m/z = 430.51 [M + H
+
].  
Anal. calcd for C24H35N3O4: C, 67.11; H, 8.21; N, 9.78, Found: C, 67.01; H, 8.13; 
N, 9.38. 
Ethyl-5-(1,4-diazepan-1-ylmethyl)-1,2-dimethyl-1H-indole-3-carboxylate (29)  
Compound 23n (0.054 g, 0.12 mmol) was dissolved in dichloromethane (1 mL) 
and trifluoroacetic acid (13 µL, 12 mmol)) were added dropwise and the mixture 
stirred till starting material was consumed. The solvent was removed under 
reduced pressure, the crude treated with 10% NaOH till pH-12 and the residue 
extracted with ethyl acetate twice, recovering a yellow oil (0.040 g).  




Nature of compound: Yellow oil; Yield: (40 mg) 99%. 
 
1
H NMR (250 MHz, CDCl3): δ 8.08 (s, 1H), 7.23-7.31 (m, 2H), 4.37 (q, J = 7.1 
Hz, 2H), 3.82 (s, 2H), 3.68 (s, 3H), 3.45 (m, 6H), 2.75 (s, 3H), 2.68 (br s, 2H), 1.86 
(app t, J = 5.4 Hz, 2H), 1.45 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ 166.1, 141.4, 134.8, 126.7, 125.3, 120.9, 118.3, 
110.5, 103.4, 61.1, 60.8, 53.6, 48.6, 47.1, 35.6, 29.4, 14.1, 5.3. 
MS (ESI): m/z = 352.44 [M + Na
+
].  
Anal. calcd for C19H27N3O2: C, 69.27; H, 8.26; N, 12.76, Found: C, 68.97; H, 
7.93; N, 12.18. 
Ethyl-1-methyl-5-[(1-methylpyrrolidin-1-ium-1-yl) methyl]-2-
(phenylsulfanylmethyl) indole-3-carboxylate iodide (30)  
A solution of compound 28d (0.015 g, 0.036 mmol) in ethyl acetate (4 mL) was 
stirred with iodomethane (10 µL, 0.14 mmol) for 3h. Purified using 
CHCl3/MeOH/NH3 1/1/0.2.  
Nature of compound: White solid; Yield: (0.020 g) 99%. 
 
1
H NMR (300 MHz, CD3OD): δ 8.26 (s, 1H), 7.62 (s, J = 8.2 Hz, 1H,), 7.33-7.38 
(m, 6H), 7.24-7.63 (m, 4H), 4.81 (s, 6H), 4.67 (s, 2H), 4.27 (q, J = 7.2 Hz, 2H), 
3.81 (s, 2H), 3.81 (s, 3H), 3.07 (s, 3H), 2.28 (app s, 4H), 1.34 (t, J = 7.2 Hz, 3H). 
13
C NMR (75 MHz, CDCl3): δ 166.3, 141.5, 136.4, 133.8, 131.7, 129.8, 129.6, 
126.8, 126.2, 125.2, 120.2, 118.5, 111.0, 103.5, 69.7, 66.3, 60.9, 49.3, 35.2, 22.6, 
22.1, 14.3. 
MS (ESI): m/z = 573.05 [M + Na
+
].  
Anal. calcd for C25H31IN2O2S: C, 54.54; H, 5.68; N, 5.09; S, 5.82,  Found: C, 
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 The aldol addition is one of the most powerful synthetic tools for carbon-carbon 
bond formation in a large variety of organic syntheses due to its broad utility.
1
 
Aldol structural units are found in many important molecules, whether naturally 
occurring or synthetic,
2
 it has been the subject of intense research in recent years. 
Aldol products (and especially hydroxymethyl derivatives) have extensively been 
used for the synthesis of important biologically active compounds,
3
 and represents 
a valuable tool with regard to chiral economy. Asymmetric syn and anti aldol 
reactions have been used for synthesis of the natural products containing lactone 
moieties. 
 “Aldol” is an abbreviation of aldehyde and alcohol. When the enolate of an 
aldehyde or a ketone reacts at the α-carbon with the carbonyl of another molecule 
under basic or acidic conditions to obtain β-hydroxy aldehyde or ketone, this 
reaction is called Aldol Reaction. 
The aldol addition of aldehyde to readily enolizable 1,3-dicarbonyl compounds 
still remains a important challenge in organic chemistry, even though the products 
are valuable intermediates in the total synthesis of natural products.
4
 In the past 
very few effective methods have been developed with a limited scope 
5,6
 but even 
under very mild conditions (i.e., in the presence of weak base or weak acid or in a 
mixture of both, in metal and organocatalysed conditions, etc.), variable mixtures 
of regioisomers, dehydration products and aldol adducts have been observed.
5,7
 
For example, in the presence of the trimethylsilyl enol ether of 1,3-pentanedione 




The main difficulties of this reaction can be attributed to the scarce stability of the 
adducts and to the inadequacy of the current methodologies that favour 
condensation (Knoevenagel reaction) or retro-aldol process instead of the aldol 
reaction. For these reasons different strategies and multi-steps non-flexible 
synthesis have been developed in some cases.
8 
In particular β-keto esters and 2,4-
diketones have been successfully used as nucleophiles in the addition to acetals in 
the presence of Lewis acids to yield protected O-alkyl aldol adducts.
8b
 Recently 
CHAPTER-III Section-A:Multicomponent one-pot aldol addition/ protection reaction of β-




Sodeoka reported the first enantioselective addition of β-keto esters to allylic 
acetals in the presence of chiral palladium catalyst to give again protected O-alkyl 
compounds in good yields and ees.
8c
 Chiral O-protected β-hydroxy malonates 
have been also obtained in diastereoselective oxy-Michael reactions of alkylidene 
malonates using enantiopure alkoxides.
8d
 
However very recently a multicomponent one-pot aldol addition/protection 
reaction (MCR) of malonates to aldehydes for the obtaining of a large class of 






 are a powerful tool for the generation of collections 
of molecules; they are extremely convergent and produce a remarkably high 
increase of molecular complexity in just one step. Sequential transformations and 
multicomponent one-pot reactions are always resource effective and 
environmentally acceptable and thus greener as compared to multi-step 
reactions.
11
 They offer significant advantages over conventional linear step 
syntheses, by reducing time, saving money, energy and raw-materials thus 
resulting in both economical and environmental benefits. At the same time, 




In these studies it was clearly demonstrated that the success of this challenging 
aldol addition is mainly related to the in situ trapping of the unstable aldol adducts 
by chlorosilanes reagents
9a,b
 or by their intramolecular trapping.
9c
 In this way a 
series of aromatic, hetero-aromatic and even simple aliphatic aldehydes were 
reacted with malonates to give protected aldol adducts 
9a,b
. However, under this 




3.1.2 REVIEW OF LITERATURE 
 
The most well known and explored route to the trimethylsilyl-protected aldol 
product in a mild one-pot aldol addition/protection reaction of active methylene 
compounds with aldehydes in the presence of Me3SiCl and i-Pr2EtN. In recent 
years, several important improved procedures have been reported to one-pot aldol 
addition, some of the representative methods are discussed below. 
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More recently, Mahrwald et al. reported the room temperature aldol addition of 
ethyl glyoxylate to acetoacetic ethyl ester without any solvent and also described a 
catalyst-free aldol addition of several 1,3-dicarbonyl compounds to activated 
aldehydes like ethyl glyoxylate in good to high yields. Even if this can be 
considered the most effective procedure ever reported, aromatic aldehydes were 




















Massa et al. have reported the two step-reaction aldol addition followed by 
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The success of this difficult aldol addition is reasonably related to the in situ 
trapping of the aldol adduct, it is possible to obtain directly the trimethylsilyl-
protected aldol product in a mild one-pot aldol addition/protection reaction of 
active methylene compounds with aldehydes in the presence of Me3SiCl and i-













VII VIII  
Scheme 3 
3.1.3 PRESENT WORK 
 As part of a program toward a general procedure for the aldol addition of active 
methylene compounds, my work was focused on the efforts to develop a multi-
component one-pot aldol addition/protection reactions to β-ketoesters, since the 
branched aldol adducts derived from β-ketoesters have been obtained only in few 
cases with a very limited aldehyde scope.
5,9b
   
In addition the usefulness of the obtained adducts was explored in the synthesis of 
substituted diols and alkylated products.  
During our studies we also found out that when 2-cyanobenzaldehyde was reacted 
in the presence of β-ketoesters and others 1,3-dicarbonyl compounds, a number of 
novel 3-substituted isoindolinones were obtained, as we will describe separately. 
 
3.1.4 MULTI-COMPONENT ONE-POT ALDOL 
ADDITION/PROTECTION REACTION OF β-KETOESTERS 
Under the conditions used for the one-pot aldol addition/protection reaction of 
malonates at -20 °C, β-ketoesters revealed themselves to be almost completely 
unreactive. Only p-nitro benzaldehyde in the presence of t-butyl acetoacetate 2a 
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and (-)-menthyl acetoacetate 2b gave the silylated adducts in about a 30% yield at 





Table 1. Multicomponent aldol addition/protection reaction of t-butyl acetoacetate 2a 
with aldehydes in the presence of Me3SiCl and i-Pr2EtN at -20 °C 
 





1 Ph 0 3a No reac.
 
 





0 3c 35 1/2/1 
4 4-NO2C6H4 0.3 3b 75
 
2.5/1 
5 Ph 0.3 -- No reac.  
6 4-CNC6H4 0.3 3d 79 2.5/1 
7 4-CNC6H4 - 3d 55 2.5/1 
8 2-CNC6H4 0.3 3e 80 2/1 
9 2-CNC6H4 - 3e 58  
10 4-ClC6H4 0.3 3f 20 2/1 
11 4-OMeC6H4 0.3 -- No reac.  
12 3-Phenyl  proprionaldehyde 0.3 -- No reac.  
    a
 Yields refer to chromatographically pure compounds 
    b
 Determined by 
1
H NMR analysis of crude 
    c 
Reaction performed in the presence of (-)-menthyl acetoacetate 2b 
 
In order to overcome this disappointing situation several conditions and strategies 
were explored. A significant increase of the reactivity was observed when a 
catalytic amount of DMF was used (Table 1, entry 4). Thus, we were pleased to 
observe high yields of the silylated aldol adducts in the presence of several 
aromatic aldehydes bearing strong electron-withdrawing groups like nitro and 
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cyano both in para and ortho position (Table 1, entries 4, 6 and 8), while without 
DMF a significant lower yield was observed (Table 1, cfr entries 7 and 9). The 
presence of a chlorine substituent, strongly decreased the reactivity, while 
benzaldehyde and nonactivated aldehydes did not react at all (Table 1, entries 5, 
11 and 12). As could have been expected, this MCR guarantees high 
regioselectivity in all the cases for the attack of the aldehydes at the methylene 
group only, even if 3 were obtained with rather low diastereoselectivity. 
The use of DMF was suggested by the well-know effect of activation of 
trimethylsilyl nucleophiles, like silyl enol ethers, by Lewis bases in a number of 




H NMR experiments at room temperature in 
CDCl3 of mixture of TMS-Cl, t-butyl acetoacetate and i-Pr2EtN revealed the 
formation of silyl enol ether intermediates in 1/1 ratio with unreacted starting 
materials after only 2 h at room temperature, while similar experiments in the 
presence of di-t-butyl malonate left the starting materials unreacted. Probably the 
improvement of the reaction rate is a consequence of DMF activation of these 
silyl enol ether intermediates. 
In order to improve the reactivity of less reactive aldehydes, different reaction 
temperature, higher concentrated reaction medium, different solvents and even in 
solvent-free conditions, different amines and bases in combination with Me3SiCl 
were tried. The most relevant results are summarized in Table 2 and 3.  
Starting from the conditions of Scheme 1, it can be seen that the modification of 
three parameters leads to a sufficient reactivity. In the presence of 0.3 eq of DMF, 
at room temperature and after 72 h, we obtained a 51% yield for 3a (Table 2, 
entries 1-4). In these new conditions, the effect of DMF is still evident for 
benzaldehyde (Table 2, cfr entries 3 and 4) and other aldehydes. 
 For example when p-chloro benzaldehyde and the aliphatic 3-phenyl 
proprionaldehyde were used, we observed 72% and 66% yields respectively, 
whereas without the Lewis base the yields were lower (cfr entries 7-8 and 9-10 of 
Table 2). The result of the aliphatic aldehyde is particular interesting because self-
condensation products have not been observed, while also under these conditions, 
p-methoxy benzaldehyde was not reactive (Table 2, Entries 5-6). 
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 Moreover another disappointing result was observed with methyl acetoacetate 2c 
for which the aldol adduct 3h was obtained in a 10% yield only (Table 2, Entry 
11). 
 
Table 2. Multicomponent aldol addition/protection reaction of tert-butyl acetoacetate 
with aldehydes in the presence of Me3SiCl and i-Pr2EtN 















1 Ph -20°C 0.3 48 3a No reac.  
2 Ph 0°C - 48 3a No reac.  
3 Ph rt - 72 3a 42 % 1/1 
4 Ph rt 0.3 72 3a 51 % 2/1 
5 4-MeOC6H4 rt - 72 -- No reac.  
6 4-MeOC6H4 rt 0.3 72 -- No reac.  
7 4-ClC6H4 rt - 72 3f 60 % 1.5/1 
8 4-ClC6H4 rt 0.3 72 3f 72 % 1.6/1 
9 3-Ph 
proprionaldehyde 
rt - 72 3g 45 % 1.5/1 
10 3-Ph 
proprionaldehyde 
rt 0.3 72 3g 66 % 1.7/1 
11
c
 Ph rt 0.3
 
72 3h 10 % 1.3/1 
a Yields refer to chromatographically pure compounds 
b Determined by 1H NMR analysis of crude 
c Methyl acetoacetate 2c was used instead of of tert-butyl acetoacetate 
 
Since a positive effect on the reaction rate was exerted by the increasing of the 
temperature, we used higher boiling solvents like 1,2-dichloroethane and THF at 
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Focusing on less reactive substrates, a good yield was obtained with methyl 
acetoacetate and benzaldehyde (Entry 1, Table 3). 
Table 3. Multicomponent aldol addition/protection reaction of tert-butyl acetoacetate 
with aldehydes in the presence of Me3SiCl and i-Pr2EtN 
a Yields refer to chromatographically pure compounds 
b Determined by 1H NMR analysis of crude 
c Reaction performed with 0.3 eq of DMF. 
 
However the use of DMF did not give any significant improvement to the 
reactivity and for this reason all the experiments of table 3 were performed 
without this additive (Table 3, entry 2). Longer reaction time led to the 
disappearance of the starting materials with the concomitant decrease of the yield 
due to the formation of decomposition products (Table 3, entry 3). Among the 
tested aldehydes, we observed a moderate reactivity even with the poorly reactive 
p-methoxybenzaldehyde (Table 3, Entry 5). Furfural, p-chlorobenzaldehyde and 
p-bromobenzaldehyde showed good results (Table 3, entries 6-8), while only in 











1 Ph Me 1,2 dichloroethane 8 3h 55 1.3/1 
2
c
 Ph Me 1,2 dichloroethane 8 3h 50
 
1.5/1 
3 Ph Me 1,2 dichloroethane 18 3h 32 1.3/1 
4 Ph t-Bu 1,2 dichloroethane 8 3a 57
 
1.2/1 
5 p-OMeC6H4 t-Bu 1,2 dichloroethane 8 3i 42 1.3/1 
6 p-ClC6H4 t-Bu 1,2 dichloroethane 8 3f 84 1.4/1 
7 p-BrC6H4 t-Bu 1,2 dichloroethane 8 3l 78 1.5/1 
8 2-furfural t-Bu 1,2 dichloroethane 8 3m 68 1.6/1 
9 3-Phenyl 
proprionaldehyde 
t-Bu 1,2 dichloroethane 8 3g 56 1.3/1 
10 Ph t-Bu THF 18 3a 62 1.3/1 
11 p-OMeC6H4 t-Bu THF 18 3i 35 1.2/1 
12 Ph Me THF 18 3h 39 1/1 
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the presence of 3-phenyl propionaldehyde we observed a lower yield for the 
formation of decomposition products (cfr entry 9 of Table 3 with entry 11 of 
Table 2) The use of THF led to an increase of the yield in the presence of 
benzaldehyde and t-butyl acetoacetate (Entry 10), while we did not observe any 
improvement when methyl acetoacetate and p-methoxybenzaldehyde were used 
(Table 3, entries 11 and 12). 
3.1.5 SYNTHETIC APPLICATIONS OF ALDOL ADDUCTS 
         All the developed methods can be easily employed for gram scale synthesis 
of the aldol adducts, a feature that is particularly useful for preparative purposes. 
In fact the adducts 3 show very interesting functionalities that could be subjected 
to different sets of transformations to give valuable compounds. For example, 
according to scheme 6, the versatility and the stability of 3 was firstly tested 
treating 3h with NaBH4 and with TBAF for the deprotection of the resulting crude 
mixture. This sequence easily provided the valuable known diols 4,
15a,d
 that 
otherwise require longer synthesis with the use of toxic metal reagents, but that 





H NMR analysis on the crude, all the 4 diastereomers were detected 
in comparison with those reported by Fleming et al
15a
 and the two major isomers 
4a and 4c were easily isolated by chromatography. From the comparison of the 
diastereomeric ratios of 3h and 4, we can confidently attribute the stereochemistry 
of the isomers of 3h as those described in Scheme 6. 
This stereochemical outcome can be generalised to all the adducts 3 for the 
analogy of 
1
H NMR spectra. All the aldols 3 have usually been obtained as an 
inseparable mixture of diastereomers. However the minor isomer of 3e has been 
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3h: ratio = 1.3 / 1 4a 4b
4c 4d
ratio 4a / 4b / 4c / 4d = 4.7 / 1.3 / 4 / 1
4 95 % yield from 3h
a, b
Scheme 6 
Reagents and conditions: (a) NaBH4, MeOH, 0 °C, 20 min. (b) TBAF (1M solution in 
THF), THF, 0 °C, 30 min. 
Fortunately these crystals were suitable for X-ray structural analysis, the obtained 










Figure 1: ORTEP structure of 3e 
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As it can be seen, the relative configuration of the minor isomer of 3e (SR,RS) is 
in agreement with what was previously supposed for 3h in scheme 6 even though 
with a different ester group. 
Moreover, when we submitted a 1.3/1 mixture of the two diastereomers 3a with 
the supposed configuration as shown  in scheme 7, to NaBH4 reduction, we 
obtained quantitatively a 3/1.5/1 mixture for the three main diastereomers of 5, as 



































Reagents and conditions: (a) NaBH4, MeOH, 0 °C, 20 min., 90%. (b) TBAF (1M 
solution in THF), THF, 0 °C, 30 min., 95%  
The major diastereomer 5a was isolated by chromatography and treated with 









                            Figure 2: ORTEP structure of 6. 
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This compound was crystallised again by slow evaporation of CH2Cl2 solution 
and the X-ray scattering gave the structure reported in figure 2. The configuration 
of the three stereocentres 1‟RS, 2SR, 3SR, confirmed what previously supposed by 
simple  analogy.       
The aldol addition of ethyl 2-methyl acetoacetate to benzaldehyde so as to give an 
aldol adduct with contiguous tertiary and quaternary stereocenters was 
unsuccessful under conditions of both Scheme 4 and 5. However, in order to 
further expand the range of applications of the obtained aldols 3, we examined the 
reactivity of 3a as nucleophile under alkylation conditions in the presence of CH3I 















Reagents and conditions: (a) K2CO3, CH3I, DMF, rt, 48 h, 75%, (d.r. = 95/5). 
 
Very interestingly, employing the usual 1.3/1 mixture of  the two diastereomers, 
we obtained the alkylated product 7 in the enriched 95/5 ratio in 75% yield in 48 
h. Shorter reaction time (24 h) gave 7 in rather low yield (35%). However in this 
case the unreacted 3a was recovered in 35% yield with an enriched 70/30 
diastereomeric ratio. Unfortunately 7 was obtained as an oil and we were not able 
to crystallise it for X-ray analysis for a rationalization of the stereochemical 
outcome. Considering the importance in the construction of quaternary centers in 
stereoselective manner and the fact that, at the best of our knowledge, similar 
diastereoselective alkylations are rare,
16
 further studies are in course to expand the 
scope of the aldols in this field. 
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In conclusion we have developed a multicomponent one-pot aldol 
addition/protection reactions of β-ketoesters with a wide range of aldehydes to 
give protected aldol adducts in the presence of Me3SiCl and i-Pr2EtN. The use of 
catalytic amounts of DMF led to an increase in the reactivity with aldehydes 
bearing electron withdrawing groups, while less reactive aldehydes required 
different solvents and refluxing conditions. Subsequently, the investigation of the 
formation of silyl enol ethers of β-ketoesters also gave important mechanistic 
insights into the role that DMF can play. Finally, as examples of the possibilities 
of further functionalization of the obtained aldols, 3a and 3h were submitted to a 
sequence of reduction and deprotection reactions to give valuable diols, while 
alkylation reactions afforded quaternary stereocentre with high 
diastereoselectivity. Considering the variety of versions and reaction conditions 
that this MCR of β-ketoesters can tolerate, we think that this work can give 
important perspective for a general approach to the aldol addition of other readily 
enolizable active methylene compounds. Since the class of active methylene 
compounds is very large and presents different structural motifs, in future studies 
particular emphasis will be given to other applications of this methodology and of 
the obtained aldol adducts in the synthesis of valuable compounds. Other studies 
are also in course for the development of enantioselective versions of these 
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3.1.7 EXPERIMENTAL SECTION 
i) Procedures 
a) Procedure for one pot aldol-silylation reaction in the presence of Me3SiCl 
and i-Pr2EtN (Scheme 4). 
In a flame-dried, 2-necked, round-bottom flask, aldehyde (0.40 mmol) was added 
to a solution of i-Pr2EtN (2.3 eq., 0.92 mmol), β−ketoester (1.5 eq., 0.60 mmol) 
and Me3SiCl (2.0 eq., 0.80 mmol) in dry dichloromethane (2.0 mL) under 
nitrogen at -20 °C. At the end of the reaction, the mixture was quenched with 
saturated aqueous NaHCO3 (5 mL), extracted with 15x3 mL of CH2Cl2 and dried 
over anhydrous Na2SO4. After removing the solvent under reduced pressure, the 
crude oil was purified by flash chromatography from hexane to 95/5 hexane / 
AcOEt mixture to afford the pure products 3. 
b) Procedure for one pot aldol-silylation reaction in the presence of Me3SiCl 
and i-Pr2EtN (Scheme 5). 
In a flame-dried, 2-necked, round-bottom flask equipped with a condenser, 
aldehyde (0.80 mmol) was added to a solution of i-Pr2EtN (2.0 eq., 1.60 mmol), 
β−ketoester (1.1 eq., 0.88 mmol) and Me3SiCl (2.0eq., 1.60 mmol) in dry 1,2-
dichloroethane/THF (4.0 mL) under nitrogen at reflux. At the end of the reaction, 
the mixture was quenched with saturated aqueous NaHCO3 (5 mL), extracted with 
15x3 mL of CH2Cl2 and dried over anhydrous Na2SO4. After removing the 
solvent under reduced pressure, the crude oil was purified by flash 
chromatography from hexane to 95/5 hexane/AcOEt mixture to afford the pure 
products 3. 
c) Procedure for conversion of 3a into 5 (Scheme 7). 
NaBH4 (0.27 mmol) was added to a solution of 3a (0.25 mmol) in methanol (1.0 
mL), at 0°C and reacted for 20 min. Then the reaction was quenched with 
saturated aqueous NaHCO3 (5 mL), extracted with 15x3 mL of CH2Cl2 and dried 
over anhydrous Na2SO4. After removing the solvent under reduced pressure, the 
crude oil was purified by flash chromatography with hexane/AcOEt mixture from 
90/10 to 1/1 to afford the pure products 5. 
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d) Procedure for conversion of 5a into 6 (Scheme 7) 
5a was dissolved in THF (1.0 mL) and TBAF (25 μl of 1.0 M solution in THF) 
was added at 0 °C and reacted for 30 min. Then the mixture was treated with 
saturated aqueous NaCl (5 mL), extracted with 15x3 mL of CH2Cl2 and dried over 
anhydrous Na2SO4. After removing the solvent under reduced pressure, the crude 
oil was purified by flash chromatography with 1/1 mixtures of hexane and AcOEt 
to afford the pure product 6. 
e) Procedure for alkylation of 3a (Scheme 8) 
K2CO3 (0.27 mmol) was added to a solution of 3a (0.11 mmol) and CH3I (0.33 
mmol) in DMF (1.0 mL), at r.t. and reacted for 48 h. Then ethyl acetate (20 mL) 
was added and the mixture was extracted with brine (10x3 mL) and dried over 
anhydrous Na2SO4. After removing the solvent under reduced pressure, the crude 
oil was purified by flash chromatography with hexane/AcOEt mixture from 95/5 
to 90/10 to afford the pure products 7. 




experiment about formation of silyl enol 
ethers: 
 In a flame-dried, 2-necked, round-bottom flask, Me3SiCl (0.20 mmol) was added 
to a solution of i-Pr2EtN (1.0 eq.) and t-butyl aceoacetate (1.0 eq.) in 0.8 mL of 
anhydrous CDCl3 at r.t. The resulting solution was transferred into a dry NMR 
tube and 
1
HNMR spectra were recorded.  
 ii) Charaterization data 
Note: Compounds 3a-d, 3f and 3h are known and were characterised comparing 
their spectroscopic data with those previously reported in literature
9b
 and the diols 
4a, 4b, 4c and 4d are known and were characterised comparing the spectroscopic 
data with those previously published.
15a 
2-[(2-Cyano-phenyl)-trimethylsilanyloxy-methyl]-3-oxo-butyric acid tert-
butyl ester(3e)  (mixture of two diastereomers) 
 IR (KBr): 871, 1130, 1250, 1714, 1738, 2222, 2927 cm
-1
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H NMR (CDCl3; 300 MHz): δ 7.76 (m, 1+1H), 7,64-7.53 (m, 2+2H), 7.37 
(m,1+1H), 5.58 (d, J = 9.0 Hz, 1H), 5.54 (d, J = 9.0 Hz, 1H, major diastereomer ), 
4.04 (d, J = 9.2 Hz, 1H, major diastereomer, ), 3.98 (d, J = 9.0 Hz, 1H), 2.33 (s, 
3H), 2.05 (s, 3H), 1.47 (s, 9H), 1.21 (s, 9H), -0.02 (s, 9H), -0.04 (s, 9H). 
13
C NMR (CDCl3; 75 MHz): δ 202.8, 202.2, 165.8, 165.1, 145.5, 144.9, 134.1, 
134.0, 133.1, 132.5, 129.5, 128.8, 128.4, 128.2, 117.4, 117.3, 111.3, 111.1, 82.3, 
82.1, 71.9, 71.0, 68.9, 67.5, 30.7, 29.5, 27.8, 27.4, -0.25, -0.34. 
MS (ESI): m/z = 384 (M + Na
+
).  
Anal. Calcd for C19H27NO4Si: C, 63.13; H, 7.53; N, 3.87 Found: C, 63.28; H, 
7.44; N, 3.75. 
2(RS)-3-Oxo-2-[1’(SR)-(2-cyanophenyl)-trimethylsilanyloxy-methyl)-butyric 
acid  tert-butyl ester (3e) (minor diastereomer) 
The minor diastereomer was separated by chromatography and was obtained as a 
solid (recrystallised in CH2Cl2). M.p.: 49-52 °C.  
 
IR (KBr): 870, 1132, 1255, 1715, 1739, 2221, 2923 cm
-1
 .  
1
H NMR (CDCl3; 300 MHz): δ 7.65 (d, J = 6.0 Hz, 1H), 7,57-7.52 (m, 2H), 7.39 
(m,1H), 5.56 (d, J = 9.0 Hz, 1H), 4.06 (d, J = 9.0 Hz, 1H), 2.35 (s, 3H), 1.23 (s, 
9H), -0.02 (s, 9H). 
13
C NMR (CDCl3; 75 MHz): δ 200.9, 165.1, 145.0, 133.1, 132.5, 128.8, 128.4, 
117.5, 111.4, 82.3, 71.9, 67.5, 30.7, 27.5, -0.32. 
MS (ESI): m/z = 384 (M + Na
+
).  
Anal. Calcd for C19H27NO4Si: C, 63.13; H, 7.53; N, 3.87 Found: C, 63.29; H, 
7.61; N, 3.99.  
2-Acetyl-5-phenyl-3-trimethylsilanyloxy-pentanoic acid tert-butyl ester (3g) 
The title compounds were obtained as Oil.
 
  
 IR (KBr): 660, 840, 1157,  1258, 1461, 1697, 1730, 2930 cm
-1
 .  
1
H NMR (CDCl3; 300 MHz): δ 7.28-7.16 (m, 5+5H), 4.45-4.43 (m, 2H), 3.64 (d, 
J = 3 Hz,1H, major diastereomer), 3.61 (d, J = 3 Hz,1H), 2.97 (bt, 1H), 2.81 (bt, 
1H), 2.72-2.64 (m, 4H), 2.27 (s, 3H), 2.20 (s, 3 H), 1.91-1.79 (m, 4H), 1.47 (s, 
9H), 1.45 (s, 9 H, major diastereomer), 0.16(s, 9 H), 0.13 (s, 9 H, major 
diastereomer). 
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C NMR (CDCl3; 75 MHz): δ 202.9, 202.2, 166.9, 166.7, 141.8, 128.5, 128.3, 
128.2, 126.2, 125.7, 81.9, 81.7, 71.4, 70.5, 66.8, 65.7, 37.3, 36.7, 31.8, 31.1, 30.9, 
30.2, 29.6, 29.2, 27.9, 27.8, 0.41, 0.31.  
MS (ESI): m/z = 387.50 (M + Na
+
).  
Anal. Calcd for C20H32O4Si: C, 65.89; H, 8.85. Found: C, 65.71; H, 8.76. 
2-[(4-Methoxy-phenyl)-trimethylsilanyloxy-methyl]-3-oxo-butyric acid tert-
butyl ester (3i)   
The title compounds were obtained as Oil. 




H NMR (CDCl3; 300 MHz): δ 7.27 (d, J=9.0 Hz, 2H), 6.81 (d, J=9.0 Hz, 2H), 
5.18 (d, J=9.0 Hz, 1H), 3.76 (d, J=9.0 Hz, 1H), 3.73 (s, 3H), 2.31 (s, 3H), 1.20 (s, 
9H), 0.08 (s, 9H). 
13
C NMR (CDCl3; 75 MHz): δ 202.1, 165.7, 159.2, 133.6, 128.3, 113.3, 81.6, 
74.0, 69.4, 55.1, 30.4, 27.5, -0.1. 
MS (ESI): m/z = 389.33 (M + Na
+
).  
Anal. Calcd for C19H30O5 Si: C, 62.26; H, 8.25. Found: C, 62.40; H, 8.13. 
2-(Furan-2-yl-trimethylsilanyloxy-methyl)-3-oxo-butyric acid tert-butyl ester 
(3m) 
 The title compounds were obtained as Oil.
  




H NMR (CDCl3; 250 MHz): δ 7.35-7.33 (t, 2H), 6.30-6.27 (m, 2H), 6.24-6.22 
(m, 2H), 5.27 (d, J=9.0 Hz, 1+1H), 4.10 (d, J=9.0 Hz, 1H), 4.05 (d, J=12.0 Hz, 
1H, major diastereomer), 2.31 (s, 3H, major diastereomer), 2.03 (s, 3H), 1.46 (s, 




C NMR (CDCl3; 75 MHz): δ 201.5, 200.6, 165.8, 165.4, 153.5, 153.2, 142.0, 
141.9, 110.2, 110.1, 107.9, 107.6, 81.9, 81.8, 67.0, 66.9, 66.6, 65.5, 30.8, 29.8, 
27.8, 27.5, -0.40, -0.46.     
MS (ES)-: m/z = 349.15 (M + Na
+
).  
Anal. Calcd for C16H26O5 Si: C, 58.87; H, 8.03. Found: C, 58.76; H, 8.11. 
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butyl ester (3l) 
The title compounds were obtained as Oil.
  
IR (KBr): 693, 760, 1081, 1145, 1256, 1461, 1699, 1719, 2994 cm
-1
 .  
1
H NMR (CDCl3; 300 MHz): δ 7.46-7.41 (m, 2+2 H), 7.24-7.22 (m, 2+2 H), 
5.22-5.19 (d, J = 9 Hz, 1+1H), 3.82 (d, J = 9 Hz, 1H), 3.75 (d, J=9 Hz, 1H, major 
diastereomer) 2.31 (s, 3H, major diastereomer) 1.92 (s, 3H), 1.48 (s, 9H), 1.22 (s, 
9H, major diastereomer) -0.04 (s, 9H), -0.06 (s, 9H, major diastereomer). 
 13
C NMR (CDCl3; 75 MHz): δ 201.4, 200.9, 165.9, 165.5, 140.9, 140.7, 132.0, 
131.3, 131.1, 130.8, 128.8, 128.7, 121.7, 82.0, 81.8, 73.6, 73.0, 70.1, 69.0, 30.7, 
29.5, 27.8, 27.5, -0.08, -0.15.  
MS (ESI): m/z = 437.09 (M + Na
+
).  





H NMR (250 MHz; CDCl3): δ 7.44–7.25 (m, 5H), 5.17 (dd, J =7.5 and 4.5 Hz, 1 
H), 4.20 (br sextet, J = 6.5, 1 H), 3.73 (d, J = 7.5, 1 H), 3.56 (s, OMe, 3 H), 2.84 







H NMR (250 MHz; CDCl3) δ 7.35–7.28 (m, 5 H), 5.10 (d, J= 9.0 Hz, 1 H), 4.34 
(quintept, J = 7.0 Hz, 1 H,), 3.55 (2H, bs), 3.38 (s, 3 H), 2.81 (t, J = 9.0 Hz, 1 H), 
1.25 (d, J = 6.0 Hz, 3 H). 
(2SR,3SR)-3-Hydroxy-2-(1’(RS)-phenyl-trimethylsilanyloxy-methyl)-butyric 
acid tert butyl ester (5a) 
The title compounds were obtained as Oil. 
IR (KBr): 693, 760, 1081, 1145, 1256, 1461, 1699, 1719, 2994, 3260. 
 1
H NMR (250 MHz; CDCl3): δ 7.33-7.29 (m, 5H), 4.99 (d, J=7.5 Hz, 1H), 3.83-
3.78 (m, 1H), 2.78 (dd, J = 7.5 and 6.4 Hz, 1 H), 2.29 (bs, 1H), 1.44 (s, 9H), 1.10 
(d, J = 5 Hz), 4H), -0.03 (s, 9 H). 
13
C NMR (75 MHz; CDCl3): δ 171.2, 141.9, 128.3, 127.9, 126.9, 80.8, 74.6, 66.1, 
61.7, 27.9, 20.2, -0.09. 
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MS (ESI): m/z = 361.42 (M + Na
+
).  
Anal. Calcd for C18H30 O4Si: C, 63.87; H, 8.93. Found: C, 63.70; H, 8.80.   
 (2SR,3SR)-3-Hydroxy-2-(1’(RS)-hydroxy-phenyl-methyl)-butyric acid tert 
butyl ester (6) 
The title compounds were obtained as solid. 
 IR (KBr): 690, 765, 1090, 1140, 1451, 1690, 1729, 2984, 3320.  
1
H NMR (400 MHz; CDCl3): δ 7.34-7.24 (m, 5H), 5.20-5.17 (m, 1H), 4.25-4.23 
(m, 1H), 3.94 (bd, J=4 Hz), 2.77 (bs, 1H), 2.71 (dd, J= 7.0 and 3.9 Hz, 1 H), 1.31 
(d, J=4 Hz, 3H), 1.24 (s, 9H). 
13
C NMR (75 MHz; CDCl3): δ 172.7, 141.8, 128.1, 127.1, 125.4, 81.9, 71.1, 66.7, 
59.1, 27.6, 21.0. 
MS (ESI): m/z = 289.15 (M + Na
+
). 
Anal. Calcd for C15H22 O4 : C, 67.64; H, 8.33. Found: C, 67.50; H, 8.25. 
2-Methyl-3-oxo-2-(phenyl-trimethylsilanyloxy-methyl)-butyric acid tert-butyl 
ester (7) 
The title compounds were obtained as an oil. 
 
IR (KBr): 680, 770, 1073, 1131, 1250, 1442, 1693, 1709, 2971. 
1
H NMR (400 MHz; CDCl3): δ 7.34-7.24 (m, 5H), 5.45 (s, 1H), 2.36 (s, 3H), 1.40 
(s, 9 H), 1.16 (s, 3H), -0.02 (s, 9H). 
13
C NMR (75 MHz; CDCl3): δ 204.8, 170.2, 139.9, 127.8, 127.5, 127.4, 81.7, 
66.3, 28.6, 27.8, 27.1, 15.7, -0.07. 
MS (ESI): m/z = 351.19 (M + H
+
).  
Anal. Calcd for C19H30O4Si: C, 65,10; H, 8,63. Found: C, 65,25; H, 8,73. 
iii) Crystal data and refinement details for structures 
Single crystal diffraction data were collected on a Oxford Xcalibur CCD area 
detector diffractometer, using graphite monochromatic Mo Kα (λ = 0.71069Å) 
radiation. Data reduction and absorption correction were performed using 
CrysAlis RED 1.171.26 (Oxford Diffraction). The structure was solved by direct 
methods using SIR2008
3
 and refined by full-matrix least squares using SHELX-
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 Hydrogen atoms were generated in calculated position using SHELX-97 
(Table 4). 
 
Table 4. Selective X-Ray crystallographic data for compound 3e and compound 6. 
 Comp. 3e Comp. 6 
Empirical formula C19N1O4Si1H25  C25O4H21 
Formula weight 359 265 
Temperature 293(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic Triclinic 
Space group P 21/n P-1 
 
 
Unit cell dimensions 
 
a = 9.8157(4) Å    
   b = 15.5367(5) Å   
            b= 98.289(4)° 
   c = 14.1068(7) Å 
a = 6.155(5) Å   
             a= 80.620(5)° 
  b = 9.280(5) Å   
 b= 86.561(5)° 
    c = 14.021(5) Å  





Z 8 2 









F(000) 848 139 
Theta range for data 
collection 
4.20 to 30.38° 4.35 to 29.78° 
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Reflections collected 29674 6039 
Independent reflections 5512 [R(int) = 0.0488] 3684 [R(int) = 0.1379] 
Completeness   85.9 % (to theta=30.38°) 86.3 % (to theta = 29.78°) 
Refinement method Full-matrix least-squares on F
2 




Final R indices 
[I>2sigma(I)] 
R1 = 0.0647, wR2 = 0.1751 R1 = 0.1148, wR2 = 0.2118 
R indices (all data) R1 = 0.1271, wR2 = 0.2241 R1 = 0.3540, wR2 = 0.3341 
Largest diff. peak and hole 0.403 and -0.249 e.Å
-3 
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The chemistry and reactivity of the isoindolinone ring system is currently an area 
of interest for many research groups due to its biological activity and its large 
number of applications in therapeutic activities.
1
 2,3-Dihydro-1H-isoindol-1-ones 
are known under different names in the literature such as isoindolinones or 










Fig- 1. Skeleton structure of Isoindolinone 
In this case, should be specifically mentioned taliscanine,
2a
 which occurs in the 
rhizomes of Aristolochia taliscanina, enterocarpam II,
2b
 isolated from the stem 
bark of Orophea enterocarpa (Annoniacae), or vellutina
2c
 extracts of leaves and 








Fig-2.                
                                                                   Taluscanine (R1 = R2 = OMe) 
                                                                    Enterocarpam II (R
1
 = OMe, R
2
 =OH) 
                                                                        Valutinam (R
1
 = OH, R
2
 = OMe) 
 
Recently, it has been recognized that 3-substituted isoindolinones possess 
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 and platelet aggregation inhibitory
8b
 properties have 
also been observed.  
Consequently, considerable effort has been devoted to the synthesis of this 
benzoannelated nitrogen heterocycle which also act as useful synthetic building 
blocks and intermediates in organic synthesis.  
3.2.2 REVIEW OF LITERATURE 
Several traditional methods are available for the synthesis of isoindolinones,
9
 














 In recent years several new approaches have been 
developed for the synthesis of substituted isoindolines, of which the most 
generally useful involve palladium catalysed reactions
11
 or lithiation procedures.
12 
However, such methods generally require multiple reaction steps, inflexible 
strategies for the construction of the heterocyclic ring
13,14
 and are unsatisfactory 
both in yield and generality. For these reasons the interest for the development of 
new and simple methods for the construction of 3-substituted isoindolinones has 
grown over the past decades.  
Ramström approach 
Ramström et al have very recently proposed a useful one-pot tandem nitroaldol 
(Henry reaction)–cyclization–rearrangement reaction for the synthesis of 3-
substituted isoindolinones by reaction of 2-cyanobenzaldehyde with nitroalkanes 
in the presence of tertiary base.
15 




















Scheme 1. Synthesis of Isoindolinone  in a Diastereoselective One-pot Tandem   
Reaction-Cystallization Protocol. 
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This process was possible thanks to the relatively acidic protons of nitro 
compounds: in fact by using secondary nitroalkane the most acidic proton was 
eliminated from the molecule and the reaction could be halted at intermediate 











1 6 7 8  
 
Scheme 2. Synthesis of Intermediate analogue 
 
 
3.2.3 PRESENT WORK 
Based on Ramstrom approach, our idea is related to the development of a more 
general approach which exploits the aldol addition of readily enolizable 1,3-
dicarbonyl compounds to 2-cyanobenzaldehyde. It is important to note that the 
aldol addition of readily enolizable 1,3-dicarbonyl compounds, such as β-keto 
esters and malonates, to aldehydes is very difficult to achieve, and very few 
applications are available, whereas the nitroaldol is a well-established procedure.          
Recently we demonstrated that trapping of these unstable aldol adducts in the 
presence of chlorosilane reagents is a straightforward strategy to drive these 
difficult aldol additions to completion.
16
 Thus, based on this concept, the 
intramolecular trapping of the intermediate aldol adducts by irreversible 
cyclization at the cyano group would allow the synthesis of different types of 3-
substituted isoindolinones. On the basis of these considerations, according to 
Scheme 3, a series of readily enolizable 1,3-dicarbonyl compounds (9) reacted 
with 2-cyanobenzaldehyde (1) in the presence of triethylamine, and the results are 
reported in Table 1. 
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              Scheme 3 
 
Under optimized conditions we were pleased to observed that all the model 
nucleophiles, representing the classes of malonates, β-ketoesters, and 1,3-
diketones, gave the new 3-substituted isoindolinones 10 in good to high yields. 
(Table 1).  
 
Table 1: Synthesised 3-substitued isoindolinones 
Entry Adduct 9 Product 10 Yield
a
  (%) dr
b
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    a  
Yields ref chromatographically pure compounds.
 b
 The diastereomeric ratio were calculated on 
the basis of 
1
H NMR spectrum of the crude product. 
 
Only acetylacetone, under the same conditions, showed significantly lower 
reactivity (entry 5). 
However, a good yield was observed in a very short time (10 min) when it was 














               Scheme 4 
         
It is worthy to note that the obtained isoindolinones 10 show very interesting 
functionalities and they could be very useful for further transformations in the 
synthesis of valuable compounds. For example, according to Scheme 5, the 
decarboxylation of the β-keto ester derivative 10b, was carried out by employing 




Scheme 5: Krapcho decarboxylation approach 
 
The Krapcho decarboxylation is the chemical reaction of esters with halide 
anions. The ester must contain an electron-withdrawing group in the β-position, 
such as β-ketoesters, malonic esters, α-cyanoesters, or α-sulfonylesters. It works 
best with methyl esters, since it is basically a SN2-reaction at carbon. It is driven 
by the entropy of the overall reaction, as the by-products chloromethane and CO2 
are lost as gases.  
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This approach led to known compound 13 (Scheme 6), previously obtained from 
by less effective synthesis employing a cobalt(II) catalyst.
11
 The decarboxylation 
of compound 10b reacted with LiCl, DMSO and H2O at reflux for 4 hr to formed 





By using the same decarboxylation procedure a well-known intermediate 
(compound 14)
12a
 in the synthesis of a series of achiral and chiral piperazine 
derivatives 15 for dopamine D4 receptor, a good target for the treatment of 
schizophrenia, that otherwise required a longer and more tedious method of 
synthesis
12a 
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The decarboxylation of compound 10a gave compound 14 in 70 % yield.  
 
As reported by Ramström, we demonstrated that the presence of two acidic 
protons in the α-position of 1,3-dicarbonyl compounds is the fundamental 
requisite that allows the isoindolinone ring to be obtained.
15
 In fact, when ethyl 2-
methylacetoacetate (16) or dimethyl methylmalonate (17) were reacted under the 
conditions of Scheme 3, new products were obtained in significantly lower yields.  
The structure of these compounds was attributed to the iminoisobenzofurans 18 





      Scheme-8 
 
 
Thus, on the basis of the obtained results, a general pathway can reasonably be 
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After the reversible deprotonation of 9 and its subsequent nucleophilic addition to 
the aldehyde 1, the unstable adduct 20 gives the iminoisobenzofuran 21 by 
cyclization at the cyano group. Deprotonation of 21 in the presence of a base and 
rearrangement gives the acyclic intermediate 22. Finally, the intramolecular 
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3.2.4 BIOLOGICAL ACTIVITY 
The obtained 3-substituted isoindolinones were preliminary screened on two 
different virus (Hepatitis C Virus (HCV) and Chikungunya virus (CHIKV)) to 
evaluate potential activity on the virus replication in Hepatoma Human Cells (Huh 
5-2 containing 1b genotype) and Vero cells respectively. CC50, EC50 and EC90 
values of the compounds comparing with arbidol are shown in Table 2 
 
Table-2.  In vitro antiviral activity of 3-substituted isoindolines derivatives 
  HCV   CHIKV  
          Compounds CC50 EC50 EC90 CC50 EC50 EC90 
 
10a 
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ND = not determined 
CC50 = 50 % Cytostatic/Cytotoxic Concentration (concentration at which 50 % adverse effect is 
observed on the host cell) 
EC50 = 50 % Effective Concentration (concentration at which 50 % inhibition of virus replication 
is observed) 
EC90 = 90 % Effective Concentration (concentration at which 90 % inhibition of virus replication 
is observed) 
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Unfortunately it was found that all compounds were not active: however further 
explore diverse biological activity could be explored by High-Throughput 
Screening. In addition because of the simplicity of the method, other studies could 
be desiderable to functionalize this scaffold for example by introduction of 
different substituents on the aromatic ring (starting from substituted 2-
cyanobenzaldeydes) or by alkylation of the amidic nitrogen or both as in 





In conclusion, a study of the aldol addition of readily enolizable 1,3-dicarbonyl 
compounds to 2-cyanobenzaldehyde gave us the possibility to develop a simple 
and general access to a series of new 3-substituted isoindolinones in the presence 
of tertiary amines under very mild conditions.  
We synthesized a series of new 3-substituted isoindolinones derivatives and 
examined their anti-HCV activities and Chikungunya virus. Unfortunately it was 
found that all compounds were not active. 
3.2.6 EXPERIMENTAL SECTION: 
i) General remarks  
All reactions were performed in oven-dried (140 °C) or flame-dried glassware 
under dry N2. Dichloromethane was reagent grade and was dried and distilled 
immediately from CaH2 before use. Column chromatographic purification of 
products was carried out using silica gel 60 (70–230 mesh, Merck). The reagents 
(Aldrich and Fluka) were used without further purification. The NMR spectra 
were recorded on Bruker DRX 400, 300, 250 spectrometers (400 MHz, 300MHz, 
250MHz, 
1
H; 100 MHz, 75MHz, 62,5MHz 
13
C). Spectra were referenced to 
residual CHCl3 (7.26 ppm,
 1
H, 77.23 ppm, 
13
C). Coupling constants J are reported 
in Hz. Yields are given for isolated products showing one spot on a TLC plate and 
no impurities detectable in the NMR spectrum. Mass spectral analyses were 
carried out using an electrospray spectrometer, Waters 4 micro quadrupole. 
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Elemental analyses were performed with FLASHEA 1112 series-Thermo 
Scientific for CHNS-O apparatus. 
ii) General Procedures 
 a) Dihydro-1H-isoindol-1-ones (10) 
2-Cyanobenzaldehyde 1, (0.40 mmol) was added to a solution of 1,3- dicarbonyl 
compound 9 (0.44 mmol) and Et3N (0.40 mmol) in CH2Cl2 (2.0 mL). At the end 
of the reaction (TLC monitoring), the mixture was diluted with EtOAc (2 mL) and 
the solvent evaporated under reduced pressure. Then the crude product was 
purified by flash chromatography (hexane–EtOAc, 8:2 to 1:1) to afford pure 
products. 
b) Decarboxylation Reaction To Give 13 or 14  
Compound 10a or 10b (0.22 mmol), DMSO (4.0 mL), H2O (0.30 mL), and LiCl 
(0.50 mmol) were placed in a round-bottom flask equipped with a magnetic bar 
and a reflux condenser. The solution was heated to refluxing using an oil bath 
with stirring for 4 h. After cooling to r.t., the solution was added to EtOAc (60 
mL), extracted with brine (3 × 20 mL), and dried (anhydrous Na2SO4). Then the 
solvent was removed under reduced pressure and the crude product was purified 
by chromatography (hexane:EtOAc, 8:2 to 1:1). 
 
c) 1,3-Dihydroisobenzofuran-1-imines 18 and 19; 
2-Cyanobenzaldehyde (1, 46 mg, 0.40 mmol) was added to a solution of ethyl 2-
methylacetoacetate 16, (62 mL, 0.44 mmol) or dimethyl methylmalonate 17, (58 
mL, 0.44 mmol) and Et3N (61 mL, 0.44 mmol) in CH2Cl2 (1.0 mL) at r.t. At the 
end of the reaction (TLC monitoring), the mixture was diluted with EtOAc (2 mL) 
and the solvent evaporated under reduced pressure. Then the crude was purified 
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iii) Characterization data  
Note: Compound 10h is known and was characterised comparing its 
spectroscopic data with those previously reported in literature.
11
 
Dimethyl 2-(3-Oxo-2,3-dihydro-1H-isoindol-1-yl)malonate (10a) 
Nature of compound: Solid; yield: 91 mg (87 %); mp 154–155 °C.  




H NMR (250 MHz, CDCl3): δ 7.82 (d, J = 7.5 Hz, 1H), 7.53–7.47 (m, 2H), 7.32 
(m, 2H), 5.18 (d, J = 7.5 Hz, 1H), 3.81 (s, 3H), 3.67 (s, 3H), 3.62 (d, J = 7.5 Hz, 
1H). 
13
C NMR (100 MHz, CDCl3): δ 171.3, 168.8, 168.3, 144.9, 133.3, 133.2, 130.2, 
125.3, 124.1, 57.1, 56.1, 54.3, 53.2. 
MS (ESI): m/z = 286 [M + Na
+
]. 
Anal. Calcd for C13H13NO5: C, 59.31; H, 4.98; N, 5.32. Found: 59.45; H, 5.04; 
N, 5.15 
Ethyl 3-Oxo-2-(3-oxo-2,3-dihydro-1H-isoindol-1-yl)butanoate (10b) 
Nature of compound: Solid; yield: 70 mg (67 %); mixture of diastereoisomers.  
IR (KBr): 3237, 2982, 2925, 2854, 1701, 1616, 1470, 1359, 1308, 1204, 1096, 




H NMR (250 MHz, CDCl3): δ 7.84 (d, J = 6.60 Hz, 2H), 7.54–7.46 (m, 4H), 
7.34–7.26 (m, 2H), 6.86–6.83 (m, 2H), 5.24 (d, J =8.02 Hz, 2H), 4.36–4.27 (q, 
2H), 4.16–4.08 (q, 2H), 3.81 (d, J =7.65 Hz, 1H), 3.65 (d, J = 8.37 Hz, 1H), 2.34 
(s, 3H), 2.18 (s, 3H), 1.34–1.28 (t, 3H), 1.15–1.10 (t, 3H). 
13
C NMR (100 MHz, CDCl3): δ 202.9, 201.9, 171.0, 170.9, 168.4,167.8, 145.4, 
145.4, 133.3, 133.3, 133.2, 130.2, 130.1, 125.5, 125.4, 124.1, 65.4, 64.1, 63.5, 
63.4, 55.7, 55.6, 32.4, 30.9, 15.2, 15.0. 
MS (ESI): m/z = 284 [M + Na
+
]. 
Anal. Calcd for C14H15NO4: C, 66.36; H, 5.79; N, 5.36. Found: C, 66.47; H, 
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 tert-Butyl 3-Oxo-2-(3-oxo-2,3-dihydro-1H-isoindol-1-yl)butanoate(10c) 
Nature of compound: Solid; yield: 101 mg (87 %); mixture of diastereomers. 
1
H NMR (300 MHz; CDCl3): δ 7.86 (br d, J = 6.0 Hz, 1 + 1H), 7.56–7.49 (m, 3 + 
2H), 7.31 (d, J = 6.0 Hz, 1H), 7.12 (br s, 1H), 6.68 (br s, 1H), 5.18 (d, J = 8.0 Hz, 
1H), 5.14 (d, J = 6.0 Hz, 1H), 3.78 (d, J = 6.0 Hz, 1H), 3.60 (d, J = 8.0 Hz, 1H), 
2.35 (s, 3H), 2.17 (s, 3H), 1.42 (s, 9H), 1.29 (s, 9H). 
13
C NMR (100 MHz; CDCl3): δ 202.3, 201.1, 169.9, 169.8, 166.1, 165.5, 144.4, 
144.3, 132.1, 132.0, 131.9, 131.8, 128.7, 128.6, 123.9, 123.3, 122.8, 83.4, 83.3, 
64.8, 63.3, 54.5, 54.4, 30.7, 29.5, 27.7, 27.5. 
MS (ESI): m/z = 290 [M + H
+
]. 
Anal. Calcd for C16H19NO4: C, 66.42; H, 6.62; N, 4.84. Found: C, 66.35; H, 
6.53; N, 4.90. 
 
2-(3-Oxo-2,3-dihydro-1H-isoindol-1-yl)cyclohexane-1,3-dione (10d) 
Nature of compound: Solid; yield: 63 mg (65%); mp 210 °C (dec).  




H NMR (400 MHz; CD3OD): δ 7.71 (d, J = 8.0 Hz, 1 H), 7.50–7.46 (t, 1 H), 
7.39–7.35 (t, 1 H), 7.25 (d, J = 8.0 Hz, 1 H), 5.96 (s, 1H), 2.40–2.29 (m, 4 H), 
1.96–1.91 (q, 2 H). 
13
C NMR (100 MHz; CD3OD): δ 191.5, 173.7, 150.8, 133.4, 132.4, 127.7, 123.4, 
122.9, 110.5, 53.1, 35.1, 21.8. 
MS (ESI): m/z = 244 [M + H
+
]. 
Anal. Calcd for C14H13NO3: C, 69.12; H, 5.39; N, 5.76. Found: 69.31; H, 5.28; 
N, 5.67. 
3-(3-Oxo-2,3-dihydro-1H-isoindol-1-yl)pentane-2,4-dione (10e) 
Nature of compound: Solid; yield: 70 mg (76%); mp 146.7–147.8 °C.  





H NMR (250 MHz; CDCl3): δ 7.81 (d, J = 5.0 Hz, 1 H), 7.56–7.46 (m, 4 H), 
7.30 (d, J = 7.5 Hz, 1 H), 5.64 (s, 1 H, enol form), 5.25 (d, J = 5.0 Hz, 1 H), 4.06 
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(d, J = 7.5 Hz, 1 H), 2.40 (s, 3 H, enol form), 2.26 (s, 3 H), 2.08 (s, 3 H), 1.41 (s, 3 
H, enol form). 
13
C NMR (100 MHz, CDCl3): δ 203.5, 202.3, 198.4, 190.6, 172.9, 171.5, 148.3, 
145.4, 133.8, 133.5, 133.3, 133.2, 130.2, 129.8, 125.5, 125.2, 124.1, 123.6, 108.0, 
72.3, 56.2, 32.7, 31.8, 25.6, 24.1. 
MS (ESI): m/z = 254 [M + Na
+
]. 
Anal. Calcd for C13H13NO3: C, 67.52; H, 5.67; N, 6.06. Found: C, 67.45; H, 
5.78; N, 6.12. 
Ethyl 2-cyano-2-(1-oxoisoindolin-3-yl)acetate(10f): 
Nature of compound: solid, yield = (11 mg) 12 %. 
 
Mp 164.2-165.9 °C. 
1
H NMR (250 MHz; CDCl3): δ 7.68-7.65 (t, 1+1H), 7.64 (d, J=2.5 Hz, 1H), 7.62-
7.55 (m, 3+2H), 7.49 (d, J=7.5 Hz, 1H), 7.40 (s, 1H), 5.20 (d, J=2.5 Hz, 1H), 5.15 
(d, J=7.5 Hz, 1H), 4.42-4.32 (m, 2+2H), 4.14 (d, J=2.5 Hz, 1H), 3.76 (d, J=10 Hz, 
1H), 1.38-131 (m, 3+3H). 
13
C NMR (100 MHz; CDCl3): δ 171.3, 171.1, 165.4, 143.4, 143.2, 134.0, 133.9, 
133.3, 132.8, 131.1, 125.9, 125.6, 124.8, 123.4, 115.1, 113.6, 65.2, 55.8, 55.5, 
43.8, 43.7, 31.4, 30.9, 15.1. MS (ESI): m/z = 267.41 (M + Na
+
).  
Anal. Calcd for C16H19NO4: C, 63.93; H, 4.95; N, 11.47. Found: C, 63.32; H, 
4.83; N, 11.24. 
Di-tert-butyl 2-(1-oxoisoindolin-3-yl)malonate (10g): 
Nature of compound: solid, yield = (38 mg) 27 %. 
1
H NMR (300 MHz; CDCl3): δ 7.84 (d, J=8.0 Hz, 1H), 7.56-7.46 (m, 2 H), 7.43 
(d, J=8.0 Hz, 1H), 6.82 (s, 1H), 5.08 (d, J=8.0 Hz, 1H), 3.52 (d, J=4.0 Hz, 1H), 
1.50 (s, 9H), 1.29 (s, 9H). 
13
C NMR (100 MHz; CDCl3): δ 169.8, 166.7, 165.6, 144.0, 132.1, 131.1, 128.6, 
123.7, 123.1, 82.9, 82.7, 57.5, 54.7, 27.7, 27.5. 
MS (ESI): m/z = 348 (M + H
+
).  
Anal. Calcd for C19H25NO5: C, 65.69; H, 7.25; N, 4.03. Found: C, 65.64; H, 
7.28; N, 4.01. 
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Methyl (1Z)-N-[(4-methylbenzyl)sulfonyl]-2-phenylethanimidoate (10j) 
Nature of compound: solid, yield = (45 mg) 25 %,
 
Mp 141.6-142.7 °C.  
1
H NMR (400 MHz; CDCl3): δ 7.84 (d, J = 7.24 Hz, 1H), 7.74 (d, J=8.12 Hz, 
2H), 7.54 (s, 3H), 7.42 (s, 5H), 7.26-7.21 (m, 4H), 7.16 (d, J = 8.0 Hz, 1H), 6.07 
(dd, J=7.68 Hz & 10.56 Hz, 2H), 5.27 (d, J=7.2 Hz, 1H),5.12 (d, J=10.4 Hz, 1H), 
3.91 (s, 3H), 3.90 (s, 3H), 2.40 (s, 3H), 2.37 (s, 3H). 
 
13
C NMR (100 MHz; CDCl3): δ 172.6, 172.5, 168.1, 145.6, 145.4, 144.7, 139.8, 
139.4, 134.2, 133.8, 133.4, 132.8, 131.2, 130.9, 130.6, 130.5, 130.3, 130.2, 129.8, 
129.5, 128.0, 127.9, 125.2, 123.9, 123.8, 83.8, 83.4, 57.4, 57.2, 54.9, 54.8, 30.9, 
22.7.  
MS (ESI): m/z = 435 (M + H
+
).  
Anal. Calcd for C16H19NO4: C, 66.34; H, 5.10; N, 6.45. Found: C, 66.31; H, 




Nature of compound: Solid; yield: 26 mg (62%); mp 132.7–134.1 °C. 
1
H NMR (400 MHz, CDCl3): δ 7.86 (d, J = 7.3 Hz, 1H), 7.65–7.36 (m, 2H), 7.38 
(d, J = 7.3 Hz, 1H), 6.68 (br s, 1H), 4.94 (br d, J = 7.8 Hz, 1H), 3.21 (dd, J = 3.2, 
18.5 Hz, 1H), 2.59 (dd, J = 10.2, 18.5 Hz, 1H), 2.24 (s, 3H). 
MS (ESI): m/z = 190 [M + H
+
]. 
Anal. Calcd for C11H11NO2: C, 69.83; H, 5.86; N, 7.40. Found: C, 69.62; H, 
5.70; N, 7.68. 
Methyl (3-Oxo-2,3-dihydro-1H-isoindol-1-yl)acetate (14) 
Nature of compound: Solid; yield: 32 mg (70 %); mp 145.6–157.7 °C. 
1
H NMR (250 MHz, CDCl3): δ 7.86 (d, J = 7.1 Hz, 1H), 7.59–7.40 (m, 3H), 6.93 
(br s, 1H), 4.93 (dd, J = 10.2, 3.3 Hz, 1H), 3.78 (s, 3H), 3.03 (dd, J = 3.4, 17.1 Hz, 
1H), 2.46 (dd, J = 10.2, 17.2 Hz, 1H), 2.24 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ 171.6, 170.0, 145.6, 132.0, 131.7, 128.6, 124.1, 
122.2, 52.6, 52.2, 39.2. 
MS (ESI): m/z = 206 [M + H
+
]. 
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Anal. Calcd for C11H11NO3: C, 64.38; H, 5.40; N, 6.83. Found: C, 64.52; H, 
5.30; N, 6.68. 
Ethyl 2-(3-Imino-1,3-dihydroisobenzofuran-1-yl)-2-methyl-3-oxobutanoate 
(18) 
Nature of compound: Oil; yield: 51 mg (46 %); mixture of diastereomers. 





H NMR (400 MHz, CDCl3): δ 7.83 (d, J = 7.47 Hz, 1H), 7.51–7.45 (m, 2H), 
7.35 (d, J = 6.90 Hz, 1H), 6.26 (s, 1H), 6.24 (s, 1H, minor), 4.28–4.15 (m, 2H), 
2.33 (s, 3H), 2.17 (s, 3H, minor), 1.30–1.12 (m, 3H), 1.09 (s, 3H), 1.06 (s, 3H, 
minor). 
13
C NMR (100 MHz, CDCl3): δ 203.5 (minor), 202.0, 169.4, 168.9 (minor), 
166.7, 143.5, 143.3 (minor), 132.2, 130.4 (minor), 129.9, 129.3, 123.8, 123.7, 
123.2, 83.7 (minor), 83.3, 64.3 (minor), 63.8, 62.2 (minor), 61.9, 29.5, 26.6, 26.4 
(minor), 13.7 (minor), 13.6. 
MS (ESI): m/z = 276 [M + H
+
]. 
Anal. Calcd for C15H17NO4: C, 65.44; H, 6.22; N, 5.09. Found: C, 65.53; H, 
6.17; N, 5.01. 
Dimethyl 2-(3-Imino-1,3-dihydroisobenzofuran-1-yl)-2-methylmalonate (19) 
Nature of compound: Oil; yield: 39 mg (35 %). 
IR (KBr): 3298, 2954, 1732, 1694, 1468, 1435, 1355, 1268, 1157, 1112, 1034, 
978, 839, 779, 751, 662 cm–1. 
1
H NMR (250 MHz, CDCl3): δ 7.55 (d, J = 5.75 Hz, 1H), 7.53–7.41 (m, 3H), 
6.20 (s, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 1.13 (s, 3H). 
13
C NMR (100 MHz, CDCl3): δ 169.59, 169.16, 166.7, 143.0, 132.2, 130.2, 
129.3, 123.8, 123.2, 83.4, 57.9, 53.1, 52.8, 14.0. 
MS (ESI): m/z = 278 [M + H
+
]. 
Anal. Calcd for C14H15NO5: C, 60.64; H, 5.45; N, 5.05. Found: C, 60.75; H, 
5.49; N, 5.12. 
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